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ABSTRACT
Obstructive sleep apnea (OSA), a disorder in which the airway intermittently collapses
and obstructs during sleep, is associated with increased cardiovascular and
cerebrovascular morbidity and mortality, increased risk of motor vehicle accidents,
metabolic syndrome, hypertension, and depression. Treatment of OSA attenuates or
reverses many of these associated risks. However, most cases of OSA are unrecognized
and untreated. The two most recent studies using 1990s data found that only 6.5 – 15.4%
of OSA cases, depending on severity, are clinically recognized in mixed gender
populations. Based on a conceptual framework of improved physician awareness of OSA,
and reduced diagnostic access bias with the increased availability of sleep laboratory
services, increased OSA recognition since the 1990s was predicted. Study participants
with clinically recognized OSA were identified using the resources of the Rochester
Epidemiology Project, while the Berlin Questionnaire OSA high risk classification was
used as a surrogate for prevalent OSA in this population. Analysis in a mixed gender
population determined that OSA clinical recognition among those with prevalent OSA
was 22.7 % (95% CI 19.6 – 25.8%) for mild or greater OSA severity leaving more than
75% of prevalent OSA clinically unrecognized and untreated in this population. Obesity
and male gender were associated with increased likelihood of clinical recognition in
bivariate and multivariate analyses, though even among obese men only 36.5% of OSA
was clinically recognized. In order to support positive social change and address these
inequities of OSA clinical recognition, strategies that enhance OSA recognition overall,
and more specifically target recognition of OSA among women and the nonobese, should
be developed and implemented. Further research regarding such strategies should
consider whether they reduce OSA associated morbidity and mortality.
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CHAPTER 1: INTRODUCTION TO THE STUDY
Background
Obstructive sleep apnea is a disorder in which the airway collapses causing an
airway obstruction during sleep and recurrent arousals from sleep (Parish & Somers,
2004). The airway collapse and the resulting sleep interruptions produce the common
symptoms of OSA that include excessive snoring, daytime sleepiness, and pauses in
breathing reported by sleeping partners (Caples, Gami, & Somers, 2005; Parish &
Somers, 2004).
Across the population, OSA of at least mild severity is not rare. In one early,
classically cited, population-based epidemiologic study the prevalence of OSA with
daytime symptoms was found to be 2% and 4% in women and men, respectively.
However, the prevalence of at least mild OSA with or without symptoms was found to be
9% and 24% in women and men, respectively (Young et al., 1993). A later larger
multicenter study demonstrated a similar prevalence with at least moderate OSA present
in 11% and 25% of women and men, respectively (Young, Shahar et al., 2002). Overall
those with sleep apnea are usually older, more obese, and more likely male with the
prevalence higher among African-Americans and Asians (Young, Peppard, & Gottlieb,
2002).
OSA is associated with a variety of significant health problems including
increased cardiovascular (Caples, Garcia-Touchard, & Somers, 2007) and
cerebrovascular (Yaggi et al., 2005) morbidity and mortality, metabolic syndrome
(Coughlin, Mawdsley, Mugarza, Calverley, & Wilding, 2004), hypertension (Duran,
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Esnaola, Rubio, & Iztueta, 2001), and depression (Peppard, Szklo-Coxe, Hla, & Young,
2006). In addition, OSA is associated with increased risk of motor vehicle accidents
(Young, Blustein, Finn, & Palta, 1997).
OSA Diagnosis and Treatment
The “gold standard” diagnostic technique for OSA is polysomnography (PSG)
(Schlosshan & Elliott, 2004) which involves sleeping overnight in a laboratory with
multichannel monitoring of brain, eye, and muscle activity, respiratory effort, heart rate,
and blood oxygen saturation (Chesson et al., 1997). The diagnosis of OSA is then based
on an evaluation of this array of physiologic parameters that determines the stage of
sleep, number of apneas, hypopneas, and oxygen desaturations that occur and are then
correlated with respiratory effort movements. The number of apneas plus the number of
hypopneas occurring per hour of sleep represents the apnea-hypopnea index (AHI) which
is a measure of OSA severity. OSA is generally considered present if the AHI is greater
than five with daytime symptoms such as sleepiness, or greater than 15 with or without
symptoms (Berry & Foster, 2005; Silber, Krahn, & Morgenthaler, 2004).
Continuous positive airway pressure (CPAP) is considered to be first-line therapy
for those with moderate to severe OSA, especially those that have symptomatic daytime
sleepiness (Giles et al., 2006; Kushida et al., 2006). CPAP devices use airflow generated
by a fan and applied to the patient’s airway by way of tubing and a nasal or oronasal
mask to maintain the patency of the airway during sleep. Thus, CPAP functionally
represents a pneumatic splint that prevents OSA-related airway obstruction (Hirshkowitz
& Sharafkhaneh, 2005). A review of eight studies comparing OSA therapy with CPAP
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against a placebo of sham CPAP therapy demonstrated effectiveness in reducing OSA
severity (Gay, Weaver, Loube, & Iber, 2006).
There is evidence that the negative long-term effects of OSA are attenuated by
treatment with CPAP. Several studies of cardiovascular morbidity and mortality have
demonstrated reductions with CPAP therapy (Doherty, Kiely, Swan, & McNicholas,
2005; Milleron et al., 2004; Peker, Carlson, & Hedner, 2006). Unfortunately the ability to
adhere to CPAP therapy among those for whom it has been prescribed has been limited
and variable. A classic study (Kribbs et al., 1993) demonstrated that only 46% were able
maintain use of CPAP at four or more hours per night. More recent studies have shown
similar adherence rates ranging from 31% (Richards, Bartlett, Wong, Malouff, &
Grunstein, 2007) to about 48% (Joo & Herdegen, 2007) with a usual pattern of care.
Historic Clinical Under Recognition of OSA
There is evidence that a significant portion of those with OSA historically have
been clinically undiagnosed. However, the extent of this under diagnosis has not been
assessed since the 1990s. In the 1980s it was thought that less than 1% of prevalent OSA
had been diagnosed clinically (Dement, 1993; Strohl & Redline, 1996). There are only
two population-based studies that evaluated the portion of prevalent OSA that was
clinically diagnosed, both based on data collected in the 1990s (Kapur et al., 2002;
Young, Evans, Finn, & Palta, 1997). These studies demonstrated that 2 – 18% of OSA
had been clinically diagnosed varying based on gender and OSA severity. Thus, from the
1980s to the 1990s there had been some increase in the proportion prevalent OSA that
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was clinically diagnosed. However, most OSA, 82 – 98%, remained undiagnosed in the
1990s.
The under recognition of clinical OSA has been identified by the Institute of
Medicine as an unmet public health problem (Colten & Altevogt, 2006). Among the
potential explanations for limited clinical OSA recognition are the following: (a) limited
OSA awareness by physicians (Papp, Penrod, & Strohl, 2002; Reuveni et al., 2004; R.
Rosen & Zozula, 2000), (b) limited access to sleep laboratories and specialists (Flemons,
Douglas, Kuna, Rodenstein, & Wheatley, 2004; Morgenthaler et al., 2006), and (c) the
expensive and intrusive nature of laboratory-based PSG (Colten & Altevogt, 2006; van
de Mortel, Laird, & Jarrett, 2000).
Changes in health professional education, access to PSG, and the development of
new OSA diagnostic techniques not requiring PSG are described in chapter 2. These
changes could all provide a basis for an increase in OSA clinical recognition in the past
decade. However, there has been no research measuring the rate of OSA clinical
recognition subsequent to the 1990s.
In the first of the two studies evaluating clinical diagnosis of OSA, the following
characteristics were associated in bivariate analysis with a greater likelihood having been
diagnosed: male gender, previous cardiovascular disease, age, Caucasian race, and
higher socioeconomic status based on income and education (Young, Evans et al., 1997).
In the second of these studies (Kapur et al., 2002) bivariate analysis identified male
gender, history of hypertension, higher body mass index (BMI), college graduation, and a
lower high density lipoprotein (HDL) cholesterol levels as more common among those
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diagnosed. However, in multivariate regression analyses, only gender and BMI remained
predictive of a clinical diagnosis in this study.
Problem Statement
OSA is associated with increased cardiovascular and cerebrovascular morbidity
and mortality (Caples et al., 2007; Yaggi et al., 2005). The diagnosis and subsequent
treatment of OSA attenuates this long-term morbidity and mortality (Doherty et al., 2005;
Milleron et al., 2004; Peker et al., 2006). However, most OSA is clinically unrecognized
and untreated (Dement, 1993; Kapur et al., 2002; Strohl & Redline, 1996; Young, Evans
et al., 1997). There is some evidence that clinical OSA recognition in the 1990s had
improved from the 1980s, but still only 2 – 18% of OSA was diagnosed (Kapur et al.,
2002; Young, Evans et al., 1997). Since the 1990s there have been improvements in
several of the factors associated with under diagnosis (Marshall et al., 2007; Namen et al.,
2002; Zozula, Rosen, Jahn, & Engel, 2005). The proportion of prevalent OSA that has
been clinically diagnosed has not been assessed since a previous analysis of data obtained
in 1995 – 1998 (Kapur et al., 2002). With this most recent analysis of the clinical
recognition of OSA having been done more than ten years ago, factors predictive of
clinical recognition have not been evaluated following the changes of the past decade.
Nature of the Study
An expansion of an existing population-based study was used to determine the
proportion of prevalent OSA that had been diagnosed clinically, and identify predictors
of clinical diagnosis. The longitudinal Prevalence of Asymptomatic Ventricular
Dysfunction Study (PAVD Study) (Redfield et al., 2003) was initiated in 1997. This
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study identified a population-based sample randomly selected from the residents of
Olmstead County, Minnesota who were at least 45 years old on January 1, 1997. In the
PAVD study OSA risk was characterized using a modified Berlin Questionnaire (Netzer,
Stoohs, Netzer, Clark, & Strohl, 1999). Data collection that would allow the OSA risk
characterization, either high or low, for all PAVD round two participants, was completed
in 2004 as part of the ongoing study.
This study used the resources of the Rochester Epidemiology Project (Melton,
1996) to link PAVD participants and their OSA risk with their clinical records. This
matching allowed the determination of (a) the frequency of clinical evaluation for OSA,
(b) the prevalence of a clinical diagnosis of OSA among those at high risk for OSA, and
(c) the differential characterization of those diagnosed and undiagnosed with OSA among
those at high risk for the disorder.
Thus, the research questions addressed by this study are as follows:
1. What proportion of those at high risk for OSA based on the Berlin
Questionnaire have been clinically evaluated for OSA?
2. What is the prevalence of clinically diagnosed OSA among those at high risk
for OSA based on responses to the Berlin Questionnaire?
3. Has the prevalence of clinically diagnosed OSA increased in the past decade?
4. What factors were predictive of the clinical diagnosis of OSA among those at
high risk of OSA?
The hypotheses (HA) which were evaluated by this study include the following:
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1. There is a portion of those at high risk for OSA that has not been clinically
evaluated.
2. There is a portion of those at high risk for OSA that has not been clinically
diagnosed.
3. There has been an increase in the proportion of prevalent OSA that is
diagnosed clinically compared to the mid-1990s.
4. Among those at high risk for OSA the following characteristics will be more
common among those with a clinical diagnosis of OSA than among those
undiagnosed: age, male gender, higher BMI and higher socioeconomic status.
Thus the null hypotheses (H0) for this study were the following:
1. There is no difference between the population at high risk for OSA and those
that have been clinically evaluated.
2. There is no difference between the population at high risk for OSA and those
that have been clinically diagnosed.
3. There has been no change in the proportion of prevalent OSA that is
diagnosed clinically compared to the mid-1990s.
4. Among those at high risk for OSA there is no difference regarding the
following characteristics among those with a clinical diagnosis of OSA than
among those undiagnosed: age, gender, BMI, and socioeconomic status.
Purpose of the Study
The purpose of this study was to determine if the proportion of OSA that is
clinically recognized had changed since the mid-1990s. Those who are at high risk for
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OSA based on the modified Berlin Questionnaire (Netzer et al., 1999) were identified by
the use of the instrument in the PAVD study (Redfield et al., 2003). Through matching of
this sample with clinical records those with clinically diagnosed OSA will be identified.
Factors predictive of clinical diagnosis were identified.
In this study the independent variables include OSA risk based on the modified
Berlin Questionnaire and demographic variables including age, gender, BMI,
socioeconomic status, and other clinical parameters assessed in the PAVD study. The
dependent variable was the clinical diagnosis of OSA based on a review of clinical
records.
Theoretical Basis
The under recognition of OSA has been partly attributed to limited physician
awareness of the disorder. The clinical diagnostic process has been studied for many
years and has been described as an iterative process of hypothesis generation followed by
deductive hypothesis testing. Together, these processes are referred to as the
hypothetico-deductive strategy (Round, 2001). Theory of hypothesis generation requires
that the diagnostician have some prior knowledge of a disorder in order for that disorder
to be among the diagnostic hypotheses generated (Bockenholt & Weber, 1993; Round,
2001). Simply put, clinicians are unable to diagnose disorders about which they have no
awareness. Thus, if there is increased awareness of OSA among physicians, one would
predict an increased prevalence of clinical recognition.
The theory of diagnostic access bias has been defined as the nonidentification of
patients “because they have no access to diagnostic process” (Choi & Pak, 2000, p. 76).
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In applying this theory to the clinical recognition of OSA, the lack of access to PSG
(which is the primary clinical diagnostic technology for OSA) would be expected to limit
OSA clinical recognition. Therefore the clinical recognition of OSA would be expected
to increase as access to PSG technology increases.
One qualitative study of patients undergoing PSG (van de Mortel, Laird, &
Jarrett, 2000) generated a satisfaction-compliance theory which states “The degree of
satisfaction with the sleep studies experience is to some degree a predictor of
compliance” (p. 167). If sleep centers have been at all successful in pursuing improved
patient satisfaction with PSG since the completion of the original OSA clinical
recognition studies (Kapur et al., 2002; Young, Evans et al., 1997), this theory would
predict increased compliance with completing PSG, and thus a higher prevalence of
clinically recognized PSG.
In summary, a theoretical basis exists relative to (a) physician OSA awareness, (b)
PSG diagnostic access, and (c) satisfaction-compliance theory for increased prevalence of
OSA clinical recognition since its previous assessments based on data collected about 10
years ago.
Operational Definitions
For the purposes of this study operational definitions and acronyms as described
below are used.
Apnea: the termination of airflow at the mouth or nose for 10 seconds or more
(Berry & Foster, 2005).
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AHI: Apnea-hypopnea Index, the total number of apneas and hypopneas
occurring per hour of sleep as quantified by polysomnography (Berry & Foster, 2005).
BMI: Body mass index, an index of obesity calculated as the weight in kilograms
divided by the height in meters squared (Thomas, 1997)
Clinically diagnosed obstructive sleep apnea: a patient whose clinical records
indicate that their healthcare provider had made the diagnosis of sleep apnea typically
based on polysomnography.
Hypopnea: a reduction in thorocoabdominal abdominal respiratory movement or
airflow that is 30% or more less than baseline associated with an oxygen desaturation that
is four per cent or more less than baseline during polysomnography (Meoli et al., 2001)
CPAP: Continuous Positive Airway Pressure, a breathing support device used
primarily at night involving transmission of air pressure produced by a fan through tubing
and a nasal or oro-nasal mask producing a pneumatic airway splint designed to prevent
airway obstruction (Hirshkowitz & Sharafkhaneh, 2005).
OSA: Obstructive Sleep Apnea, a sleep-related breathing disorder in which the
upper airway collapses during sleep producing an obstructed airway. Respiratory efforts
continue despite the obstruction often leading to arousal due to falling oxygen saturation
levels (Berry & Foster, 2005).
OSA Risk: Obstructive Sleep Apnea Risk, in the context of this study OSA risk is
determined based on the Berlin Questionnaire, a previously validated instrument that
classifies respondents in a binary manner as “high” or “low” risk (Netzer et al., 1999).

11
PAVD Study: Prevalence of Asymptomatic Ventricular Dysfunction Study, a
longitudinal population-based study in Olmstead County, Minnesota primarily to assess
the cardiac dysfunction over time that now also includes an assessment of obstructive
sleep apnea risk (Redfield et al., 2003).
PSG: Polysomnography, sleeping overnight in an observational clinical
laboratory with a multichannel monitoring system for brain, eye, and muscle activity,
respiratory efforts, heart rate, and blood oxygen saturation (Chesson et al., 1997).
RDI: Respiratory Disturbance Index, generally equivalent to the AHI, though
some centers use a respiratory effort-related arousal rather than hypopneas to calculate
this index (Berry & Foster, 2005).
Assumptions and Limitations
Several assumptions are inherent in the design of this study. This study used a
modified Berlin Questionnaire (BQ) as the method of identifying those with OSA. High
risk for OSA was used as a proxy for prevalent OSA making the assumption that all of
those identified as at high risk for OSA actually have the disease. The basis for this
assumption is the high positive and negative predictive values for the BQ from the
originally published validation study (Netzer et al., 1999). Further analysis of the BQ,
along with its modification and diagnostic performance in multiple subsequent studies is
provided in the literature review. Thus, it is important to recognize the weakness of this
assumption, namely, that those classified as high risk by the BQ represent all of those
with prevalent OSA. Though the definitive measure of prevalence would be performance
of PSG on the entire sample, such an evaluation with a sample size of over 1400 patients
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would be cost prohibitive. There will be opportunity to assess the diagnostic performance
of the BQ in this sample based on the results of the polysomnography studies done
clinically; however diagnostic performance based on these results will itself be subject to
test verification bias (Roger et al., 1997).
The random selection and longitudinal nature of the PAVD study (Redfield et al.,
2003) that provided the population-based sample for this study requires consideration of
assumptions regarding participation bias and attrition. Participation bias in the original
sample in round one was considered previously with little evidence of impact on overall
results (Jacobsen et al., 2004). A further analysis of round two participation bias is
presented in chapter 4.
The outcome measure for this study was the clinical diagnosis of OSA and thus
will assume consistency of diagnostic criteria and methodology in making that diagnosis.
However, in making the diagnosis of OSA it has been recognized that there is variability
in the gold standard PSG sensors (Redline & Sanders, 1999), the definition of hypopnea
(Tsai, Flemons, Whitelaw, & Remmers, 1999), patient night-to-night variability
(Bittencourt et al., 2001), and inter-rater variation (Loredo, Clausen, Ancoli-Israel, &
Dimsdale, 1999). Some of this variation has been addressed by recently published PSG
scoring criteria (Redline et al., 2007). With the clinical diagnoses for the study coming
from primarily two sleep laboratories involving multiple clinicians over a period of years
there will be variation in the basis for the diagnoses. Chapter 4 presents an analysis of the
clinical diagnosis in relationship to a PSG diagnosis based on AHI alone. Since this
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outcome measure is by its definition a measure of the clinical process of care over time,
this variation is expected and acceptable.
This population-based sample was drawn from the Olmstead County, Minnesota
population in 1997. Olmsted County had been 95.6% Caucasian in 1990, 90.3% in 2000,
and more recently, 88.9% in 2006. In 2000 the Olmsted County adult population (age 18
and over) was 99.1% Caucasian (US Census Bureau, 2007). The sample for this study
having been drawn from those ages 45 and older in 1997 was by self-report 97.9%
Caucasian. This appears representative of the county at the time of sampling. However,
because less than 3% of the sample was non-Caucasian, the results of the study are
interpreted in light of this limited racial diversity.
Significance of the Study
In a recent monograph (Colten & Altevogt, 2006) OSA was identified as a public
health problem by the Institute of Medicine which recommended that there be support for
“additional surveillance and monitoring of sleep patterns and sleep disorders.” (p. 11).
This study measured changes in the clinical recognition of OSA in the past decade during
which time enhanced physician awareness of OSA and improved access to PSG may
have increased the likelihood of clinical recognition. This information is of value to
public health officials and the health care system for allocation and organization of the
systems that evaluate and treat OSA in order to improve health outcomes.
The Pickwickian syndrome, an early term for what is now recognized as OSA,
was epitomized by Fat Joe from Charles Dickens and represents the classic description
characteristics associated with sleep apnea (Conti, Conti, & Gensini, 2006). Indeed
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snoring, obesity, male gender, and age are all considered to be among the risk factors for
the disorder (Young, Peppard et al., 2002). Previous studies evaluating the clinical
recognition of OSA (Kapur et al., 2002; Young, Shahar et al., 2002) have suggested that
these factors, along with socioeconomic status as measured by income and education,
increase the likelihood of clinical recognition. Because this study identified the
characteristics of those both likely to and unlikely to be clinically diagnosed with OSA,
those factors are useful in guiding future strategies for clinical recognition. This study
represents a timely assessment of progress related to OSA clinical diagnosis in the past
decade and provides information useful in (a) guiding future diagnostic strategies,
particularly for those more likely to be previously undiagnosed; and (b) resource
allocation to address OSA as public health problem.
Summary
OSA is a sleep-related breathing disorder that is associated with significant
cardiovascular and cerebral vascular morbidity and mortality. Treatment with CPAP
does attenuate this increased morbidity and mortality, but adherence to CPAP is
challenging and limited. More importantly, most OSA is undiagnosed. Previous research
has shown that no more than 18% of prevalent OSA was clinically diagnosed in the
1990s. OSA along with other sleep-related problems has been identified as public health
problem by the Institute of Medicine.
In the past decade there have been efforts to increase health professional
awareness and PSG diagnostic capacity for OSA. Thus, this study represents a timely
evaluation of the impact of these efforts on OSA clinical diagnosis. In addition, the study
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differentially identifies characteristics of those likely and unlikely to be among those with
clinically diagnosed OSA.
The study identified those at high risk for OSA using the previously validated BQ
in a population based sample from Olmsted County, Minnesota. The sample was
matched with clinical records including PSG to determine the clinical diagnostic rate and
factors that predict having clinically diagnosed OSA.
In chapter 2 a literature review is presented which addresses in greater detail OSA
risk factors, diagnostic considerations, and treatment characteristics. The literature
regarding validation, modification, and performance of the BQ as a screening instrument
for OSA is also be reviewed. Previous research estimating OSA clinical recognition is
evaluated along with factors thought to contribute to under recognition.
The methods used in this study are described in chapter 3. This includes the
population sampling and OSA screening methods used as part of the ongoing PAVD
research. The method of identifying those with clinical PSGs and OSA using the
resources of the Rochester Epidemiology Project (REP) (Melton, 1996) are also
described.
Analyses of the study’s data related to participation bias, validation of the REP
methods for identifying those participants that had undergone PSG and were clinically
recognized with OSA, and analysis of the application of the BQ are presented in chapter
4. The results addressing the four research questions are also presented.
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Finally in chapter 5 these results are interpreted along in light of the study’s
strengths and weaknesses. Based on these results recommendation for action and further
research regarding OSA clinical recognition are made.

CHAPTER 2: LITERATURE REVIEW
Introduction
A review of the literature related to the epidemiology, diagnosis, and treatment of
obstructive sleep apnea (OSA), previous assessments of the prevalence of the clinical
diagnosis OSA, the use of the BQ for assessing OSA risk, and the use of patient clinical
records for epidemiologic research is provided in this chapter.
Organization of the Literature Review
This chapter is organized in a series of five sections designed to systematically
provide readers background necessary for the study’s context, a review of previous
studies of the under diagnosis of OSA, and the nature of the study’s instrument and
methods. A background review of the epidemiology, diagnosis, and treatment of OSA is
provided in the first section of this chapter and is the scientific context for this study’s
analysis of OSA clinical recognition. A critical review of the previous assessments of the
OSA under diagnosis, a description of factors potentially explaining that under diagnosis,
and the changes that have occurred regarding these factors are presented in the second
section. A review of the development, use, and performance characteristics of the BQ as
a tool for identifying those at high risk for OSA is presented in the third section. The a
review of the use of patient clinical records for epidemiologic research, in particular the
structure and resources of the Rochester Epidemiology Project is presented in section
four. Finally a review of the Prevalence of Asymptomatic Ventricular Dysfunction study
(Redfield et al., 2003) which had created the population-based sample in which the
prevalence of clinically recognized OSA was evaluated is presented in the fifth section.

18
Literature Search Strategies
The identification of publications for this review has been carried out through
multiple iterative searches using primarily the MEDLINE database of the National
Library of Medicine (NLM) searched with the proprietary search interface known as the
Ovid Web Gateway™ (Ovid Technologies, Inc., Norwood, MA). In addition, the
EMBASE, CINAHL, and PsycINFO databases were also used for some selected topics.
Most literature regarding OSA was identified from among over 5600 publications
indexed under the NLM’s medical subject heading (MeSH) “Sleep Apnea, Obstructive”
although some searches were expanded to include citations indexed under the MeSH
terms “Sleep Apnea Syndromes” which together include nearly 17,000 citations.
Additional searches using the terms “Continuous Positive Airway Pressure” with over
2200 citations, or “Polysomnography” also with over 10,000 citations were carried out.
In addition, the reference lists from retrieved papers, review articles, and relevant texts
were searched to identify citations not otherwise identified. Papers identified were most
commonly retrieved through the digital resources of the Mayo Clinic Libraries ("Mayo
Clinic Libraries," 2007) including interlibrary loan, with supplementation from the
Walden University Library, and personal subscriptions providing access to the journal
Sleep, and the Journal of Clinical Sleep Medicine. Generally only English language
papers were reviewed, although for selected topics uniquely addressed by German or
Italian papers these were also reviewed. Except for topics related to the historical
development of OSA science, review was largely limited to papers published since 1990.
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Epidemiology, Diagnosis, and Treatment of OSA
Prevalence of Obstructive Sleep Apnea
In the past 27 years there have been at least 27 papers (see Table 1) that have
estimated the prevalence of obstructive sleep apnea in various populations. These studies
have been done in several countries including Italy, Spain, Sweden, Hong Kong, Korea,
India, the United Kingdom, Australia, New Zealand, and Brazil in addition to the United
States. In comparing the reported prevalence from these studies there is substantial
variability with a range from less than 1% (Lavie, 1983) to over 50% in adult, nonelderly,
male populations (Redline, Schluchter, Larkin, & Tishler, 2003). Previous commentators
have suggested that this variability could be attributed to variation in the definition used
for the disorder, study design, sample selection, physiologic parameter measurement
methods, and the day-to-day variability of these sleep parameters (Lindberg & Gislason,
2000; Young, Peppard et al., 2002).
OSA is a chronic condition along a continuum of severity in the symptoms and
physiologic measures used to define the disorder including snoring, hypersomnolence,
sleep fragmentation, apneas, hypopneas, blood oxygen saturation, and sleep arousal.
There are several syndromes described along this continuum including sleep apnea (SA),
obstructive sleep apnea syndrome (OSAS), sleep apnea hypopnea syndrome (SAHS), and
upper airway resistance syndrome (UARS), all of which can be considered to be part of
the global continuum of sleep-related breathing disorders (SBD). For any one of these
syndromes there is considerable variation in the study definition used leading to divergent
reports of prevalence (Lindberg & Gislason, 2000; Young, Peppard et al., 2002).

Table 1
Studies Reporting Population Prevalence of Obstructive Sleep Apnea in Chronological Order
Year
Sleep
First Author
Location
Gender
Age
Study Design
Published
Monitor
Lavie
Berry
Gislason

1983
1986
1988

Israel
Florida
Sweden

Men
Men
Men

≥18
>30
30-70

NP 2-stage
NP 1-stage
PB 2-stage

L-PSG
L-PSG
L-PSG

Cirignotta

1989

Italy

Men

30-70

PB 2-stage

L-PSG

Ancoli-Israel

1991

San Diego

Both

≥65

PB 1-stage

H-PSG

Stradling

1991

United Kingdom

Men

35-65

NP 2-stage

L-PSG

Young

1993

Wisconsin

Both

30-60

PB 2-stage

L-PSG

Redline
Olson
Kripke
Ohayon

1994
1995
1997
1997

Cleveland
Australia
San Diego
United Kingdom

Both
Both
Both
Both

≥16
35-70
40-65
≥15

NP
PB 1-stage
PB 1-stage
PB 1-stage

H-PSG
PulOx+
PulOx
Qust-SE

Bixler

1998

Pennsylvania

Men

≥20

PB 2-stage

L-PSG

Netzer

1999

Cleveland

Both

≥15

NP 2-stage

H-PSG

Bixler

2001

Pennsylvania

Both

≥20

PB 2-stage

L-PSG

Duran

2001

Spain

Both

30-70

PB 2-stage

L-PSG

Young

2002

Multicenter USA

Both

39-99

PB 2-stage

H-PSG

OSA
Criteria
AI≥10
AHI≥5
RD>30
AHI≥5
AHI≥10
AI≥5
RDI≥10
ODI>5
sev. OSA
AHI≥5
AHI≥5 a
RDI≥15
RDI≥15
ODI≥20
ICSD
AHI≥10
AHI≥10a
RDI≥5
RDI≥15
AHI≥15
AHI≥10 a
AHI≥5
AHI≥10
AHI≥10 a
AHI≥15

OSA Prevalence (%)
All
♂
♀
0.9b
13
1.3 b
4.0 b
2.7 b
24
28
20
62
70
56
5
0.3 b
24
9
4
2
26
13
3.6 b
25.9
7.7
9.3
5.2
1.9
3.5
1.5
10.5
3.3
66
38
7.2
2.2
3.9
1.2
26.2
28.0
19.0
14.9
3.4
3.0
25
11
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Netzer

2003

Cleveland

Both

≥15

NP

Qust-B

HR

Year
Published

Location

Gender

Age

Study Design

Sleep
Monitor

OSA
Criteria

Kim

2004

Korea

Both

40-70

PB 2-stage

H-PSG

Udwadlia

2004

India

Men

35-65

PB 2-stage

H-PSG

Roehrs

2006

Detroit

Both

31-40

NP 1-stage

L-PSG

Sharma

2006

India

Both

30-60

PB 2-stage

L-PSG

Hiestand
Reddy
Mihaere
Tufik

2006
2009
2009
2010

continental USA
Delhi, India
New Zealand
Sao Paulo, Brazil

Both
Both
Both
Both

≥18
30-65
30-59
20-80

PB 1-stage
PB 2-stage
PB 1-stage
PB 3-stage

Qust-B
L-PSG
H-PSG
L-PSG

First Author

AHI≥5
AHI≥5 a
AHI≥10
AHI>5
AHI>5 a
RDI≥5
RDI≥10
AHI>5
AHI>5 a
HR
AHI≥5
RDI≥5
AHI≥5 a

32.3

37.9
27.8
(table continues)
OSA Prevalence (%)
All
♂
♀
27.1
16.8
4.5
3.2
18.9
6.7
19.5
7.5
12.5
0.5
5.2
0
13.7
19.7
7.4
3.6
4.9
2.1
26
31
21
9.3
13.5
5.5
12.5
3.4
32.9
40.6
26.1
(table continues)
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Notes.
AHI: Apnea Hypopnea Index calculated as the number of apneas plus the number of hypopneas divided by the number of hours of sleep; AI: Apnea Index calculated
as the number of apneas divided by the number of hours of sleep; H-PSG: Home polysomnography, a portable device recording system that measures a subset of the
typical laboratory polysomnography parameters in the participant’s home without an attendant present with later data scoring; HR: High risk: defined by the BQ
(Netzer et al., 1999); ICSD: International Classification of Sleep Disorders as defined by symptoms in groups A, B, and C (Thorpy, 1990), p. 57); L-PSG:
Laboratory polysomnography, an in laboratory monitoring of a complete montage of sleep and breathing parameters carried out with an attendant and both real-time
and post data collection analysis and scoring; NP: nonpopulation-based sampling design; ODI: oxygen desaturation index, calculated as the number of oxygen
desaturations greater than 4% below baseline divided by the number of hours of sleep; OSA: Obstructive Sleep Apnea; PB: population based sampling design;
PulOx: pulse oximetry monitoring including recording continuous oxygen saturation and audio recording of breathing sounds; PulOx+: pulse oximetry monitoring
recording including continuous oxygen saturation, and audio recording of breath sounds with the addition of chest and abdominal movement sensor recordings
Qust-B: questionnaire evaluation using the BQ (Netzer et al., 1999; "Reprinting of the Berlin Questionnaire," 2000); Qust-SE: questionnaire evaluation using the
computerized Sleep-Eval knowledge based system (Ohayon, Guilleminault, Priest, & Caulet, 1997); RD: the number respiratory disturbances per night without
regard to the number of hours of sleep; RDI: Respiratory Disturbance Index calculated as the number of respiratory disturbances divided by the number of hours of
sleep; sev. OSA: severe OSA as defined by long-term symptoms, and AHI≥20;
a

these criteria require a constellation of daytime symptoms in addition to the minimum required AHI;

b

considered the lower limit of prevalence with the assumption that all OSA in the population was identified in the studied sample.
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As examples of this variability, Lavie’s (1983) early report of the prevalence of
sleep apnea uses the apnea index (AI) which was defined by apneas alone with a criterion
of at least 10 per hour of sleep. In contrast, a later paper by Redline and colleagues
(2003) which reports the highest prevalence, used the respiratory disturbance index (RDI)
which included both apneas and hypopneas with the later defined as a “discrete
reductions in airflow or chest impedance, lasting at least 10 seconds and associated with
at least a 2.5% fall in oxygen saturation” (p. 704). Here the criterion for OSA was at least
five apneas and hypopneas per estimated hour of sleep with no requirement for daytime
symptoms. Thus, the particular syndrome evaluated and the specific criterion used to
define that syndrome impact the reported prevalence of the disorder.
A variety of methods for sample selection and identification of OSA have been
used, often including a two-stage design in which a questionnaire or interview screening
process was used to identify a segment of the population with a high likelihood of sleep
disordered breathing. Then participants in this high risk group are selected (or in some
studies, over-sampled for study along with a sample from the remaining lower risk
portion of the population) to undergo a more definitive evaluation for the actual presence
of a SBD syndrome based on the definition used in the study. Some papers using a multistage method have reported a population prevalence based on a weighting of the
prevalence obtained from high and low risk groups (E.O. Bixler et al., 2001; E.O. Bixler,
Vgontzas, Ten, Tyson, & Kales, 1998; Tufik, Santos-Silva, Taddei, & Bittencourt, 2010).
By contrast, other papers have made the assumption that all those with SBD in the
population are detected by the screening questionnaire and did not definitively study any
participants in the low risk population segment. In recognition that the questionnaires
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used are neither 100% sensitive nor 100% specific, several of these papers have reported
the resulting prevalence as the lower limit of the population prevalence (Duran et al.,
2001; Gislason, Almqvist, Eriksson, Taube, & Boman, 1988; Lavie, 1983; Olson, King,
Hensley, & Saunders, 1995; Stradling & Crosby, 1991).
Though many of these papers have used a population based sampling method with
either a single or two-stage case detection method, other papers have not used populationbased sampling. For example, Redline and colleagues (1994) used a population
consisting of relatives and neighbors of participants with known sleep apnea. Two other
studies (Netzer et al., 2003; Netzer et al., 1999) used a convenience sample of patients
presenting to selected primary care physicians offices. Though the samples resulting from
these methods may have a resemblance to the general population in the areas from which
they are drawn, that resemblance might be considered accidental rather than by design.
Studies have used a variety of testing methods to identify OSA in their sampled
populations. As described in the “Sleep Monitor” column of Table 1, about half of the
studies reviewed here used the clinical gold-standard of polysomnography conducted in
the sleep laboratory monitored by a trained sleep laboratory technician (L-PSG:
laboratory PSG). About one-third of the studies used a type of the less expensive portable
polysomnography carried out in the participants’ homes without the benefit of an
attending sleep laboratory technician (H-PSG: Home PSG). A few studies have also used
detection methods based primarily on oxygen saturation monitoring (Kripke et al., 1997;
Olson et al., 1995) or a purely questionnaire based detection method (Hiestand, Britz,
Goldman, & Phillips, 2006; Netzer et al., 2003; Ohayon et al., 1997). Thus, these varying
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techniques may generally detect those with a syndrome along the SDB continuum, the
exact syndrome, and associated severity reported is variable for these methods.
A number of these studies (E.O. Bixler et al., 2001; Ip et al., 2001; Kim et al.,
2004; Sharma, Kumpawat, Banga, & Goel, 2006; Udwadia, Doshi, Lonkar, & Singh,
2004; Young et al., 1993) have reported population prevalence using a particular AHI or
RDI criterion both with and without regard to daytime symptoms for the particular AHI
criterion. In all of these studies the symptomatic prevalence is much lower, ranging from
about one sixth to one half of the prevalence when daytime symptoms are not included in
the criteria.
The inclusion of a daytime symptom requirement in the research diagnostic
criteria for OSA by the American Academy of Sleep Medicine Task Force (Flemons et
al., 1999) was suggested as an “operational definition” (p. 670) but it was recognized that
there were no studies validating this criterion. There is evidence that adverse long-term
outcomes result from SDB regardless of the presence of daytime symptoms. The two
largest OSA prevalence cohorts (Young et al., 1993; Young, Shahar et al., 2002) have
demonstrated increased risk of hypertension for those with mild OSA without regard to
daytime symptoms (Nieto et al., 2000; Young, Peppard et al., 1997). Another large study
(E. O. Bixler et al., 2000) demonstrated associations of SDB with hypertension even for
those with AHI<5, again without regard for daytime symptoms. There is also evidence
that those with mild SDB and no pathologic sleepiness demonstrate reduced AHI (a
measure of OSA severity) and improved mood, functional status, general health, and
energy with standard CPAP treatment for OSA (Redline et al., 1998).
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Daytime sleepiness is associated with increased OSA severity as demonstrated in
the large Sleep Heart Health Study where the Epworth Sleepiness Scale (ESS) showed a
statistically significant correlation with RDI severity (Gottlieb et al., 1999). In addition,
sleepiness has been found to be predictive of diminished cardiac output even when OSA
severity, as measured by RDI, was held constant (J. B. Choi et al., 2006). Thus, daytime
sleepiness appears to be a marker of OSA disease severity, though as a binary marker,
sleepiness seems to be a poor criterion for the presence or absence of OSA.
Analysis of the varying prevalence demonstrated in Table 1 shows that if one
considers studies with population based samples that used an AHI or RDI criterion of
greater than or equal to five without a daytime sleepiness requirement eight of the ten
such studies (Ancoli-Israel et al., 1991; Cirignotta et al., 1989; Duran et al., 2001; Ip et
al., 2001; Kim et al., 2004; Mihaere et al., 2009; Reddy et al., 2009; Sharma, Kumpawat
et al., 2006; Udwadia et al., 2004; Young et al., 1993) report a rather consistent male
OSA prevalence of 12.5% – 28%. The two papers among these eight that substantially
deviate from this population prevalence include one which selected for PSG study only
40 every-night snorers with the assumption that all those with OSA snore (Cirignotta et
al., 1989). The remaining study (Ip et al., 2001) made a similar conservative assumption
that there was no OSA among those who did not undergo PSG. Thus, these two studies
(Cirignotta et al., 1989; Ip et al., 2001) used analytic methods that would under-report
OSA.
The six other population based studies in Table 1 include those that used criteria
involving either AHI cut-off values of 10 or more (E.O. Bixler et al., 2001; E.O. Bixler et
al., 1998; Young, Shahar et al., 2002), or were based other indexes including oxygen
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desaturation index (ODI) (Kripke et al., 1997) and total respiratory disturbances during
the night (RD) (Gislason et al., 1988). Thus, these studies might be expected to underrepresent the OSA prevalence that would be expected based on an AHI cut-off of 5.
Despite these differences one of these studies reports a male OSA prevalence of 25.9%
(Olson et al., 1995), similar to the range noted previously. Thus, it seems that a
population prevalence estimate of 19 – 25% for OSA in males using an AHI greater than
or equal to 5 without a daytime sleepiness requirement represents a rather consistent
estimate across these studies.
Reviews of the gender prevalence of OSA and SDB have suggested that the male
to female ratio is in the range of 1.5 – 3:1 (Jordan & McEvoy, 2003; Kapsimalis &
Kryger, 2002). Similar to the male analysis described above, there are six population
based studies that report a female prevalence using an AHI or RDI greater than or equal
to five without a daytime sleepiness requirement (Ancoli-Israel et al., 1991; Duran et al.,
2001; Kim et al., 2004; Sharma, Kumpawat et al., 2006; Young et al., 1993; Young,
Shahar et al., 2002). These studies show male to female ratios that range from 0.9 –
2.7:1 with the one study showing a greater prevalence for females compared to males
having been conducted in Spain (Duran et al., 2001). For the other population based
studies that report prevalence for both genders using other OSA criteria, the male to
female ratios range from 1.8 – 3.4:1 (E.O. Bixler et al., 2001; Kripke et al., 1997; Olson
et al., 1995). Though the origins of these differences are not well established, there is the
suggestion that women may less commonly present with classical symptoms leading to
relatively greater under-recognition (Jordan & McEvoy, 2003; Kapsimalis & Kryger,
2002; Young, Hutton, Finn, Badr, & Palta, 1996).
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OSA Symptoms and Risk Factors
The most common symptom associated with OSA is snoring which has been
found in as many as 97% of those with OSA (Whyte, Allen, Jeffrey, Gould, & Douglas,
1989). Among men with OSA about 85% report habitual snoring defined as snoring at
least three nights per week (Flemons, Whitelaw, Brant, & Remmers, 1994; Rowley,
Aboussouan, & Badr, 2000), and about 90% of those with OSA having at least some
snoring regardless of gender (Rowley et al., 2000). However, some reports acknowledge
that snoring is not present in significant portions of some populations with OSA such as a
Danish study which found that 48% women and 19% of men with OSA did not report
snoring (Jennum & Sjol, 1992).
In the general adult population 59% report snoring (Hiestand et al., 2006) and in
other studies 25 - 28% and 44 - 46% of women and men, respectively, report habitual
snoring (Duran et al., 2001; Young et al., 1993). These two population-based studies
demonstrated an independent association between snoring and OSA with the odds ratios
for sleep apnea that range from 2.87 to 4.72 with habitual snoring after adjusting for age,
gender, race, BMI, neck girth, and waist to hip ratio in a multicenter American population
(Young, Shahar et al., 2002), and age and gender in a Spanish population (Duran et al.,
2001), respectively. Often those with OSA report such severe, disruptive snoring that it
can be considered socially isolating even within a marital relationship (Cartwright &
Knight, 1987). Thus, snoring is a common and sometimes isolating symptom of OSA.
However, it is neither a necessary or sufficient condition for the presence of OSA and is
conversely also quite common in the general population without OSA.
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Excessive sleepiness is the most common daytime symptom among those with
OSA (Engleman & Douglas, 2004). It too is a relatively common symptom in the general
population with 26% reporting that they wake up feeling tired or fatigued (Hiestand et al.,
2006). As a subjective symptom, sleepiness is better characterized and often measured
with a descriptive tool such as the Epworth Sleepiness Scale (ESS) (Johns, 1991; Kirsch
& Chervin, 2007). When sleepiness was originally measured among those with OSA
using the ESS the score correlated with the severity of OSA based on RDI (Johns, 1991).
This relationship between OSA severity and sleepiness as defined by the ESS was also
demonstrated in a large population-based study, the Sleep Heart Health Study (Gottlieb et
al., 1999). However, it is important to note that nearly two-thirds of those with severe
OSA (AHI>30) do not meet the ESS criteria for excessive daytime sleepiness (ESS
score>10) (Gottlieb et al., 1999).
Obesity has long been associated with OSA as illustrated by the prototypical case
of sleep apnea, Joe, the Fat Boy, from Charles Dickens (Conti et al., 2006). Of the
studies reviewed in Table 1 above, all 20 of the studies that considered obesity as a
covariate for either presence or severity of OSA found an association. The remaining
studies (Gislason et al., 1988; Lavie, 1983; Roehrs, Kapke, Roth, & Breslau, 2006) did
not present an analysis of obesity as an OSA covariate. Some reviewers (Young, Peppard
et al., 2002) have suggested that there is “little controversy that the associations seen in
observational studies represent a causal role of excess weight in OSA” (p. 1228).
In the multicenter Sleep Heart Health Study a one standard deviation difference
(5.3 kg/m2) in Body Mass Index (BMI) increased the odds of OSA by about 55% when
age, gender, race, and snoring were held constant (Young, Shahar et al., 2002). In
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addition, a longitudinal weight increase of 10% is associated with a 32% increase in OSA
severity as measured by the apnea-hypopnea index, whereas a 10% reduction in weight
reduces OSA severity by 26% (Peppard, Young, Palta, Dempsey, & Skatrud, 2000).
Thus, though difficult to achieve, weight loss can be effective in treating OSA (Veasey et
al., 2006).
Male gender has been considered an OSA risk factor. OSA is generally two to
three times more common among men than women (Strohl & Redline, 1996). In the two
large population based studies of OSA prevalence male to female gender ratios ranged
from 1.67:1 (Baldwin et al., 2001) to 3.7:1 (Young et al., 1993) depending on the severity
criteria used to define OSA. Among sleep clinic populations the male predominance
was much greater with reviewers citing ratios of 5-8:1 (Jordan & McEvoy, 2003) to as
high as 90:1 (Strohl & Redline, 1996). This suggests that men are more likely to be
referred for sleep clinic evaluation possibly because they have more severe disease and
more classic symptoms (Jordan & McEvoy, 2003; Shepertycky, Banno, & Kryger, 2005;
Strohl & Redline, 1996).
OSA Clinical Diagnosis
Historically polysomnography (PSG) has been the recommended technique for
the clinical diagnosis of OSA (Chesson et al., 1997; Schlosshan & Elliott, 2004; P. L.
Smith et al., 1994). This technique involves the placement of multiple electrodes, probes,
and belts to monitor neurological, respiratory, cardiovascular, and other physiologic
parameters during sleep. It is typically carried out in a hospital-like setting with a sleep
technician present to supervise and monitor the recording of these multiple parameters
(Berry, Geyer, & Carney, 2005; Bloch, 1997; Chesson et al., 1997; Schlosshan & Elliott,
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2004). Thereafter the PSG recording is interpreted by a physician to formulate an
interpretation and clinical diagnosis.
Accepted OSA diagnostic criteria (Flemons et al., 1999) include both subjective
symptoms and objectively measured obstructive events during sleep. Obstructive sleep
events occurring at a rate of least 15 per hour of sleep (AHI ≥ 15), regardless of
subjective symptoms, meets these criteria for OSA, as does an AHI of five or more, but
less that 15, with subjective symptoms such as excessive daytime sleepiness, choking or
recurrent sleep awakenings, unrefreshing sleep, daytime fatigue or impaired
concentration. OSA severity is graded based on AHI with 5 – 15 classified as mild
whereas 15 – 30, and >30 being considered moderate and severe, respectively.
Though full, attended polysomnography is the primary OSA diagnostic method,
other unattended testing methods with fewer recorded physiologic parameters (Collop et
al., 2007; Ghegan, Angelos, Stonebraker, & Gillespie, 2006; Littner, 2005) and
alternative clinical diagnostic strategies have been considered (Brietzke, Katz, &
Roberson, 2004; Mulgrew, Fox, Ayas, & Ryan, 2007; Senn, Brack, Russi, & Bloch,
2006). The unattended diagnostic devices and methods have been classified as Levels II
to IV based on the number and type of physiologic sleep parameters monitored during the
study; full, attended PSG is then designated a Level I study (Littner, 2005). Clinical
guidelines developed by the American Academy of Sleep Medicine recommend that
these unattended techniques only be used in the context of a comprehensive patient
evaluation system in populations where the sensitivity and specificity of the method is
known (Collop et al., 2007).
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Among the other diagnostic strategies has been a clinical medical history and
physical exam. This strategy has proven to be ineffective with a low sensitivity and
specificity even when performed by expert clinicians (Brietzke et al., 2004; Viner, Szalai,
& Hoffstein, 1991). More recently a diagnostic algorithm combined with a therapeutic
trial of CPAP and follow up overnight oximetry (a Level IV unattended monitoring) was
shown to be as effective as full PSG in making the diagnosis in a population with high
OSA prevalence. The study suggested that with this strategy treatment adherence was
improved compared to standard methods (Mulgrew et al., 2007).
Recently a coverage determination by the Centers for Medicare and Medicaid
may allow reimbursement OSA treatment with CPAP when the OSA has been diagnosed
using Level II to IV unattended diagnostic methods. (Phurrough, Jacques, Spencer,
Stiller, & Brechner, 2008) Historically CPAP was reimbursed only when OSA was
diagnosed using full PSG. Thus, it is possible that the clinical diagnosis of OSA will in
the future be more commonly made in some settings using unattended diagnostic
methods. Thus, the assessment of the prevalence of clinically recognized OSA in the first
decade of the 21st century would be a timely and useful benchmark for comparison to the
previous assessments in the 1990s (Kapur et al., 2002; Young, Evans et al., 1997) prior to
potential change in diagnostic methods used for the future.
OSA Treatment
There have been multiple treatment modalities employed for OSA. Weight loss
by dietary restriction has been demonstrated to reduce the severity of OSA and associated
hypertension (Kansanen et al., 1998; Suratt, McTier, Findely, Pohl, & Wilhoit, 1992).
However, the maintenance of weight loss is difficult in the long term, and OSA does
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recur even in those that are able to maintain a reduced weight (Sampol et al., 1998).
Though more than 20 different drugs have been tested for the treatment of OSA, in
clinical trials none have been proven effective (I. Smith, Lasserson, & Wright, 2006).
Several surgical and mechanical treatments have, however, been demonstrated to
be effective. A surgical tracheostomy which places a permanent opening in the airway
below the area of airway obstruction in OSA was among the first treatments shown to be
effective in the long-term (Guilleminault et al., 1981). Other surgical procedures used for
OSA involve modifications to both soft tissue and boney structures (Colin & Duval,
2005). A 1996 systematic review of the success of surgical OSA treatment found success
rates no higher than 50% (Sher, Schechtman, & Piccirillo, 1996). Subsequently the
surgical approaches have used staging systems (Friedman, Ibrahim, & Joseph, 2004; Li,
Powell, Riley, Troell, & Guilleminault, 1999) that attempt to more directly tailor the
surgical procedure(s) to the OSA patient’s specific anatomy. With such staging there has
been improved success rates in the 70 – 80% range for some OSA anatomical types
(Friedman & Schalch, 2007).
Oral and dental appliances are devices that move the mandible anteriorly or retain
protrusion of the tongue during sleep (Chan, Lee, & Cistulli, 2007). There is some
variability in the definition of treatment success in the oral appliance literature. However,
for mild to moderate OSA there is overall a 52% success rate (Ferguson, Cartwright,
Rogers, & Schmidt-Nowara, 2006). Controlled trials have demonstrated that these
appliances are generally inferior to continuous positive airway pressure treatment (Lim,
Lasserson, Fleetham, & Wright, 2006).
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Continuous positive airway pressure (CPAP) is considered to be first-line therapy
for those with moderate to severe OSA, especially those that have symptomatic daytime
sleepiness (Giles et al., 2006; Kushida et al., 2006). CPAP devices use airflow generated
by a fan and applied to the patient’s airway by way of tubing and a nasal or oronasal
mask to maintain the patency of the airway during sleep. Thus, CPAP functionally
represents a pneumatic splint that prevents OSA-related airway obstruction (Hirshkowitz
& Sharafkhaneh, 2005).
There have been two recent comprehensive literature reviews (Gay et al., 2006;
Weaver & Chasens, 2007) of studies of CPAP therapy efficacy for OSA in adults.
Combined these two reviews considered a total of 34 published studies that met the
quality criteria regarding relevance and study design for the respective review. Of these
studies a wide variety of study end points were used including AHI reduction, improved
sleep architecture, reduction in daytime sleepiness and other OSA-related symptoms,
improved neurobehavioral symptoms, functional status, quality of life, blood pressure,
cardiac function, coagulation factors, cholesterol, and nocturia (Gay et al., 2006; Weaver
& Chasens, 2007).
Collectively in these two reviews (Gay et al., 2006; Weaver & Chasens, 2007) a
total of 28 of the 34 papers demonstrated some beneficial effect for CPAP with OSA with
respect to at least one of the endpoints studied. These studies included variable study
designs, disease severities, ages, treatment, and endpoint definitions. Endpoints involving
daytime sleepiness, snoring, gasping, cognitive processing, memory, executive function,
motor speed, and nonverbal learning variably demonstrated improvement in one or more
studies. When studied in populations with moderate and severe OSA (defined as an AHI
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greater than 15 with daytime sleepiness) the following endpoints demonstrated more
consistent improvement with CPAP: AHI, sleep architecture, blood pressure, cardiac
contractility, stroke volume, vascular resistance, and platelet coagulability (Gay et al.,
2006; Weaver & Chasens, 2007).
Gay and colleagues (2006) found that eight studies that had reported no
improvement for the endpoints considered did not report a power analysis estimating the
probability of Type II error for these negative results. Of the additional six negative
studies (Barbe et al., 2001; Henke, Grady, & Kuna, 2001; Kajaste, Brander, Telakivi,
Partinen, & Mustajoki, 2004; Robinson, Pepperell, Segal, Davies, & Stradling, 2004;
Robinson, Smith, Langford, Davies, & Stradling, 2006) included in the later review
(Weaver & Chasens, 2007) only one reported a power analysis (Robinson et al., 2006).
That study (Robinson et al., 2006) used a power analysis based on detection of a 5
mm of Hg blood pressure reduction with CPAP. However, from the cardiovascular
literature, a meta-analysis of 29 studies involving more than 150,000 patients a
population mean blood pressure reduction as small as two mm of Hg produced
statistically significant reduction in risk for stroke and cardiovascular disease (Turnbull,
2003). So the study by Robinson and colleagues (2006) may not have been sufficiently
powered to detect the smaller blood pressure changes that other studies have shown to be
associated with cardiovascular risk reduction. Therefore, these 14 negative studies
generally may not have been of sufficient size to avoid Type II errors in evaluating
physiologic endpoints.
Indeed two subsequent meta-analyses specific to the effect of CPAP on blood
pressure (BP) in randomized controlled clinical trials, indicate that mean BP is reduced
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about 1.7 mm Hg based on 572 participants (Haentjens et al., 2007) whereas systolic BP
is reduced about 2.5 mm Hg based on 818 participants (Bazzano, Khan, Reynolds, & He,
2007). An additional small study (Hui et al., 2006) not included in these meta-analyses
demonstrated a reduction in 24 hour mean BP of 3.8 mm Hg. Thus, the identification and
treatment of those with OSA is associated with a population BP reduction of a magnitude
that has produced a reduction of stroke and cardiovascular risk in pharmacologic
treatment studies.
The benefits of CPAP treatment in those with moderate to severe OSA including
daytime symptoms has been well established and accepted (Gay et al., 2006; Weaver &
Chasens, 2007) even by those taking a conservative position regarding CPAP treatment
in OSA (Montserrat, Barbe, & Rodenstein, 2002; Wright & Sheldon, 2000). Whether to
treat mild to moderate OSA, and those without daytime symptoms has been much more
controversial having been the topic of two point-counterpoint pairs of editorials in the
sleep literature (Davies & Stradling, 2000; Levy, Pepin, & McNicholas, 2002; Montserrat
et al., 2002; Wright & Sheldon, 2000).
A recent meta-regression of randomized controlled trials of CPAP demonstrated
that, across the spectrum of OSA severity, the reduction in blood pressure with CPAP
though larger with a higher AHI, approaches zero with a pre-treatment AHI between 10
and 20 (Haentjens et al., 2007, Figure 3A, p. 762). In reviewing randomized studies of
CPAP treatment restricted to those with mild to moderate disease Gay and colleagues
(2006) report that CPAP did reduce AHI, did not improve objective sleepiness or blood
pressure, and had mixed results for subjective sleepiness, and quality of life. However, a
later meta-analysis (Marshall et al., 2006) that included one additional study (Marshall,
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Neill, Campbell, & Sheppard, 2005) not available to Gay and colleagues (2006) that was
able to demonstrate collectively a statistically significant improvement in both subjective
sleepiness by the Epworth Sleepiness Scale, and objectively with the Maintenance of
Wakefulness Test. In this analysis (Marshall et al., 2006) a significant improvement with
the Multiple Sleep Latency Test was not found. Thus, though the treatment effect is
smaller, and thus more difficult to detect without larger samples or pooled data, there
does appear to some benefit to CPAP treatment of mild to moderate OSA.
Research regarding efficacy of CPAP has been challenging in the selection of an
adequate control for the CPAP treatment (Babar & Quan, 2003; Hein, 2002; Wright,
Johns, Watt, Melville, & Sheldon, 1997). In the review by Weaver and Chasens (2006)
eight of the 26 controlled trials reviewed used a placebo tablet, and four used
conservative measures such as a low calorie diet and behavioral therapy, whereas 12
studies used subtherapeutic or sham CPAP as the control. Subtherapeutic or sham CPAP
involves the participants’ use of a CPAP machine that is either set to provide a pressure
so low that it should be ineffective, or with a CPAP system modified to prevent it from
delivering a therapeutic pressure (Farre et al., 1999). Not surprisingly there is evidence
from research with acupuncture that there is a differential placebo effect between sham
devices and tablet placebos (Kaptchuk et al., 2006). There has also been controversy
regarding the ethics of the deception associated with the use of sham CPAP and other
placebos in CPAP research (Karlawish & Pack, 2001). Thus, it seems there is no ideal
placebo control for the evaluation of CPAP efficacy, and this research must be interpreted
in light of these limitations.
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Overall, CPAP treatment effects have been most consistently beneficial in those
with moderate to severe disease with symptoms of daytime sleepiness (Gay et al., 2006;
Weaver & Chasens, 2007). However, as described in the analysis of Table 1 above there
is evidence that those with mild sleep disordered breathing even without daytime
sleepiness are also at increased risk of hypertension, a known cardiovascular risk factor
(E. O. Bixler et al., 2000; Nieto et al., 2000; Young et al., 1993; Young, Peppard et al.,
1997; Young, Peppard et al., 2002). Because the evidence from controlled trials, albeit
some underpowered studies, has not demonstrated a clear benefit from CPAP treatment
in mild OSA without daytime symptoms, treatment with CPAP in this population remains
controversial (Gay et al., 2006; Hedner & Grote, 2001; Levy et al., 2002; Weaver et al.,
2007).
The ability to adhere to prescribed CPAP therapy among those with OSA has
been limited and variable. A classic study (Kribbs et al., 1993) had demonstrated that
only 46% were able maintain use of CPAP at ≥4 hours per night. A recent review of the
CPAP adherence literature (Weaver & Grunstein, 2008) using a standard of at least 4
hours of CPAP application per night, found a wide range of adherence from 17 – 71%.
This review suggested that OSA disease severity, as measured by AHI and level of night
time hypoxia, were only weak predictors of adherence. Technological CPAP innovations
such various mask interfaces, heated humidification, and automatic pressure titration or
bilevel positive airway pressure devices have been shown to only minimally enhance
adherence (Haniffa, Lasserson, & Smith, 2004; Weaver & Grunstein, 2008) despite the
fact that many of these innovations have often been marketed for improved adherence
(Weaver & Grunstein, 2008). Other adherence enhancement interventions involving
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cognitive behavioral therapy have demonstrated an increase in the average number of
hours used nightly by 1.5 (Hoy, Vennelle, Kingshott, Engleman, & Douglas, 1999) to 2.9
hours (Richards et al., 2007). Thus, it is likely that clinical optimization of adherence
will require a multidimensional program involving device technical support and, more
importantly, cognitive behavioral support (Engleman & Wild, 2003).
Limited Clinical Recognition of OSA
Historically most people with OSA have been clinically undiagnosed. Among the
earliest reports was a published letter from British physicians (Apps, Gillon, & Stradling,
1983) suggesting that the disorder was under diagnosed in the United Kingdom relative
to America. Then, based on hospital discharge diagnostic code data from 1985 to 1987, it
was reported that only 36 from the database of about ten million discharges were found to
reference OSA (Dement, 1993; Strohl & Redline, 1996). If the OSA population
prevalence in this mixed gender population is postulated to be about 3% based on a
population based study initiated in 1988 (Young et al., 1993) and making the assumption
of an approximately equal gender mix among these hospital discharges, there would have
been about 300,000 participants with OSA in this cohort. Thus, the 36 diagnostic
references to OSA among these discharge diagnoses might suggest a very low prevalence
of clinical diagnosis at about 0.012%.
Given that OSA is generally managed in the outpatient setting there is some
weakness in assessing clinical OSA recognition from such an inpatient database.
However, in a diagnostic review of outpatient charts for ten northern California primary
care clinics in 1991 there was no mention of an OSA diagnosis for any of the participants
in the nonpopulation-based sample (Strohl & Redline, 1996). Thus, though recognizing
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the weaknesses of these early assessments of OSA clinical recognition, it appears that as
recently as 1991 OSA was very infrequently identified by the clinical care system.
Population-based studies of OSA clinical recognition
There have been two systematic population-based studies conducted using data
collected in the 1990s that have assessed the clinical recognition of OSA (Kapur et al.,
2002; Young, Evans et al., 1997). The earlier of these two studies (Young, Evans et al.,
1997) was based on data from the Wisconsin Sleep Cohort (Young et al., 1993) and
identified participants clinically diagnosed with OSA based on their indication on a
mailed survey that they had been told by a physician that they had sleep apnea. From the
4925 who responded to the survey, positive responses were received from 49 participants.
Telephone follow up of those respondents showed that only 16 had actually been
clinically diagnosed whereas nearly all of the others had only personally suspected OSA
but had never been clinically evaluated. These 16 participants represented 15.4% of those
ultimately identified with moderate to severe OSA, and 6.5% of those identified with the
broader spectrum of mild to severe OSA based on the study’s screening and
polysomnography methods. When stratified by gender it was estimated that only 7% and
18% of women and men, respectively, with moderate to severe OSA, and 2% and 10%,
respectively, with mild to severe OSA had been diagnosed. A demographic comparison
of those diagnosed clinically and those identified by study screening showed that only
male gender and age statistically predicted clinical diagnosis. In addition, there was a
trend toward a history of hypertension or cardiovascular disease and higher income
among those diagnosed clinically (Young, Evans et al., 1997).
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This study (Young, Evans et al., 1997) has a number of strengths including its
population-based sample, two stage screening with both high risk and low risk
participants undergoing PSG, diagnosis of OSA based on in laboratory rather than in
home PSG, and confirmation of survey reports of physician OSA diagnosis. Among the
weaknesses are the truncated age range that involved no patients over age 60, the fact that
only positive responses to the physician diagnosis survey question were confirmed, and
the lack of medical record verification of physician diagnoses. Overall, within these
limitations the study appears well done.
The later study (Kapur et al., 2002) was based on data from the multicenter Sleep
Heart Health Study (Quan et al., 1997) which included a total of nearly 16,000
participants. Those clinically diagnosed with OSA were identified based on their positive
response to question “Have you ever been told by a physician that you have sleep
apnea?” (Kapur et al.,2002, p. 50). The study’s screening for prevalent OSA was based
on participants’ response to survey questions regarding frequency of snoring and
excessive daytime sleepiness. Participants that reported snoring three or more nights per
week and feeling excessively sleepy more than five days per month were identified as
being “consistent with a higher probability” (Kapur et al.,2002, p. 50) of OSA,
particularly those with moderate to severe OSA.
By survey responses 253 participants reported having a physician diagnosis of
OSA with 90 of these under treatment whereas 650 participants met the proxy criteria for
OSA. Of the 650 participants meeting the OSA proxy criteria, 54 or 8.3% reported
physician diagnosis. Demographic analysis of these participant groups demonstrated that
the following factors were statistically more common among those at risk for moderate to
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severe OSA who reported being diagnosed and treated for OSA: male gender, body mass
index, hypertension, lower HDl cholesterol, and being a college graduate. In a logistic
regression model using these factors only male gender and body mass index remained
statistically significant.
In their analysis of these results Kapur and colleagues (2002) noted that OSA
prevalence using this proxy criteria was 4.1% which was comparable to that in a previous
population based sample (Young et al., 1993). However, among the 10 sites involved in
the study the prevalence varied from 1.55% to 7.23% with prevalence of physician
diagnosed, and physician diagnosed and treated OSA showing comparable inter-site
variation albeit at much lower prevalence rates. The authors also noted that some in the
physician diagnosed, and physician diagnosed and treated groups did not meet the study’s
OSA proxy criteria. These OSA proxy criteria were not validated as a part of the study
nor were they specifically validated as OSA proxy criteria in any of the references cited
in support of these criteria (Bradley et al., 1998; Newman et al., 2001; Strohl & Redline,
1996). Rather, these references identified these criteria as important risk factors, among
others, for OSA. Therefore the sensitivity, specificity, and other performance
characteristics of the proxy criteria used for OSA in the study are unknown.
From the nearly 16,000 participants in the study (Kapur et al., 2002) some 6400
were elsewhere reported to have undergone in home polysomnography (Shahar et al.,
2001). Thus, an opportunity existed for validating the proxy criteria in the same sample,
or alternatively, the study could have been performed using home polysomnography as
the basis for OSA diagnosis. The study’s methods (Kapur et al., 2002) also did not
attempt to verify survey respondents’ reports of physician OSA diagnosis and treatment,
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though it did acknowledge the resulting possibility of misclassification. Based on the
earlier study (Young, Evans et al., 1997) where only 33% of those reporting a physician
diagnosis of OSA were confirmed, it is unfortunate that this study did not attempt to
validate, even a portion of these positive responses.
In comparing these two studies (Kapur et al., 2002; Young, Evans et al., 1997),
the point prevalences reported for clinically recognized moderate to severe OSA are
generally compatible with Kapur and colleagues (2002) having reported 8.3% whereas
Young and colleagues (1997) had reported 7% and 18% in women and men, respectively,
and 15.4% overall. Though the larger sample size represents a strength of the Kapur
(2002) study, with the lack of validation for the study’s method of identifying OSA, and
lack of confirmation for any of the participant reported physician OSA diagnoses, it
seems that this study has less credibility relative to the early study (Young, Evans et al.,
1997).
There have been two more recent nonpopulation-based studies that analyzed OSA
clinical recognition (Brown et al., 2009; Warmouth et al., 2008). The first, presented in
abstract form (Warmouth et al., 2008), involved a sample of patients undergoing
preoperative assessment for surgery that found 159 participants from a sample of 2614
had been previously diagnosed with OSA. Of the remaining participants that completed
OSA screening using the BQ (n = 2316) there were 671 (29%) who were identified as
high risk for OSA. A total of 830 participants were identified with OSA or at high risk for
OSA by either clinical report or the BQ, respectively. Thus, the prevalence of clinical
recognition for this group of 830 participants from a nonpopulation-based sample was
19.2%.
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The second study (Brown et al., 2009) conducted as an online survey of
professional orchestra players identified 348 (31%) participants as being high-risk for
OSA based on the BQ in a mixed gender sample. Of these, 66, representing 19.1% of
those with BQ identified OSA, had been clinically recognized based on participant selfreport.
The prevalence of clinically recognized OSA reported by these two studies is
similar to that reported in the population-based sample by Young and colleagues (1997)
for men, but higher than that reported for women by Young and colleagues (1997) and in
a gender mixed population by Kapur (2002).
In summary, in population based studies there is very limited clinical recognition
of moderate to severe OSA with a range from 7-18% for women and men, respectively,
with the most recent credible study having been conducted in the mid-1990s.
Analysis of the OSA under-recognition problem
A report from the National Commission on Sleep Disorders Research (Dement,
1993) suggested that some 70 million Americans suffered from a spectrum of sleep
disorders including OSA that had consequences including “reduced productivity, lowered
cognitive performance, increased likelihood of accidents, higher morbidity and mortality
risk, and decreased quality of life” (p. vi). The Commission estimated that in 1990 the
associated direct sleep-related costs totaled more than $15.9 billion with billions of
additional indirect costs related to accidents and diminished productivity. The report’s
analysis (Dement, 1993) suggested that general public ignorance and a lack of health
professional education regarding sleep-related disease were among the factors
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responsible for the failure of American society “to recognize and attend effectively to
sleep-related issues” (p. vi).
Limited physician awareness of OSA has long been identified as one of the
explanations for the limited clinical recognition of OSA. Among the earliest published
reports of limited physician awareness of OSA came from a national sample of the
American Geriatrics Society (Haponik, 1992). This telephone survey of 45 physicians
conducted in 1990 demonstrated that, though 73% of the physicians surveyed believed
sleep problems were an important part of their practice, none identified sleep apnea an
important cause of their patients’ sleep disturbances. A decade earlier a study of medical
school curricula had demonstrated that 93% of American medical schools provided no
instruction in sleep disorders (Orr, Stahl, Dement, & Reddington, 1980), probably at least
in part, accounting for this lack of awareness.
By 1988 informal surveys suggested increased medical school instruction and a
curricular outline was provided to guide further developments (Dement et al., 1988). The
increase in sleep curricula was documented with the 1993 publication of a survey of 126
medical schools (R. C. Rosen, Rosekind, Rosevear, Cole, & Dement, 1993). This survey
demonstrated an average of about two hours of total instructional time in the preclinical
and clinical curricula, but 29.4% of medical schools continued to have no structured sleep
and sleep disorders curriculum.
A systematic study of outpatient clinical diagnoses from a nationally
representative practice sample demonstrated a 12-fold increase in the number of OSA
diagnoses made over the nine year time period from 1990 to 1998 (Namen et al., 2002).
This increase occurred while the diagnosis of common disorders such as hypertension
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and upper respiratory tract infection, and less common sleep disorders such as narcolepsy
and parasomnias, all remained essentially constant. The sampling frame of this study did
not allow assessment of the prevalence of clinically recognized OSA. The study found
over this time period a statistically significant correlation of increasing OSA diagnoses
with increases in the number of OSA publications in the medical literature and the
number of accredited diagnostic sleep laboratories. Namen and colleagues (2002)
concluded that their observations suggested “a positive response on the part of healthcare providers to the prevalence and morbidity” (p. 1747) of OSA.
Two reports have assessed physician awareness of sleep disorders. The first
conducted in late 1999 and early 2000 reported on a survey and knowledge assessment of
primary care physicians in northeastern Ohio (Papp et al., 2002). Ninety per cent of
respondents agreed that OSA was potentially life-threatening, and 84% indicated it was a
common problem. However, in the 33 item multiple choice sleep knowledge assessment,
the mean number of correct items was 12. This may suggest an increased awareness of
OSA compared to that demonstrated by Haponik in 1992, though Papp and colleagues
(2002) concluded that there was “a low rate of expertise” (p. 105).
The second study (Reuveni et al., 2004) was conducted in Israel and included no
graduates of medical schools in the United States. This study used a very different
method incorporating a standardized patient into the practices of randomly selected
primary care physicians consenting to the study. The standardized patients reported
suffering from “fatigue, reduction in work efficiency and a general reduction in mental
function” (p. 1524) and reported having recently been involved in an automobile crash
(Reuveni et al., 2004). The physician participants were then allowed to ask as many
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questions as they felt appropriate. Of the five questions identified by sleep experts as
important questions for this patient presentation only 10% of the primary care physician
sample asked three or more, 30% only asked one while 50% of the physicians failed to
ask any of the identified questions. In knowledge assessment questions following the
standardized patient interview, 87% recognized that polysomnography was needed in the
diagnosis of OSA, and 90% recognized that CPAP was useful in its treatment (Reuveni et
al., 2004). Thus, though these physicians clinical acumen for recognizing probable OSA
in their practice was quite limited, a large majority did have a basic knowledge of
strategies for OSA diagnosis and treatment.
Other studies have also demonstrated that instructional interventions for physician
can enhance their clinical recognition of OSA. In a study of primary care physicians and
medical interns, among those that had received training in sleep disorders 82% obtained a
sleep history in standardized patient encounters whereas only 13% of untrained interns
and none of the primary care physicians obtained this history (Haponik et al., 1996).
A more comprehensive intervention in Walla Walla, Washington involved the
education of physicians, along with education of the general public and the development
of a local sleep testing laboratory (Ball et al., 1997). This intervention let to an increase in
evaluation by PSG from 0.27% to 2.1% of adult patients. Of the 360 patients that
underwent PSG in the project, 276 (77%) were found to have OSA. Of the 214 patients
for whom CPAP was prescribed and whose CPAP usage status could be assessed, only
22% had returned their CPAP machine one to three years after testing. The authors (Ball
et al., 1997) concluded that community physicians can identify and care for a much larger
portion of those with OSA if provided education and support.

48
Finally, an educational intervention for medical residents and attending physicians
regarding sleep disorders that extended over a four year period demonstrated an increase
in the annual referral rate for PSG from 0.06% to 0.21% of active patients (Zozula et al.,
2005). However, the prevalence of clinical recognition only increased from 0.11% to
0.26% of active patients. Among the factors that were identified as barriers to clinical
recognition in the study were the fact that 48% of those referred for PSG failed to
complete the study, and that 16% of the PSGs completed did not have a report available
to the patients’ physicians thus limiting the opportunity for implementation of treatment.
It seems clear that physician awareness of sleep disorders such as OSA has
contributed to the lack of clinical recognition of OSA, and that instruction regarding sleep
disorders does increase the rate of clinical recognition by physicians.
Patient access to sleep laboratories and sleep specialists has also been identified as
a factor contributing to the low rate of clinical recognition of OSA (Flemons et al., 2004;
Morgenthaler et al., 2006). The first of these reports (Flemons et al., 2004) presents an
international analysis of the availability of sleep laboratories and PSG in the United
States, United Kingdom, Belgium, Canada, and Australia. That analysis found waiting
times for polysomnography ranged from two to sixty months, and that the number of
PSGs performed relative to the population varied five-fold across these countries. The
authors (Flemons et al., 2004) predict that in order to diagnose and manage currently
undiagnosed OSA (based on Young, Evans et al., 1997) over a 10-year period based on
the prevalence of only moderate to severe OSA (based on Young et al., 1993) an
additional 555 PSGs per 100,000 population would be required each year. In addition,
with the 600 PSGs per 100,000 required for new, incident cases, and if, on average, 50%
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of diagnostic PSGs are positive, the authors project the need for a total of 2310 PSGs per
100,000. In 2003 this demand exceeded the capacity in the United States by a factor of
5.4 and in the United Kingdom by a factor of 54, and fails to account for PSGs needed for
any other type of sleep disorder. Thus, despite a 12-fold increase in the number of OSA
diagnoses made in the 1990s, and a doubling of the number of accredited sleep
laboratories (Namen et al., 2002) Flemons and colleagues (2004) projected a need to
further increase the number of PSGs performed by more than 5-fold.
An analysis at one large institution’s sleep center demonstrated that sleep referrals
from within the institution exceeded capacity by nearly 100% (Morgenthaler et al., 2006).
In response, that institution developed an alternative evaluation method reducing the
physician time spend by 50% in order to increase capacity and found that patient
outcomes and satisfaction were maintained relative to standard evaluation methods.
Subsequently this alternative process was adopted as the standard at the sleep center
(Morgenthaler et al., 2006).
In studies of PSG utilization a wide variability has been found across both the
United States and Australia in the number of PSGs performed for the population
(Marshall et al., 2007; Tachibana, Ayas, & White, 2005). The American study
(Tachibana et al., 2005), based on a survey of accredited sleep laboratories found that
there were on average about 427 PSGs performed per 100,000 population on an annual
basis. However, by state this rate varied by nearly 10-fold from 121 in Colorado, to 1161
in Maryland. Thus, it would appear that availability of PSG varies substantially across the
United States. A similar variability in the PSGs performed for the population has been
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noted in Australia where the overall number of PSGs per 100,000 population has
increased by about 150% from 1995 to 2004 (Marshall et al., 2007).
In addition to increasing access to sleep laboratories and specialists,
commentators (Banno & Kryger, 2004; Pack, 2004; Tarasiuk & Reuveni, 2004) have
proposed a number of other strategies to increase access to OSA diagnosis including the
use of home PSG, overnight oximetry recordings, and symptom scoring algorithms. Two
recent trials have initiated CPAP treatment without prior diagnostic PSG (Mulgrew et al.,
2007; Senn et al., 2006). The first study used clinical improvement with CPAP as a proxy
diagnosis of OSA among participants referred for evaluation of possible OSA (Senn et
al., 2006). In this study response to CPAP at 2 weeks had positive and negative
predictive values for PSG confirmed OSA of 97% and 78%, respectively. Of those with
OSA identified by CPAP response, 94% then had a successful and sustained response to
CPAP treatment at four months (Senn et al., 2006).
In the second study, a randomized clinical trial, CPAP treatment was initiated for
presumed OSA among those with a pre-treatment probability of OSA of at least 95% and
compared to traditional diagnostic PSG followed by CPAP treatment (Mulgrew et al.,
2007). The study demonstrated similar CPAP effectiveness with and without diagnostic
PSG, and improved CPAP adherence among those treated without initial PSG (Mulgrew
et al., 2007).
Access to PSG has been a factor limiting the clinical recognition of OSA and
probably continues to remain a limitation. However, in the past 15 years there has been
an increase in the access to PSG and there are under development a number of alternative
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diagnostic and treatment strategies for OSA that are less reliant on PSG for diagnosis of
OSA.
Because laboratory PSGs are expensive and somewhat intrusive, the very nature
of the diagnostic evaluation has been a factor identified as contributing to the limited
prevalence of clinical recognition of OSA (Colten & Altevogt, 2006). The fact that one
must spend one or more nights away from home in order to be evaluated in the sleep
laboratory is particularly problematic for those with responsibility for the care of family
members (Colten & Altevogt, 2006). In addition, there is the suggestion from one
qualitative study that the challenges associated with the process of diagnosis ultimately
had a negative impact on patients’ interest and ability to adhere to therapy following
diagnosis (van de Mortel et al., 2000).
In summary the following factors have been identified as contributing to the
limited prevalence of clinical recognition of OSA: (a) limited OSA awareness by
physicians, (b) limited access to sleep laboratories and specialists, and (c) the expensive
and intrusive nature of laboratory-based PSG. There is evidence that to some extent there
have been improvements with regard to several of these factors with enhanced physician
education related to OSA, increased access to sleep studies laboratories, and the
development of diagnostic technologies less dependent on PSG. Thus, it is reasonable to
hypothesize that the prevalence of clinically recognized OSA has increased since the
1990s.
The Berlin Questionnaire
The Berlin Questionnaire is an eleven item instrument that was developed in 1996
by consensus at the Conference on Sleep in Primary Care in Berlin, Germany (Netzer et
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al., 1999). The questions were chosen to identify characteristics that placed participants
at high risk for OSA in the areas of snoring, daytime sleepiness, hypertension, and
obesity. The instrument’s scoring algorithm places participants in one of two categories,
high or low risk, for OSA. The instrument was initially validated in consecutive patients
seen for any reason in the practices of five internal medicine physicians in the Cleveland,
Ohio area (Netzer et al., 1999).
Of the 1008 BQs distributed for this initial report 744 were completed and
included in that analysis. The validation study invited the 75 participants placed by the
instrument at high risk, and the 65 participants placed at low risk, to under go in-home,
unattended PSG. Participants for PSG were selected from alphabetically ordered lists and
were visited in their homes for instruction regarding use of the PSG device. Ultimately
100 participants completed PSG with scorable studies including 69 of the 75 from the
high risk group and 31 of 65 in the low risk group. The PSGs were scored by a single
researcher who was blinded to the results of the questionnaire (Netzer et al., 1999).
The initial publication of the validation study reported sensitivities for OSA based
on RDI criteria of >5, >15, and >30 as being 0.86, 0.54, and 0.17, respectively.
Specificities at these same RDI levels were reported as 0.77, 0.97, and 0.97, respectively.
The positive predictive value (PPV) for OSA at an RDI >5 was reported as 0.89.
However, a subsequent letter to the editor raised questions about these calculations
(Strauss & Browner, 2000). Based on the published validation data from Netzer and
colleagues’ original paper (1999) sensitivities, specificities, positive and negative
predictive values (PPV and NPV) are recalculated using standard methods (Weiss, 2008)
in Table 2.
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Table 2
BQ Performance Measures Calculated From Data Published in Netzer, et al (1999)
BQ Performance Measures
RDI
criterion
for OSA

RDI > 5

OSA
positive
by PSG

OSA
negative
by PSG

Total

High Risk

59

10

69

Low Risk

7

24

31

66

34

100

High Risk

37

32

69

Low Risk

1

30

31

38

62

100

High Risk

12

57

69

Low Risk

1

30

31

13

87

100

BQ Result

Total
RDI >
15

Total
RDI >
30

Total

Sensitivity

Specificity

PPV

NPV

59/66 =
0.894

24/34 =
0.706

59/69 =
0.855

24/31 =
0.774

37/38 =
0.974

30/62 =
0.484

37/69 =
0.536

30/31 =
0.968

12/13 =
0.923

30/87 =
0.345

12/69 =
0.174

30/31 =
0.968

Thus, based on this re-calculation of these performance measures for OSA with
an RDI severity of greater than five and including no daytime sleepiness requirement the
BQ demonstrated a sensitivity of 89.4%, specificity of 70.6%, positive predictive value of
85.5%, and a negative predictive value of 77.4%. Note that this level of severity is similar
to that which rather consistently demonstrated a population prevalence of 19 – 25% for
adult men in the analysis of Table 1 above.
The questionnaire consists of 11 questions grouped in three categories
("Reprinting of the Berlin Questionnaire," 2000). Most of the questions are answered
using a series of responses on an ordinal frequency or severity scale. Based on
participants’ responses to the questions in each category that category is scored as either
positive or negative. If least two of the three categories are positive the participant is
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considered to be at “high risk” for OSA, whereas the participant is considered to be at
“low risk” if less than two categories are positive. Table 2 below enumerates the
categories and items.
The initial publication (Netzer et al., 1999) of the BQ provided a general
description of the scoring algorithm to be used for the questionnaire but without
sufficient detail to establish a specific scoring algorithm. Subsequently the questionnaire
with more detailed scoring algorithms was published (Dement & Netzer, 2000).
Unfortunately there were a number of errors in this more detailed publication of the
algorithm that were later corrected ("Reprinting of the Berlin Questionnaire," 2000).
Probably in part because the publication of this later correction was not indexed in the
journal’s table of contents, or in the medical indexes, multiple scoring methods have been
described by those that subsequently used the instrument.
These scoring methods have included some deviation from that original questions
used by Netzer and colleagues (1999) and scoring method as subsequently published
("Reprinting of the Berlin Questionnaire," 2000). Among the deviations are the
following:
1. When the instrument was reviewed by legal counsel prior to its application in
atrial fibrillation and cardiology patients (Gami et al., 2004) concern was
expressed regarding the vicarious liability associated with documenting that
participants nodded off while driving (A.S. Gami, personal communication,
July 17, 2007). Thus, items 8 and 9 (Table 3) regarding drowsy driving were
not included in the questionnaire used in this study. Similarly in another study
(West, Nicoll, & Stradling, 2006) these items were excluded because the item
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appeared to be answered inaccurately in pilot studies, and was a deterrent to
participation.
2. The original questionnaire ("Reprinting of the Berlin Questionnaire," 2000),
in addition to a the binary question regarding drowsy driving (Table 3, item
8), included a follow up question regarding frequency (Table 3, item 9). At
least four investigators (Chung et al., 2008; Gibbs, 2006; Leveque, Yu,
Musch, Chervin, & Zacks, 2007; Singh, Drake, Roehrs, Hudgel, & Roth,
2005) have omitted this follow up question and/or its associated scoring.
3. Two investigators (Tasali, Van Cauter, & Ehrmann, 2006; Ybarra, Planas, &
Pou, 2008) studying populations with near universal obesity, and a very high
prevalence of hypertension excluded responses for Category 3 in their scoring.
4. One investigator, recognizing that driving a vehicle was rare in the population
and culture being studied, introduced three alternative daytime sleepiness
items regarding sleepiness while waiting for a doctor appointment, in line to
pay a bill, and while watching television (Sharma, Vasudev et al., 2006). In
addition, this investigator used a BMI cutoff of 25 rather than 30 as was
described originally.
5. An additional question in Category 3 regarding a “very small jaw or a large
overbite” (p. 2339) was added by one investigator (H. Singh et al., 2005).
6. One investigator (Leveque et al., 2007) scored positive responses to item 5
(Table 3) as one point rather than two as originally described.
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Thus, though the basic structure of the BQ and its scoring has been consistent
across its application in over 50 publications in the past decade, there have been multiple,
generally subtle, variations in the questions and scoring algorithm used.
Table 3 highlights some of these BQ scoring algorithm variations relevant to the
present study. Included are the original instrument and algorithm used by Netzer and
colleagues (1999), the algorithm used by Gami (2004) which represented a pilot
application of the instrument for the present investigation in our institution, the most
recent detailed publication of a complete scoring algorithm (Gibbs, 2006), along with the
algorithm used in the present study (labeled PAVD for Prevalence of Asymptomatic
Ventricular Dysfunction.
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Table 3
Berlin Questionnaire Items and Scoring Algorithm
Question
Category 1: Snoring

Responses

1. Do you snore?

Yes
No/Don’t know
2. If you snore, your snoring
Slightly louder than breathing
is:
As loud as talking
Louder than talking
Very loud, heard in adjacent
rooms
3. How often do you snore?
Nearly every day
3 to 4 nights per week
1 to 2 nights per week
1 to 2 nights per month
Never or nearly never/don’t
know
4. Has you snoring ever
Yes
bothered other people?
No/Don’t know
5. Has anyone noticed that
Nearly every day
you quit breathing during
3 to 4 times a week
sleep?
1 to 2 times a week
1 to 2 times a month
Never or nearly never/don’t
know/refused
Category 2: Daytime fatigue and sleepiness
6. How often do you feel
tired or fatigued after your
sleep?

7. During your waketime, do
you feel tired, fatigued or
not up to par?

8. Have you ever nodded off
or fallen asleep while
driving a vehicle?
9. If so, how often does it
occur?

Nearly every day
3 to 4 times a week
1 to 2 times a week
1 to 2 times a month
Never or nearly never/don’t
know/refused
Nearly every day
3 to 4 times a week
1 to 2 times a week
1 to 2 times a month
Never or nearly never/don’t
know/refused
Yes
No
Nearly every day
3 to 4 times a week
1 to 2 times a week
1 to 2 times a month
Never or nearly never/don’t
know/refused

Points scored for the response based on
identified scoring algorithm
Netzer
Gami
Gibbs
PAVD
Positive if ≥2 points scored for the
following items:
1
0
1
1
0
0
0
0
0
0
1
1

0
0
1
1

0
0
1
1

0
0
1
1

1
1
0
0
0

1
1
0
0
0

1
1
0
0
0

1
1
0
0
0

1
0
2
2
0
0
0

1
0
2
2
0
0
0

1
0
2
2
0
0
0

1
0
2
2
0
0
0

Positive if ≥2 points scored for the
following items:
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
0
0
1
0
1
1
0
0
0

1
1
0
0
0
Not
scored

Not
scored

1
1
0
0
0
1
0

Not
scored

1
1
0
0
0
Not
scored

Not
scored

(table continues)
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Question
Responses
Category 3: Hypertension and Obesity

Points scored for the response based on
identified scoring algorithm
Netzer
Gami
Gibbs
PAVD
Positive if ≥1 point scored for the
following items:
1
1
1
1
0
0
0
0
1
1
1
1
0
0
0
0

10.Do you have a high blood
Yes
pressure?
No/Don’t know
>30
11.Body Mass Index (BMI):
≤30
weight (kg)/height (m)2
Overall Classification:
Participant classified as High Risk if two or more Categories are positive, Low Risk if less than two are
positive.
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As mentioned above, since its original publication the BQ has been used as an
OSA ascertainment instrument in 53 additional research publications. As depicted in
Figure 1, most of these publications have occurred in the five years from 2006 through
2010. The instrument has been used in a wide variety of settings (see Table 4), with the
instrument’s high risk classification having been used as a proxy for OSA in many of
these publications. There has also been one published abstract that did not lead to a
complete published paper that included PSG validation data (Steinel, Shaman, &
Auckley, 2007) that is also included in Table 4. Though most papers have not validated
the instrument as part of its application to that study population, thirteen publications
subsequent to the instrument’s initial publication that do report a study population
validation analysis (Ahmadi, Chung, Gibbs, & Shapiro, 2008; Chung et al., 2008; Drager
et al., 2010; Friedman et al., 2010; Gami et al., 2004; Gus et al., 2008; Olivarez et al.,
2010; Rasmin, 2006; Sharma, Vasudev et al., 2006; Tang et al., 2009; Weinreich, Plein,
Teschler, Resler, & Teschler, 2006; West et al., 2006). In addition, among the 32
published abstracts that reported using the BQ as a research instrument ("Sleep Abstract
Supplements," 2008) there was one published abstract (Steinel et al., 2007) that did not
lead to publication of a full, peer reviewed paper that used a PSG-based method to
validate the BQ in a bariatric surgery population.
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Table 4
Research Publications Using the BQ for OSA Risk Assessment Listed Chronologically
1st Author
Netzer

Year
1999

Netzer

2003

Calhoun
Gami
Moreno
Gassino
Mustafa
PrincipeRodriguez
Singh
Chen
Hiestand
Moreno

2004
2004
2004
2005
2005

Location
Cleveland
USA, Germany
& Spain
Alabama
Minnesota
Brazil
Italy
Cleveland

2005

Cleveland

2005
2006
2006
2006

Winnipeg
Taiwan
US
Brazil

Padeletti

2006

Italy

Rasmin
Sharma
Tasali
Vignatelli
Weinreich
West
Chung
Koch
Leveque
Molnar
Steinel
Ahmadi
Auckley
BaHammam
Banabilh
Chung
Daccarett
Gus
Oliven
Palma
Soleo
Ybarra
Adewole
Alexandrov
BaHammam
Blondet
Brown
Chilukuri
Facco

2006
2006
2006
2006
2006
2006
2007
2007
2007
2007
2007
2008
2008
2008
2008
2008
2008
2008
2008
2008
2008
2008
2009
2009
2009
2009
2009
2009
2009

Indonesia
India
Chicago
Italy
Germany
United Kingdom
Canada
Miami
Michigan
Budapest
Cleveland
Toronto
Cleveland
Saudi Arabia
Malaysia
Toronto
Salt Lake City
Brazil
Israel
Alabama
Italy
Spain
Nigeria
Alabama
Saudi Arabia
Puerto Rico
USA, Puerto Rico
Baltimore
Chicago

Description
Initial validation study of BQ.
Descriptive analysis of OSA symptoms & risk factors in primary care
population
Evaluated association of OSA & aldosterone in resistant hypertension.
Evaluated association of afiba with OSA, included PSG BQ validation.
Evaluated risk of OSA among Brazilian truck drivers.
Evaluated association of oral anatomy with OSA and depression.
Assessed prevalence of OSA and other sleep disorders by survey.
Assessed prevalence of OSA & other sleep disorders by survey instruments
including the BQ.
Prevalence & association of OSA with nonalcoholic fatty liver disease.
Analysis of OSA prevalence among those on chronic hemodialysis.
Evaluated OSA by BQ in national population by telephone survey.
Analysis regarding OSA in truck drivers, data from Moreno et al., 2004.
Evaluated afiba association with OSA in those with pacemakers for
bradycardia.
BQ validation with portable PSG monitoring in pilot study of 15.
Validation study of BQ modified for Indian culture.
OSA association with glucose tolerance in polycystic ovarian syndrome.
Prevalence of sleepiness, sleep quality and OSA in frontal lobe epilepsy.
Validation of BQ in a population undergoing pulmonary rehabilitation.
Prevalence of OSA by BQ for type 2 diabetic men, PSG validation.
Prevalence of OSA in a population undergoing elective surgery.
Association of OSA by BQ with ischemic stroke.
Association of OSA with central serous chorioretinopathy.
Compares OSA by BQ in hemodialysis and kidney transplant populations.
Evaluated use of BQ among bariatric surgery candidates.
Validation of BQ in a sleep clinic population.
Comparison of OSA by BQ in asthmatic& general medicine populations.
Determined prevalence of high risk by BQ for primary care males.
Evaluated BQ association with cephalometrics in children age 7-15.
Validation of BQ, Anesthesia questionnaires in pre-surgical population
OSA by BQ in daytime bradyarrhthmias and a control population
Analysis of OSA in resistant hypertension, PSG based validation study.
Evaluated association of airway closing pressures with OSA by BQ.
BQ used to exclude OSA in study of hepatopulmonary syndrome.
Assessed OSA prevalence by BQ & risk factor for cement workers.
Association of OSA with ventricular dysfunction in obese females.
Assessed OSA prevalence by BQ among two hospitals’ employees.
Assessed association of OSA with blood flow steal in acute stroke.
Determined prevalence of high risk by BQ for primary care females.
Assessed OSA prevalence by BQ with risk factor analysis.
Assessed OSA prevalence & recognition in professional musicians.
BQ-based OSA used as predictor for failure after afiba ablation.
BQ & other sleep questionnaires used longitudinally during pregnancy.
(table continues)
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1st Author
Kapsimalis
Khassawneh
Khiani
Lemos
Taj
Tang
Ybarra
Drager
Enciso
Fraser

Year
2009
2009
2009
2009
2009
2009
2009
2010
2010
2010

Location
USA
Jordan
USA
Brazil
Pakistan
Beijing, China
Spain
Brazil
California
Chicago, Atlanta

Friedman

2010

Chicago

Olivarez
2010
Sabry
2010
a
afib: atrial fibrillation

Houston
Egypt

Description
Modified BQ used to assess prevalence of OSA in national sleep poll.
Assess OSA prevalence by BQ among primary care patients.
Assessed risk of hypoxia with endoscopy for BQ-defined OSA patients.
BQ used for ascertainment of OSA in truck drivers.
Assessed BQ defined OSA prevalence for public health professionals.
Association of OSA by BQ with afiba recurrence after catheter ablation.
Evaluated correlations with BQ defined OSA in obese females.
Analysis of BQ, Epworth & metabolic syndrome in hypertensive patients.
Using BQ & airway dimensions to predict OSA in case-control study.
OSA risk assessment in men with idiopathic intracranial hypertension.
BQ & other OSA screening instruments combined & validated in sleep
clinic population.
Validation of BQ by PSG in 100 hospitalized pregnant females.
Assessed sleep disorders in hemodialysis & chronic kidney disease.
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Among these thirteen publications and the one abstract that included a validation
analysis there has been a range of reported sensitivities from 35 – 100% and specificities
ranging from 20 – 95%. Table 5 collates these studies and the associated sensitivities,
specificities, positive and negative predictive values from the validation analyses.
Together these studies have used a variety of diagnostic criteria to define OSA. Five
studies (Ahmadi et al., 2008; Chung et al., 2008; Netzer et al., 1999; Steinel et al., 2007;
Weinreich et al., 2006) have done the validation analysis using multiple severity criteria
with indexes (AHI or RDI) ranging from greater than five to greater than 30. The size of
these studies varies ranging from 15 participants (Rasmin, 2006) to more than 200
(Friedman et al., 2010; West et al., 2006).
Data published in these studies and one abstract allow the pooling of the results
from the studies that used a similar index (AHI or RDI) and criteria to define OSA. This
pooled analysis of sensitivity, specificity, PPV, and NPV is an estimates of these test
performance characteristics based on a larger number of patients than any of the
individual studies. For example, for an index >5 a total of 1038 participants are included
in the pooled analysis. Table 6 details this pooled analysis along with the 95%
confidence intervals for the resulting sensitivities, specificities, PPVs, and NPVs, and the
median value for these measures from the studies that contributed to each pooled
analysis. This analysis demonstrates that the BQ varies in its ability to predict different
levels of OSA severity across the spectrum of sleep disordered breathing.

Table 5
Studies and Abstracts Reporting BQ Validation Analyses with Sensitivity, Specificity, PPV, NPV, and Study Size
First
Year
OSA
Population Studied
Sensitivity Specificity
PPV
NPV
n
Author
Published
Criteria
RDI>5
0.89
0.71
0.86
0.77
Primary care
Netzer
1999
100
RDI>15
0.97
0.48
0.54
0.97
patients
RDI>30
0.92
0.35
0.17
0.97
Cardiology
AHI>5 &
Gami
2004
0.86
0.89
0.97
0.60
44
patients
symptoms
Pulmonary patients
AHI>5 &
Rasmin
2006
0.78
0.33
0.78
0.33
15
with suspected OSA
symptoms
Medical patients
Sharma
2006
AHI>5
0.86
0.95
0.96
0.82
104
with an OSA symptom
Pulmonary
RDI>10
0.63
0.54
0.38
0.74
Weinreich
2006
153
rehabilitation
RDI>15
0.67
0.53
0.25
0.85
Male type 2
ODI>10 &
0.75
0.54
0.27
0.91
238
West
2006
diabetes mellitus
+ PSGa
AHI>5
0.83
0.20
0.93
0.08
Steinel
2007
Bariatric surgery candidates
75
AHI>15
0.86
0.22
0.70
0.42
RDI>5
0.68
0.49
0.50
0.67
Patients referred to psychiatry
Ahmadi
2008
130
RDI>10
0.62
0.43
0.28
0.76
based sleep clinic
RDI>15
0.57
0.41
0.21
0.78
AHI>5
0.69
0.56
0.78
0.45
Preoperative patients for elective
Chung
2008
177
AHI>15
0.79
0.51
0.51
0.78
surgery
AHI>30
0.87
0.46
0.32
0.93
Patients with resistant and
Gus
2008
AHI>10
0.86
0.65
0.75
0.79
126
controlled hypertension
Recurrence of atrial fibrillation
Tang
2009
AHI>5
1.00
0.30
0.74
1.00
30
after catheter ablation
Friedman
2010
Sleep clinic patients
AHI>5
0.62
0.23
0.67
0.18
223
Drager
2010
Hypertensive adults
AHI>5
0.93
0.80
0.75
0.56
99
Oliverez
2010
Hospitalized pregnant women
AHI>5
0.35
0.64
0.19
0.64
100
a
This study validated the BQ with a two-stage process requiring an ODI>10 by overnight oximetry before undergoing full PSG. The
criteria for OSA on PSG were not published.
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Table 6
BQ Summary Performance Measures for Validation Studies Pooled by Severity Criteria
Sensitivity

Specificity

PPV

NPV

0.74

0.57

0.72

0.59

(0.71-0.77)

(0.54-0.60)

(0.69-0.75)

(0.56-0.62)

Median

0.83

0.56

0.75

0.64

Pooled value

0.84

0.75

0.93

0.55

(0.75-0.94)

(0.63-0.86

(0.86-1.00)

(0.42-0.68)

Median

0.79

0.51

0.78

0.60

Pooled value

0.75

0.54

0.51

0.77

(0.71-0.78)

(0.50-0.58)

(0.47-0.55)

(0.73-0.80)

Median

0.75

0.50

0.35

0.78

Pooled value

0.73

0.42

0.36

0.78

(0.69-0.78)

(0.37-0.48)

(0.31-0.41)

(0.74-0.82)

Median

0.79

0.48

0.51

0.78

Pooled value

0.88

0.42

0.26

0.94

(0.85-0.92)

(0.48-0.36)

(0.21-0.31)

(0.91-0.97)

0.90

0.41

0.25

0.95

Pooled value
AHI or RDI>5 without
regard to symptoms

AHI or RDI>5 with
daytime symptoms

AHI or RDI>10 without
regard to symptoms

AHI or RDI>15 without
regard to symptoms

AHI or RDI>30 without
regard to symptoms

(95% CI)

(95% CI)

(95% CI)

(95% CI)

(95% CI)
Median

Total n

Studies included

1038

Ahmadi, Chung,
Drager, Friedman,
Netzer, Oliverez,
Sharma, Steinel, Tang

56

Gami, Rasmin

566

Ahmadi, Chung, Gus,
Weinreich

357

Ahmadi, Netzer,
Steinel, Weinreich

277

Netzer, Chung

65
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To assess which level of severity is best predicted by the BQ several
characteristics can be considered, (a) likelihood ratios (LR), both positive and negative (R
Jaeschke, G. Guyatt, & J. Lijmer, 2002); (b) the Youden J statistic (Youden, 1950); and
(c) the diagnostic odds ratio (Deeks, 2001). The diagnostic odds ratio (DOR) is a single
summary measure of diagnostic performance that combines measures of sensitivity,
specificity, positive and negative likelihood ratios (Deeks, 2001). Higher diagnostic odds
ratios, positive likelihood ratios, lower negative likelihood ratios and a larger Youden’s J
statistic are indicative of stronger diagnostic performance (Deeks, 2001; R. Jaeschke, G.
Guyatt, & J. Lijmer, 2002; Youden, 1950). Thus, as depicted in Table 7 below, the BQ
best predicts OSA with an AHI > 5 with daytime symptoms. However, given the
relatively small number of participants (n = 56) contributing to this measure, and the
resulting wide confidence interval, the questionnaire also performs favorably in
predicting OSA with an AHI>5 without regard to symptoms. This later level of severity
without a daytime sleepiness requirement again was the one considered in the OSA
population prevalence analysis of Table 1 above.
Table 7
BQ Diagnostic Performance at Different Levels of OSA Severity
OSA Severity

LR +

LR -

DOR

Youden’s J (95% CI)

AHI or RDI>5 without regard to symptoms

1.72

0.46

3.75

0.31 (0.25 – 0.37)

AHI or RDI>5 with daytime symptoms

3.31

0.21

15.73

0.59 (0.46 – 0.73)

AHI or RDI>10 without regard to symptoms

1.62

0.47

3.46

0.29 (0.25 – 0.33)

AHI or RDI>15 without regard to symptoms

1.41

0.47

2.99

0.23 (0.19 – 0.27)

AHI or RDI>30 without regard to symptoms

1.52

0.28

5.53

0.30 (0.26 – 0.43)
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In summary, the BQ, first published in 1999, is an instrument designed to identify
OSA risk based on tabulation and scoring of symptoms related to snoring and daytime
sleepiness along with the presence of hypertension and obesity. The instrument has been
used in 53 original studies including fourteen that included validation of the instrument
against a PSG based gold standard. There has been subtle variability in the questions and
scoring algorithm for the instrument, though the structure of the instrument has been
generally consistent. The instrument’s diagnostic performance has also been variable. As
one might expect for an instrument based on OSA symptoms, it performs best in
predicting OSA with day-time symptoms, and not as well for OSA without a daytime
sleepiness criteria. For the range of severity without daytime symptoms, the BQ performs
best for mild OSA with an AHI (or RDI) greater than five.
A Population-based Laboratory: The Rochester Epidemiology Project
Kessler and Levin (1970) suggest that the epidemiologic study of a community as
a population-based laboratory began with the very founding of epidemiology as a science
in the sanitary surveys of the 19th century by Chadwick and Shattuck, respectively. They
(Kessler & Levin, 1970) argue that the most persuasive reasons for choosing a
community for epidemiologic study are “pragmatic and administrative” (p. 8). The
Rochester Epidemiology Project (REP) is one such population-based laboratory that has
developed because of several local circumstances, some going back to the late 19th and
early 20th centuries. In this study, the REP provided a unique opportunity to use clinical
record systems in a population-based study.
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When Dr. William W. Mayo, established his practice in Rochester in the 1860s
Rochester was a frontier center of commerce in southern Minnesota but was rather
isolated from the growing Minneapolis and St. Paul area about 90 miles away and other
developing health care centers (Clapesattle, 1990). As that practice grew from a
partnership of a few physicians to a multi-specialty group practice a single medical
record for each patient that would be shared by all of the group’s physicians was
developed by Dr. Henry Plummer in 1907 (Kurland & Molgaard, 1981). In order to
facilitate research and teaching Plummer and his secretary, Mabel Root, developed record
index systems based on (a) diagnoses by organ system, and (b) surgical procedures which
were known as the Plummer-Root indexes. As diagnostic techniques and pathogenic
understanding improved, in the 1930s Dr. Joseph Berkson developed a revised diagnostic
coding system combined with an early Hollerith punch card automated indexing and
sorting technology that became known as the Berkson file (Berkson, 1936). This coding
system was used until 1974 when a modified Hospital Adaptation of the International
Classification of Diseases, second edition (H-ICDA-2) coding system, originally
published by the World Health Organization, was adopted (Kurland & Molgaard, 1981).
As a unified multispecialty medical practice with a single record for each patient
documenting all care provided, the systematic indexing of these records by diagnosis and
surgical procedures created a substantial opportunity for clinical and epidemiologic
research.
The relative isolation of Rochester from other larger medical centers, and with the
presence of virtually every specialty and subspecialty within the Mayo Clinic, the people
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of Olmstead County where Rochester is located have little need to seek care from a
spectrum of providers across a broad, potentially multi-state region; rather they are able
to obtain nearly all of their care locally (Melton, 1996). There are several providers of
care in Olmstead County outside of Mayo Clinic, most notably the Olmstead Medical
Center which developed in the 1950s ("Learn about OMC: Our history," 2008) and now
includes over 150 providers (Yawn, 2008). In addition there are a handful of other private
practitioners, several nursing homes, governmentally provided public health services, and
Veteran’s Administration system in the region. Thus, in 1966 what would become the
Mayo Department of Health Science Research, in partnership with these other Olmstead
County and regional healthcare providers, received National Institutes of Health funding
to support the collection, archiving, and medical record linkage for records from all of
these health care institutions, and the vital records for the county (Erickson, Pankratz,
Schrage, & Stotz, 2007; Melton, 1996). Through 2004 this record linkage system has
supported the publication of more than 1500 clinical and epidemiologic research papers
(Rocca & Yawn, 2008). With this comprehensive record linkage system and a nearly
century long record system archive, the REP is a unique laboratory in which to do
longitudinal population-based epidemiology research (Melton, 1996).
The REP uses a probabilistic method to assign records from multiple sources to a
single master REP identification number along with all records later received for that
participant. This probabilistic method utilizes the following demographic information:
last name, first name, middle name, suffix, gender, birth date, social security number, and
geographic residency. Hand matching of individual records is used when missing
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demographic information makes probabilistic matching impossible. As of 2008 about
1.53 million records from 50 different sources have been matched to 788,130 unique
patients (J. St. Sauver, personal communication, October 8, 2008).
To assess the reliability of the system a random sample stratified by age of 400
REP participants was manually examined to identify records incorrectly linked to these
individuals and to identify any additional records that should have been linked to these
participants. The REP system had matched a total of 1333 records to these 400
participants with 2.5% (95% Confidence interval: 1.2 – 4.6%) of these individuals having
incorrectly matched records. In addition, 1.3% (95% Confidence interval: 0.4 – 2.9%) of
these participants appeared to have additional records that should have been matched (J.
St. Sauver, personal communication, October 8, 2008).
Together, these data suggest that the REP computer matching algorithms perform
extremely well in correctly identifying and linking medical records from multiple
institutions to single individuals, even when individual medical records have
multiple names, multiple spellings of names, name changes, and spelling errors (J.
St. Sauver, personal communication, October 8, 2008).
The REP has been identified by at least two groups as one of only six populationbased medical record linkage systems in the world that are comprehensive in both the
spectrum of diagnoses and the settings in which care is provided (Brameld, Holman,
Lawrence, & Hobbs, 2003; Holman, Bass, Rouse, & Hobbs, 1999). The other similar
systems include the Oxford Record Linkage Study (Goldacre, Kurina, Yeates, Seagroatt,
& Gill, 2000), the Scottish Record Linkage System (Kendrick & Clarke, 1993; Walsh,
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Smalls, & Boyd, 2001), the Population Health Information System in Manitoba (Roos et
al., 1995), the British Columbia health database (Chamberlayne et al., 1998), and the
Western Australian Health Services Research Linked Database (Holman et al., 1999).
Thus, the REP may be the only comprehensive record linkage system in the United
States.
In the course of developing the Western Australia database Holman and
colleagues (1999) studied and visited all of the identified databases except that found in
British Columbia. In the course of this evaluation they developed a “set of benchmarks
for international best practice” (p. 457) for such databases (Holman et al., 1999). A list
of the benchmarks and a description of the REP relative to each benchmark is provided in
Table 8.
Subsequently a similar set of general guidelines for comprehensive linkage
systems has developed recognizing that such systems each develop in very different
contexts (D.A. Holman, personal communication, October 5, 2008). Those guidelines
are as follows:
Population: The population covered by the system is ideally geographically
defined and relatively stable, of adequate size for most analyses (ideally >1
million) and with adequate longitudinal coverage (>10yr). The advantage of a
geographically defined population, as distinct from register-based populations
such as members of a health insurance plan, is that research based on the former
will enjoy the greater external validity gained from a study population more
representative of the general community.
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Data resources: Health events and other data should be ascertainable for the
whole population (not merely a sample or population subgroup) on a continuous
basis (not an ad hoc or intermittent basis). The range of data resources should be
sufficient to address the research agendas of primary interest. Linked hospital
morbidity data and deaths are arguably the minimal system, but ideally the system
should include ambulatory health service encounters, key disease registers, birth
and perinatal data and a population register such as an electoral roll.
Technical facilities: Linkage should be achieved by either high performance
probabilistic matching or a reliable unique person identification number or a
hybrid of these methods. A program of data validation and assessment of linkage
performance is highly desirable. A tracing system is desirable to censor patients
who emigrate from the geographic area and are therefore lost to longitudinal
follow-up. Geocoding of addresses will enhance the capacity for spatial analysis
and assignment of socio-economic status and remoteness indices.
Organisational [sic] supports: These include a governance structure for leadership
and management of the data linkage enterprise; instruments for co-operation
between agencies providing data (eg, MOUs); consumer participation; a
facilitative or at least nonobstructive legal framework; and multidisciplinary
research teams including collaboration with health service providers (D.A.
Holman, personal communication, October 5, 2008).
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Table 8
International Benchmarks for Record Linkage and Health Services Research Databases
Benchmark (Holman et al., 1999, p. 458)
REP description relative to benchmarks
The REP is geographically defined as the residents of Olmsted
1. Population
County, Minnesota. For Olmstead County in the six years
1.1 Geographically defined and
from 2000-2006 there was a net in-migration of 3.35% of the
relatively stable
2000 population, the second highest rate by county in the state
1.2 Adequate size for most analyses
(US Census Bureau, 2008c). The population is estimated to be
(ideally >1 million)
137,521 in 2006, smaller than referenced in this benchmark
1.3 Adequate longitudinal population
(US Census Bureau, 2008b). However, during the course of its
coverage (>10 yr)
existence the REP has matched more than 750,000 unique
individuals (J. St. Sauver, personal communication, October 8,
2008). REP allows record review for 50 or more years
(Melton, 1996)
The REP has grown to include data from essentially all
2. Data Resources
medical care providers within the county and many providers
2.1 Named population register
elsewhere in the region that might have occasion to provide
2.2 Socio-demographic data from the
care to Olmsted County residents. It includes hospital,
Census
nursing home, state mental hospital, veterans administration,
2.3 Birth and death registrations
and prison health facilities. Public health records including
2.4 Perinatal events
birth and death registrations are part of the database. The
2.5 Hospital in-patient data
REP, however, does not have direct participant linkage to
2.6 Physician contacts
socio-demographic census data, and does not include
2.7 Pharmaceutical benefits data
pharmaceutical benefit data. To the extend laboratory services
2.8 Laboratory services data
were provided through a medical care provider indexed in
2.9 Cancer notifications
REP this laboratory data is included. Currently home health
2.10 Domiciliary care data
care agency data is not included. The REP is not linked to
2.11 Residential care data
NHANES (US Centers for Disease Control and Prevention,
2.12 Residential care data
2008b) participants that might live in Olmsted County, and the
2.13 Health survey data
county is not currently in the BRFSS (US Centers for Disease
3. Technical systems
3.1 Unique person identification number
3.2 High performance probabilistic
matching
3.3 A program of validation studies
3.4 Facility for follow-up (tracer
systems)
3.5 Facility for geocoding and spatial
analysis
4. Organizational Supports
4.1 Multidisciplinary research team
4.2 Supportive legal framework
4.3 Federal health agency cooperation
4.4 State health agency cooperation
4.5 Health care practitioner collaboration

Control and Prevention, 2008a).
The REP does use a REP master identification number to
match records once received from various sources. The social
security number is one demographic identifier used in the
probabilistic matching. Validation of REP probabilistic
matching is done as reported above (J. St. Sauver, personal
communication, October 8, 2008). There is no formal follow
up tracer system to eliminate those that have emigrated.
However, study designs can be used to censor participants at
the latest recorded care provided. Participants’ residential
addresses are geocoded to facilitate spatial analysis (Erickson
et al., 2007).
The REP involves a long term multi-disciplinary research
team including epidemiologists, information technologists,
programmers, physicians, nurses, and other clinicians
(Erickson et al., 2007). Veterans Administration facilities and
state health department are federal and state agencies that
historically had cooperated with the REP, though currently
new relationships to provide current records to the REP are
being negotiated (J.J. Pankratz, personal communication,
October 14, 2008). State mental health institutions have also
been partners in the project (Erickson et al., 2007). The REP
has been able to engage essentially all health care practitioners
in the county, as well as many in neighboring counties
(Melton, 1996).
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Thus, it appears that the REP is a record linkage system that has validated linkage
performance, is internationally recognized and substantially meets available benchmarks
and guidelines for such systems. The REP provided a unique opportunity to use clinical
record systems for population-based study, such as the analysis of the prevalence of
clinically recognized obstructive sleep apnea in this study.
A Population-based Sample: The Prevalence of Asymptomatic Ventricular Dysfunction
In 1997 a population-based sample was drawn in Olmstead County, Minnesota for
the purpose of longitudinally studying asymptomatic cardiac ventricular dysfunction.
That study, known as the prevalence of asymptomatic ventricular dysfunction (PAVD)
study, included an assessment of OSA risk as part of the longitudinal follow up of
participants for the study’s second round. With the availability of this population-based
assessment of OSA risk in this study, the participants in the study provided the sample in
which the prevalence of clinically recognized OSA was assessed. Thus, the literature
regarding the establishment and nature of this study sample are reviewed.
The initial sample for the PAVD study was drawn, using the resources of the
Rochester Epidemiology Project (REP) (Melton, 1996), from the residents of Olmsted
County, Minnesota who were 45 years of age or older on January 1, 1997 (Redfield et al.,
2003). At that time the total population of the county by linear interpolation from the
decennial censuses of 1990 and 2000 was 118,931 (US Census Bureau, 2008a). A 7%
random sample of each 5 year age and gender strata were selected for participation
(Ammar et al., 2006) including a total of 4203 potential participants (Redfield et al.,
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2003). Of those invited, a total of 2,042 (47%) participated in round one of the study
(Redfield et al., 2003).
In round one of the study participants completed a 17-page questionnaire
regarding health behaviors, evidence of cardiovascular disease, and functional status. In
addition, participants completed a physical examination, pulmonary function testing,
electrocardiogram, and an echocardiogram (Jacobsen et al., 2004). Using the REP,
participants’ medical records were reviewed by trained nurse abstractors for evidence of
hypertension, myocardial infarction, coronary artery disease, diabetes mellitus, and
congestive heart failure based on specific criteria (Redfield et al., 2003). This record
abstraction did not record clinical data related to sleep-disordered breathing.
A study (Jacobsen et al., 2004) was done of the first 963 persons receiving
invitations to participate in the study that included 488 (51%) who completed all aspects
of PAVD round one. Participation rates by gender were not appreciably different with
52.7% of men, and 49.0% of women, participating. Participation by the youngest (age
45-54 years) and oldest (age ≥75 years) groups, ranging from 34.9 to 45.4%, were lower
than the remainder (age 55-74 years) which ranged from 58.0 to 61.3%. Using the
resources of the REP analysis of potential associations between disease diagnoses and
participation was carried out. Participation was not different among those with and
without a prior history of coronary artery disease, congestive heart failure, other
cardiovascular diseases, diabetes or other co-morbidities. However, those with chronic
obstructive pulmonary disease (COPD), even after adjusting for age differences, were
less likely to participate than those without COPD (19% vs 51%). This study (Jacobsen et
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al., 2004) concluded that there was “some reassurance that participation bias in this study
may have little influence on its overall findings, although this cannot be conclusive” (p.
579).
For round two of the study, beginning in 2001 all participants that had completed
round one were invited to participate approximately four years after their initial round
one assessment (Rodeheffer et al., 2000). A total of 1,402 participants participated in
Round Two of the study involving a follow up questionnaire, physical examination,
electrocardiogram, blood sample, and echocardiogram. The round two PAVD
questionnaire included the BQ items as described for PAVD in Table 3 above.
Trained nurse abstractors again reviewed round two participants’ medical records
using the resources of the REP to obtain the following information: sociodemographic
information; cardiovascular diagnostic evaluations, diagnoses, and treatment; and
laboratory samples for potential testing of lipid profiles, thyroid studies, and hematocrit
were obtained (Rodeheffer et al., 2000). In this record review and abstraction clinical data
related to sleep-disordered breathing again was not part of the protocol.
With the PAVD study, round two now including a uniform assessment of OSA
risk using the BQ, the study provided an assessment of the prevalence of the clinical
recognition of OSA in a population-based sample.
Summary
This literature review has considered a variety of aspects of the epidemiology,
diagnosis, and treatment of OSA, previous reports of the prevalence of the clinical
recognition of OSA, the performance of the BQ, and nature of the Rochester
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Epidemiology Project as community-based laboratory. This final section attempts to
summarize this data as it relates to the planned study of the prevalence of clinically
recognized OSA in a population based sample.
OSA is a disorder in the continuum of sleep-related breathing disorders. A
quarter century of prevalence studies suggest that it is relatively common with 19 – 25%
of adult men having OSA defined as an AHI ≥ 5 without regard to daytime sleepiness.
The disorder has a somewhat lower prevalence in women with a gender ratio of about
2:1, and increases in prevalence with age up to about 65 years. Obesity, snoring, daytime
sleepiness, hypertension, and male gender are all considered risk factors for OSA. Full
laboratory PSG is the gold standard diagnostic technique for OSA, though the less
cumbersome techniques of in home monitoring are gaining favor. CPAP is the first-line
therapy for OSA whereas dental appliances and surgical treatment can play a role in
selected patients. OSA is associated with increased risk of hypertension, cardiovascular,
and cerebrovascular disease. Unfortunately CPAP is a therapy that is difficult to adhere
to limiting the risk reduction associated with treatment for these associated diseases.
Studies prior to 1990 suggested that the prevalence of clinically recognized OSA
among those with OSA was no more than 1%. Two subsequent population-based studies
using data from the 1990s showed that clinical recognition of OSA could be as high as
7% and 18% in women and men, respectively. Among the limitations of these studies
was the use of a self-reported OSA diagnosis. Among the explanations for the limited
clinical recognition has been (a) limited OSA awareness by physicians, (b) limited access
to diagnostic sleep laboratories and sleep specialists, and (c) the intrusive nature and
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expense of PSG. There is evidence that there has been improvement in all of these factors
over that past decade.
The BQ is a simple survey instrument developed in the late 1990s to assess
individuals’ risk of OSA. In recent years there has been a growing research use of the
instrument with a total of 53 publications now reporting its use. In a pooled analysis of
the fourteen studies that have validated the instrument against a PSG standard, the
instrument’s performance varies with the level of OSA severity inclusion criteria used. It
performs best in detecting OSA defined by an AHI ≥ 5 both with and without a daytime
symptom criteria.
This study used REP resources to assess the prevalence of clinically recognized
OSA among those with OSA based on the BQ. The REP is a longitudinal clinical record
linkage system for the population of Olmsted County, Minnesota. Historically this
system developed as a result of the unified, shared medical record developed at the Mayo
Clinic in 1907 that has since evolved and been linked with the records of essentially all
health care providers in the region along with birth and death records through the support
of the National Institutes of Health beginning in 1966. The REP is identified as one of
only six comprehensive record linkage systems internationally, and the only such system
in the United States.
The PAVD study is a population-based longitudinal study primarily considering
myocardial ventricular function in which participants had a rather comprehensive
evaluation and medical record abstraction focused on cardiac risk factors, initially and
approximately four years later. Though no assessment or record review of sleep-related

79
breathing problems was included in either the first or second round of the study, the
survey instrument for round two included a modified BQ that identified those at high risk
for OSA in a consistent manner.
Thus, the literature suggests that OSA is rather prevalent disorder that historically
has been substantially under recognized clinically. The BQ is a reasonable instrument by
which to classify participants’ risk of OSA as has been done in Round two of the PAVD
study. With use of REP resources, participants in the PAVD study with clinically
diagnosed OSA were identified, and the prevalence of OSA clinical recognition among
those at high risk for OSA was assessed.

CHAPTER 3: RESEARCH METHOD
Introduction
OSA is a sleep-related breathing disorder that is associated with significant
cardiovascular and cerebral vascular morbidity and mortality. Treatment with CPAP,
considered to be the first-line OSA treatment, does attenuate this increased morbidity and
mortality. However, patient adherence to CPAP therapy is challenging and is limited.
More importantly most OSA is undiagnosed and thus untreated. Previous research has
shown that no more than 18% of prevalent OSA was clinically diagnosed in the 1990s.
Lack of physician awareness of OSA, access to sleep lab services and sleep medicine
specialty treatment had provided explanation for this under recognition. There is evidence
that there is now improved physician awareness and access to sleep medicine services.
Thus, this study assessed the prevalence of clinically recognized OSA among those at
high risk for OSA in a community-based sample.
The methods used to identify those considered to be at high risk for OSA, and the
method for identifying those participants in the sample that have been clinically
recognized with OSA are described in this chapter. The methods used for data collection
and analysis, and measures taken to protect participants’ rights are also described.
Research Design and Approach
This study utilized the community based sample established in 1997 for the
ongoing study titled the Prevalence of Asymptomatic Ventricular Dysfunction (PAVD)
Study (Redfield et al., 2003) to evaluate the prevalence of clinically recognized OSA
among those with BQ defined OSA. As described in chapter 2 round two of the PAVD
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study included a modified BQ. Thus, participants in this sample were classified as either
high or low risk for OSA. This study then used the resources of the Rochester
Epidemiology Project including the patient database, clinical record access system, and
technical support staff, to identify all PAVD participants that had the clinical diagnosis of
OSA. The analysis of this data identified factors predictive of clinical recognition, and
assessed whether there was evidence of increased OSA clinical recognition among those
at high risk for OSA compared to the previous studies of OSA clinical recognition.
In the two previous assessments (Kapur et al., 2002; Young, Evans et al., 1997) of
the prevalence of clinically recognized OSA, the participant’s self-reported physician
diagnosis was used as the marker of OSA clinical recognition. Although one of these
studies used a laboratory-based PSG to determine the presence of OSA in the population
(Young, Evans et al., 1997), the other study (Kapur et al., 2002) used as an OSA proxy of
self-reported symptoms of frequent snoring and excessive daytime sleepiness. Though
these factors are recognized as OSA risk factors, this two-symptom proxy had never been
validated as an OSA predictor, even in the sources cited by Kapur and colleagues (2002)
in support of its use (Bradley et al., 1998; Newman et al., 2001; Strohl & Redline, 1996).
Thus, the use of medical record verification of the clinical diagnosis of OSA, along with
a previously validated instrument, the BQ, as the OSA proxy, represented an improved
method over previous studies in this area. In addition, performing this study based on
data collected from 2001 to 2010 will represent a timely reevaluation following improved
physician recognition and sleep medicine access in the 1990s (Namen et al., 2002).
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Setting and Sample
This study was carried out using the population-based community sample
established for the PAVD study as previously described in chapter 2 (Ammar et al., 2006;
Redfield et al., 2003). That sample was drawn from the residents of Olmsted County
Minnesota who have access to sleep medicine services through the Mayo Clinic Center
for Sleep Medicine, one of the largest such centers in the United States ("Mayo Clinic:
Obstructive Sleep Apnea, Diagnosis," 2008), and the Olmsted Medical Center sleep
program ("Olmsted Medical Center: Services, Sleep Medicine/Lab," 2008). Thus, these
participants have substantial local access to sleep diagnostic and treatment services.
The sample used for this study was the participants that continued in round two of
the PAVD study. As described in chapter 2, this round two sample represents those
participants that had completed round one of the study who then chose to continue their
participation in round two. This study then analyzed this sample for participation bias
comparing these round two participants with those from round one who did not
participate in round two. A previous analysis for participation bias comparing those
participating in round one, with those invited to participate in round one but choosing not
to do so, had been carried out (Jacobsen et al., 2004). The relationship of this analysis
with the previous participation bias analysis (Jacobsen et al., 2004) after which it was
modeled is graphically demonstrated in figure 2. Note that because previous PAVD
analyses had been focused on echocardiographically defined endpoints, previously
reported participation totals had been based on completion of the echocardiogram
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(Redfield et al., 2003). This study focused on completion of the BQ, therefore the
numbers of participants deviate slightly from those previous reports.

Participants invited to participate
in PAVD study
N = 4,203
Participation bias analysis by Jacobsen et al, 2004

Round 1 Non-participants
n = 2,156

Round 1 Participants
n = 2,047
Participation bias analysis

Round 2 Non-participants
n = 630

Round 2 Participants
n = 1,417

Figure 2. PAVD participation bias analyses
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Power and Sample Size
This study planned to detect a change in the prevalence of OSA clinical diagnosis
among those at high risk for OSA compared to previous studies (Kapur et al., 2002;
Young, Evans et al., 1997). These earlier studies had demonstrated prevalence of clinical
recognition among those with OSA as shown in Table 9.
Table 9
Prevalence of Clinical OSA recognition among those with OSA
Prevalence of Clinical
OSA Recognition
Study
Gender
among those with
OSA
Young, Evans et al., 1997
Male
0.18
Young, Evans et al., 1997
Female
0.07
Young, Evans et al., 1997
Combined
0.154
Kapur et al., 2002
Combined
0.082

Number
with OSA
(n)
77
27
104
650

With this study being part of a larger longitudinal study, the sample size has been
fixed by the design and participation rates in rounds one and two of the overall PAVD
study. Thus this analysis of power and sample size considered the power of this study
using this sample to detect a difference in the prevalence of OSA clinical recognition
from these previous studies.
The design considered the proportion of those with clinically recognized OSA in
round two of the PAVD study compared to the two previous studies (Kapur et al., 2002;
Young, Evans et al., 1997). Thus, this represents a comparison of two binomial
proportions resulting from independent samples. A method for calculating the power in
such circumstances has been described (Rosner, 2006) that involves the following
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parameters as applied to this study: the proportion with clinically recognized OSA in the
two samples (p1 and p2), the difference in the proportions in the two samples (Δ), the
complimentary proportion with clinically unrecognized OSA in each sample (q1 and q2),
the average of the proportions and the complimentary proportions in the two samples
( p and q ), the number of participants, in this case with OSA, in the two samples (n1 and
n2), and the level of statistical significance (α) where phi (Φ) is the cumulative
distribution function of a standard normal distribution. From Rosner (2006) that
calculation takes the following form (p. 418):
⎡
⎢
⎢
Δ
− z1−α / 2
Power = Φ ⎢
p
q
p
q
⎢ 1 1+ 2 2
⎢ n1
n2
⎣

⎛1
1 ⎞⎤
pq ⎜⎜ + ⎟⎟ ⎥
⎝ n1 n2 ⎠ ⎥
⎥
p1 q1 p 2 q 2 ⎥
+
n1
n2 ⎥
⎦

A preliminary analysis of the BQ results from PAVD round two classified a total
of 527 participants as being at high risk for OSA including 328 men and 199 women with
these participants representing the sample size (n2) in the study for the comparisons with
previous reports. Use of the high risk classification on the BQ as an OSA proxy then
provided the denominator for calculation of the prevalence. With increased physician
awareness of OSA and increased availability of sleep laboratories as described in chapter
2, it was highly unlikely that the clinical recognition of OSA would have decreased
compared to that noted in the 1990s. Thus, a one-sided power analysis with a z term of
z1-α is used here rather than z1-α/2 as described above by Rosner (2006).
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For this study this method of power calculation (Rosner, 2006) was used to
determine the largest prevalence difference that can be detected with a power of at least
80% relative to the four previously reported prevalence rates. As illustrated in Table 10
below, an increase in the prevalence of 0.171 compared to the previously reported
prevalence would be detected with a power of 0.80 for females. For males and the two
previously reported prevalence values for combined gender populations, there is a 0.80
power to detect even smaller increases in prevalence as demonstrated in Table 10. Thus,
this study had a power of 80% to detect an increase of prevalence of clinically recognized
OSA to 31% in males, 24% in females, and 26% in a combined gender population with
the probability of type I error less than 5%.

Table 10
Power Analysis: Minimum Prevalence Increase Detected with a Power of ≥0.80 Based on a One-sided Analysis
Prevalence increase
Number with
Number with
Original
Prevalence
detected with a
OSA or proxy in OSA proxy in
prevalence
detected with a
Gender
power of 0.8
original study
proposed study
power of 0.8
(n1)
(n2)
(p1)
(Δ)
(p2)
Male
(Young, Evans et
77
328
0.180
0.133
0.313
al., 1997)
Female
27
199
0.070
0.171
0.241
(Young, Evans et
al., 1997)
Combined
(Young, Evans et
104
527
0.154
0.105
0.259
al., 1997)
Combined
650
527
0.082
0.045
0.127
(Kapur et al., 2002)
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Instrumentation and Materials
Berlin Questionnaire
As part of the PAVD round two evaluation participants completed a 21-page
survey developed by the PAVD investigators in cooperation with the Mayo Survey
Research Center titled “Olmsted County Heart Survey.” That instrument included a wide
variety of questions related to cardiovascular symptoms, and previous cardiovascular
care, and was largely similar to the 17-page survey previously used in round one. The
items from the BQ, with the exception of items eight and nine related to nodding off
while driving (see Table 3 above), were included in the round two questionnaire. As
described previously, after review by legal counsel these items were omitted from this
questionnaire due to concerns about vicarious liability associated with recording
participants’ propensity for nodding off while driving without ability to intervene in the
research setting (A.S. Gami, personal communication, July 17, 2007).
The BQ is, as originally described (Netzer et al., 1999; "Reprinting of the Berlin
Questionnaire," 2000), an 11 item survey instrument that considers three categories of
symptoms and conditions associated with OSA. Those three categories are (a) snoring,
(b) daytime fatigue and sleepiness, and (c) the presence of hypertension and obesity. For
these categories there are five, four, and two items, respectively, in the instrument’s
original presentation each with either binary scoring, or scoring based on a five-point
ordinal scale of severity (Netzer et al., 1999; "Reprinting of the Berlin Questionnaire,"
2000).
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As described in chapter 2 the BQ has been used as a research instrument in 53
previous publications including fourteen that published a validation study for the
instrument with a PSG-based diagnostic method for OSA as the gold standard. Though
the overall structure of the instrument has been consistent in these studies, there have
been a number of variations in the questions scored, and the exact scoring methods used
in these studies. The details of these variations are described in chapter 2.
In pooled analysis of these validation studies (see Tables 6 and 7) the BQ appears
to perform best in predicting OSA defined by an AHI or RDI>5 with or without daytime
symptoms. Thus, the BQ, used in this manner, is an appropriate instrument to use in
predicting OSA in the proposed study population.
Using the REP for identification of PAVD participants with clinical OSA diagnosis
The REP, as described in chapter 2, is a comprehensive medical record data
linkage system that allows population-based study of a wide variety of health phenomena
in Olmsted County, Minnesota (Melton, 1996). Using a method typical for studies using
the REP, the PAVD study had originally been initiated using REP resources to randomly
select a population-based sample of those ages 45 and older on January 1, 1997 from the
overall county population (Ammar et al., 2006; Redfield et al., 2003). With the REP’s
comprehensive data linkage system, it was possible to use REP resources to
electronically return to the PAVD sample and identify participants likely to have
undergone PSG or carry a clinical diagnosis of OSA.
This was accomplished through the identification of the medical procedure billing
and diagnostic codes potentially associated with PSG, OSA and other sleep-related

91
breathing disorders, and with the first-line therapy for OSA, CPAP. Then the medical
records identified through the REP were reviewed to identify details of the diagnostic
evaluation, the actual clinical sleep diagnosis, and the nature of any associated treatment.
This study identified all participants from round one (which includes all round two
participants) that had undergone PSG or carried a diagnosis of OSA. The inclusion of the
round one participants that did not participate in round two allowed a comparative
analysis of those participants with round two participants for possible participation bias.
In Olmsted County there are two sources of sleep laboratory evaluation, one at the
Mayo Clinic, and the second at Olmsted Medical Center. A comprehensive electronic
database of the PSGs performed at Mayo Clinic is available. Thus, as iterations of the
REP search criteria for PSG, OSA, and sleep-related diagnoses were developed, the
resulting patient population was compared to the Mayo Sleep Laboratory Database
(MSLD) as a means of assessing the performance of the search criteria in identifying all
PAVD participants known to have had PSG performed in the Mayo Clinic Sleep
Laboratory. This comparison of the participants identified using the REP search with
roster of those already known to have undergone a Mayo PSG provided an indirect
method of evaluating the validity and efficiency of the REP search criteria as they were
developed.
In the developing a search strategy for this study the first iteration of REP criteria
was as follows: Either a PSG or CPAP procedure code AND one of a broad, inclusive
list of sleep breathing-related diagnostic codes. The list of the codes selected is displayed
in Table 11. This iteration of the search identified 169 participants from the 2,042
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participants that completed round one of the PAVD study. These 169 participants
included 151 of the 235 PAVD participants known to have had a PSG based on the
MSLD, and 18 additional participants. These 18 participants included 16 that were found
to have had a PSG at the Olmsted Medical Center, one found to have had a PSG at Mayo
Clinic that was not recorded in the MSLD, and an additional participant whose clinical
records note an OSA diagnosis, but make no reference to when or where a PSG might
have been performed. With 152 of these 169 participants having had PSGs performed at
Mayo Clinic, whereas 16 were performed at Olmsted Medical Center, an approximate
9.5:1 ratio of studies performed in the two institutions was demonstrated.

93
Table 11
Sleep Breathing-related Diagnostic Codes
Code
Description
7735110
Insomnia, NOS
7735111
Disorder, Sleep, NOS
Deprivation, Sleep
7735112a
7735113
Disturbance, Sleep
7735115
Insufficiency, Sleep (Syndrome)
7735120
Sleepiness, NOS
7735130
Sleepiness, Cause Specified
7735132
Disorder, Excessive Somnolence
7781510
Hypoventilation, NOS
7781511
Syndrome, Hypoventilation, NOS
7781520
Syndrome, Hypoventilation, Cause Specified
7781521
Hypoventilation, Cause Specified
7782210
Respiration, Cheyne-Stokes, NOS
7782211
Cheyne-Stokes See Also Respiration
7782220
Respiration, Cheyne-Stokes, Cause Specified
7782410
Apnea, NOS
7782411
Apnea, Sleep
7782412
Sleep, Disordered Breathing
34199754
Clinic, Sleep Disorder Center
327.1
Organic Hypersomnia, Unspecified
327.11
Idiopathic Hypersomnia With Long Sleep Time
327.12
Idiopathic Hypersomnia Without Long Sleep Time
327.13
Recurrent Hypersomnia
327.14
Hypersomnia Due To Medical Condition
327.15
Hypersomnia Due To Mental Disorder
327.19
Other Organic Hypersomnia
327.2
Organic Sleep Apnea, Unspecified
327.21
Primary Central Sleep Apnea
327.22
High Altitude Periodic Breathing
327.23
Obstructive Sleep Apnea (Adult)(Pediatric)
327.24
Idiopathic Sleep Related Nonobstructive Alveolar Hypoventilation
327.25
Congenital Central Alveiolar Hypoventilation Syndrome
327.26
Sleep Related Hypoventilation/Hypoxemia In Conditions Classifiable Elsewhere
327.27
Central Sleep Apnea In Conditions Classified Elsewhere
327.29
Other Organic Sleep Apnea
780.5
Sleep Disturbances
780.5
Unspecified Sleep Disturbance
780.51
Insomnia With Sleep Apnea, Unspecified
Insomnia, Unspecified
780.52 a
780.53
Hypersomnia With Sleep Apnea, Unspecified
780.54
Hypersomnia, Unspecified
780.55
Disruption Of 24-Hour Sleep-Wake Cycle, Unspecified
780.56
Dysfunctions Associated With Sleep Stages Or Arousal From Sleep
780.57
Unspecified Sleep Apnea
780.58
Sleep Related Movement Disorder
780.59
Other Sleep Disturbances
Other Dyspnea And Respiratory Abnormality
786.09 a
a
Diagnostic code eliminated in the third iteration of the REP search criteria.
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Because these criteria had failed to identify 35.7% of the PAVD participants
known to have undergone PSG based on the MSLD, the criteria were modified to be
more inclusive. This second iteration of the REP Search Criteria was then submitted as
follows: Either a PSG or CPAP procedure code OR one of the same broad, inclusive list a
sleep breathing related diagnostic codes from Table 11. That search then identified 690
participants including 229 of the 235 PAVD participants identified in the MSLD, and 443
additional participants that were not in that database or among the 18 participants
identified by the first iteration as having had sleep studies or OSA apart from that
database. The six participants in the database not identified in the second iteration of the
search criteria all had PSGs performed more than 12 years ago and thus may have had
their studies coded in a different manner.
An analysis of the specific diagnostic codes leading to the identification of these
690 second iteration participants showed that the number of participants identified in the
MSLD by each code compared to the other participants identified by that code varied
widely as illustrated in Table 12. Some codes exclusively identified participants known
to have had PSGs, whereas other codes identified only participants not found in the
MSLD, and other codes identified a mix of MSLD participants and the others.
The ratio of participants with known PSGs to those without known PSGs is one
indicator of the relative efficiency of each code in identifying participants that have
undergone PSG. A ratio of 1 participant with a known PSG for every 10 participants
without a known PSG was arbitrarily selected as a threshold ratio for inclusion of the
code in the search criteria. This analysis demonstrates that elimination of four codes
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would be predicted to reduce the number of participants identified but not found in the
MSLD by 95, while leaving seven participants with PSGs unidentified. Recognize that
the seven participants with known PSGs but not identified by the REP criteria did still
ultimately contribute to the PSG analysis as they had been identified in the MSLD. Given
the 9.5:1 ratio of Mayo to non-Mayo PSGs, the elimination of these codes was predicted
to have missed less than one participant with a non-Mayo PSG.
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Table 12
Participants Identified by REP Search Criteria, Iteration 2
Participants with
Participants without
Ratio of participants with known PSGs
a known PSG
a known PSG
to those without a known PSG
Code
n
n
93.9 a
0
1
0.00
b
327.23
3
0
780.5
2
9
0.22
b
780.51
1
0
2
31
0.06
780.52 a
b
780.53
1
0
780.57
10
3
3.33
5
58
0.09
786.09 a
7735110
17
153
0.11
7735111
9
52
0.17
0
5
0.00
7735112 a
7735113
5
38
0.13
7735115
1
2
0.50
7735120
1
9
0.11
7735132
1
2
0.50
b
7781510
1
0
b
7781521
1
0
7782410
1
5
0.20
7782411
177
62
2.85
7782412
6
8
0.75
34199754
3
5
0.60
Total
247
443
a
diagnostic codes eliminated for iteration 3
b

ratio cannot be calculated as it involves division by zero
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Thus, a third iteration of the REP search criteria is as follows: Either a PSG or
CPAP procedure code OR one of a shorter, but still inclusive list a sleep breathing related
diagnostic codes. This iteration of the search criteria identified a total of 608 participants
from the 2,042 that had participated in PAVD round one including the same 229
identified in the second iteration from the MSLD, and the 18 participants previously
recognized as having had PSG at the Olmstead Medical Center in the first iteration of the
search criteria. This reduction of the number of participants identified in iteration three
effectively reduced the number of participants outside of the MSLD by 81 to 362. Based
on the analysis above it appears unlikely that a further modification of these search
criteria will substantively affect the efficiency of participant identification.
The roster generated by iteration three then represents the PAVD participants
identified by the REP search as likely having had PSG and carrying an OSA diagnosis.
In the proposed study these participants’ linked records were reviewed to verify the
performance of PSG, identify the facility at which it was performed and extract the
date(s) of testing, quantitative and narrative diagnostic results from the PSG, and
available information regarding the OSA therapies recommended. When available any
references to patients’ current adherence to the recommended therapy was also abstracted
from the records.
To validate this REP search method and these final criteria, a random sample of
50 participants not identified as having had PSG or an OSA diagnosis were also manually
reviewed. As described in chapter 4, that sample indicated that less than 6% of
participants (n<3) not identified by the REP search method actually had PSGs or carried a
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sleep-related diagnosis, thus these search criteria were accepted, having identified 95% or
more of PAVD participants undergoing PSG or having a sleep breathing related
diagnosis.
Data Collection and Analysis
Existing PAVD data including the demographic parameters and many of the
clinical parameters to be used in this proposed study are maintained by the PAVD data
management staff in an electronic format based on standard research procedures for the
Mayo Clinic. The author of this study completed and maintained the necessary ethics
training for Mayo Clinic and REP research, and had obtained IRB approval for the
research at both the Mayo Clinic and the Olmsted Medical Center. Thus, the author had
the necessary institutional approvals to access this data and carryout the proposed
research. In addition, the author had obtained the approval of the Walden University IRB
to carry out the analysis of this data once collected.
The REP search criteria were developed in cooperation with a REP data
analyst/programmer who then wrote the script that implements the search using the REP
electronic resources. The REP data analyst/programmer then provided an electronic
spreadsheet roster of the participants identified by the search with additional associated
data fields appropriate to chart review and analysis (Erickson et al., 2007).
Chart review and data collection
Using this electronic roster of participants meeting the REP search criteria a
systematic review of participant records was done. The first step was to use the electronic
REP browser to identify the types and location of records available for each patient. This
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browser allows electronic access to listings of the medical procedure billing and
diagnostic codes searched and scanned records that are archived by the REP. Manual
review of these codes allowed the identification of the dates, type of records, and
locations likely to provide the details of the PSGs performed and the final sleep-related
breathing clinical diagnosis and treatment (Erickson et al., 2007).
Once the dates and location of these records were identified the next step was
accessing and reviewing those records. For those records maintained in an electronic
medical record, the necessary information was abstracted directly from these records. If
the necessary records were maintained in a paper only format, the investigator provided a
roster of these records to the REP research study assistant who then organized the
collection of these paper charts at the appropriate institutional site and scheduled a time
for the investigator to visit that record department for the abstracting review (Erickson et
al., 2007).
The record review focused on the PSG report, clinical notes that led to the
ordering of the PSG, clinical notes subsequent to the PSG in which a sleep-related
treatment had been ordered, and more recent notes that provided indications of current
adherence to the currently prescribed sleep-related treatment. In addition, where a PSG
report or other definitive descriptions of sleep-related evaluations and treatments were
not available, a general review of the record was carried out to determine the basis for the
record’s identification by the REP search criteria.
For this study the following data were then abstracted into an electronic
abstraction record: (a) date and location of all PSGs performed; (b) PSG reported
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parameters including the AHI or RDI, oxygen saturation nadir, portion of sleep time with
oxygen saturation less than 90%, oxygen desaturation index, the central and obstructive
AHIs, and total sleep time, (c) the clinical diagnosis from the narrative PSG report; (d)
the sleep-related prescription recommended to the patient following the PSG; (e)
narrative indications of the patient’s subsequent and current adherence to that therapy;
and (f) a description of the dates and locations of the records reviewed. This abstraction
record was maintained on a laptop computer to allow use at the multiple locations at
which charts must be reviewed. The electronic abstraction record was a password
protected file that is electronically regularly backed up.
At the conclusion of the abstraction the abstraction file was reviewed for
consistency of data with corrections made as indicated noting that the original patient
records remained available if needed to clarify inconsistencies.
Analysis
The analysis of the data obtained was approved by the Walden University IRB
and was carried out in several stages. The first stage was designed to provide assurance
of the validity of the REP search criteria for the identification of at least 95% those with
PSGs and clinically diagnosed OSA. As described above, this involved the review of 50
randomly selected patient records not identified by the REP criteria for participants that
had completed round one of PAVD. If there were three or more participants (≥6%) from
this sample of 50, the search criteria would have been reevaluated based on the
characteristics of those additional participants with PSG or OSA-related diagnoses. Since
there were two or fewer participants in this sample with a PSG or OSA-related diagnosis
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the criteria were accepted as having effectively identified 95% or more of those in the
PAVD study that have had PSG or an OSA-related diagnosis.
The second stage of the analysis was to determine if there was evidence of
participation bias by comparing those participating in round two with those from round
one that did not participate. Similar to the earlier evaluation for participation bias in
round one (Jacobsen et al., 2004), this analysis included age, gender, marital status,
educational attainment, BMI, history of cardiovascular diseases including coronary artery
disease, congestive heart failure, hypertension, history of atrial fibrillation, other
cardiovascular disease, diabetes, chronic obstructive pulmonary disease, and history of
clinical PSG or diagnosis OSA. Descriptive statistics were tabulated for these participant
characteristics in round two participants and nonparticipants stratified by age and gender.
For categorical variables statistical comparison was by chi-square test whereas
continuous and ordinal variables were compared using the Student t-test. The
participation bias found was acknowledged in interpretation of the study’s results.
Stage three of the analysis addressed the subtle difference in the scoring algorithm
used in a BQ validation study previously done in our institution (Gami et al., 2004)
compared to the original validation study (Netzer et al., 1999; "Reprinting of the Berlin
Questionnaire," 2000). Table 3 illustrates that the scoring of item one in the
questionnaire varied from the original scoring algorithm. Thus, analysis of the resulting
difference, if any, in the population prevalence of OSA by the BQ proxy was performed
to determine the impact of this difference.
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Once the first three stages of analysis were completed, the fourth stage involved a
descriptive analysis of the participants with and without clinically diagnosed OSA among
those with the OSA proxy based the modified BQ. This descriptive analysis included
demographic factors such as gender, age, educational attainment, and marital status. In
addition clinical factors previously recorded for the PAVD study were assessed,
including BMI, change in BMI from round one to round two, a history of coronary artery
disease, congestive heart failure, hypertension, atrial fibrillation, cerebral vascular
accident (CVA), diabetes, chronic lung disease, and a cardiovascular disease composite,
systolic and diastolic myocardial function, and lipid profile. For continuous variables
mean, median, and standard deviation will be reported, and where appropriate continuous
variables were analyzed in categorical groups. For example, BMI was considered
categorically in normal, overweight, and obese groups in addition to a comparison of
means. Since many of these variables were collected in both round one and round two,
the more recent round two data was generally used, and an analysis based on the changes
of relevant parameters from round one to round two was also performed.
Based on these bivariate analyses factors statistically associated with clinical
recognition of OSA were entered in a multiple logistic regression analysis to identify
factors that independently predicted the clinical diagnosis of OSA among those with the
BQ OSA proxy after adjustment for other variables. The dependent variable was the
presence or absence of clinically diagnosed OSA among those with OSA based on the
BQ. The regression analysis proceeded with a stepwise, backward strategy. Those
factors from the bivariate analysis with a statistically significant difference (p ≤ 0.05)
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between those clinically recognized and unrecognized were all included in the regression
model initially. Independent variables that then had insignificant coefficients (p>0.05)
were the removed from the model one at a time starting with the variable with the highest
p-value. This process was continued until all of the variables remaining in the model
were significant. The final model then had identified the factors that are statistically
independent predictors of clinical recognition of OSA among those with OSA based on
the BQ proxy.
The results of this analysis were then used to formulate strategies to better
recognize those most likely to have undiagnosed OSA. The prevalence of clinically
recognized OSA among those with the BQ OSA proxy were also determined and
compared to that previously reported in population-based studies using 1990s data
(Kapur et al., 2002; Young, Evans et al., 1997).
Protection of Participants Rights
Prior to participation participants in the PAVD study completed a consent form
approved by the Institutional Review Boards of both the Mayo Clinic and Olmstead
Medical Center. That document includes a detailed description of the nature of the study,
risks, and benefits of participation, the opportunity to withdraw from the study, and
provides participants the opportunity to authorize investigators to review personal health
records for relevant study information. In addition, patients obtaining healthcare from the
Mayo Clinic and the Olmsted Medical Center have the opportunity to provide general
permission for review of their records for research purposes when they seek routine care
at these institutions. Patients who choose not to grant that permission have their clinical
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identification numbers censored in the REP browser, and thus their records are
inaccessible to review (Erickson et al., 2007). Thus, both the informed consent process
within the PAVD study, and the routine consent process in obtaining care in Olmsted
County provided mechanisms to protect participant rights for this study.
All of the round two PAVD data, along with data previously obtained in round
one of the PAVD study are maintained by the PAVD data management staff in a secure
electronic format with appropriate electronic and paper data backup by standard research
procedures for the Mayo Clinic. Those with appropriate research ethics training and
Mayo Institutional Review Board (IRB) approval for specific PAVD research projects
may have access to this data within the limits of their IRB approved research role. This
allows for investigators to obtain a working data extract, typically in a standard
spreadsheet or statistical analysis software format, from the primary, secure database for
the approved project (Erickson et al., 2007). In addition, projects utilizing REP resources
must have IRB approval from the Olmsted Medical Center, the other primary REP
institutional partner, in order to access those REP resources. The author of this study had
completed and maintains the necessary ethics training for Mayo Clinic and REP research.
In addition, the author had submitted and obtained IRB approval for the research at both
the Mayo Clinic and the Olmsted Medical Center. Finally the author had obtained
approval of the Walden University IRB for the plan to analyze this data. Thus, the author
had the necessary institutional approvals to access this data and carryout the research.
Since the data collected by this study is the property of the larger PAVD study, at the
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study’s conclusion it will be submitted to the PAVD data management staff to be
permanently archived with the rest of the PAVD data.
Summary
This study built on the longitudinal, population-based PAVD study of adults who
were age 45 and older on January 1, 1997 to assess the prevalence of clinically
recognized OSA in the population. In the second round of that study participants
completed the modified BQ which classified participants’ risk of OSA as high or low,
and was used as a proxy for OSA. Using the resources of the REP, PAVD participants
from both rounds one and two with clinically recognized OSA were identified using
billing codes for PSG and CPAP along with a group of diagnostic codes for sleep-related
breathing diagnoses. The charts of identified participants were reviewed to abstract
parameters measured in the clinical PSG, the clinical diagnosis of OSA, and, where
possible, any OSA treatment recommended and the participants’ adherence to that
treatment was also abstracted.
A preliminary analysis of the BQ responses demonstrated that a total of 527 of the
original 1,402 participants in round two were at high risk for OSA including 199 women
and 328 men. Thus, the study was powered at 80% to detect increases in clinical
recognition of 13.3% among men, 17.1% among women, and 4.5 – 10.5% in a mixed
gender populations compared to the two previous population based assessments of OSA
clinical recognition (Kapur et al., 2002; Young, Evans et al., 1997).
The study’s analysis included a validation analysis to assess the effectiveness of
the REP search criteria used to identify participants with the clinical diagnosis of OSA by
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reviewing 50 randomly selected charts not selected by these criteria. The possibility of
participation bias was considered by an analysis comparing the baseline characteristics
and the clinical diagnoses of OSA for participants that participated in the round two with
those that chose not to participate. A descriptive analysis determined the prevalence of
clinically recognized OSA among those with a high risk of OSA based on the BQ. Finally
both bivariate and multivariate analyses of factors predictive of OSA clinical recognition
were performed.
The study protected participants’ rights through a careful informed consent
process that was a part of the PAVD study and when participants were provided
opportunity to consent the to use of their clinical records in the course of obtaining
routine medical care in Olmsted County.

CHAPTER 4: RESULTS
Introduction
This study utilized the community-based sample established in 1997 for the
ongoing Prevalence of Asymptomatic Ventricular Dysfunction (PAVD) Study to evaluate
the prevalence of clinically recognized obstructive sleep apnea (OSA) among those at
high risk for OSA (Redfield et al., 2003). The survey completed by PAVD participants in
round two included a modified BQ which was used to predict which participants were at
high risk for OSA (Netzer et al., 1999; "Reprinting of the Berlin Questionnaire," 2000).
To identify participants with clinically recognized OSA the resources of the REP
(Melton, 1996) were used to ascertain those participants’ medical records containing one
of the sleep-related diagnosis and procedure codes in Table 12. The records of these
participants were then reviewed to obtain information about any clinical PSG the
participant had undergone and the clinical diagnosis of OSA.
The responses to the BQ items and a host of demographic and clinical parameters
had been collected by the PAVD study in Round 1 and/or Round 2. These data points
had been electronically archived by study staff that then provided a data extract of the
relevant data for this study. The REP search for sleep-related procedure and diagnosis
codes was carried out in October 2008 and identified 609 participants. The medical
records of these participants were systematically reviewed recording PSG and OSArelated parameters. To validate the REP code search process an additional 50 participants
not selected by that process were randomly selected and manually reviewed for evidence
of a clinical PSG testing or OSA diagnosis. Data from the REP identified charts that were
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reviewed, the 50 participant validation study, the BQ responses, and other relevant fields
from the archived PAVD study were then merged to form a single data set used for this
study. Coded responses from the BQ were placed in an electronic algorithm to rate
participants’ OSA risk based on the method of the original BQ validation study as
modified for application in this setting(Netzer et al., 1999; "Reprinting of the Berlin
Questionnaire," 2000).
The research questions this study sought to answer were the following:
1. What proportion of those at high risk for OSA based on the Berlin Questionnaire
(BQ) have been clinically evaluated for OSA?
2. What is the prevalence of clinically diagnosed OSA among those at high risk for
OSA based on responses to the Berlin Questionnaire?
3. Has the prevalence of clinically diagnosed OSA increased in the past decade?
4. What factors are predictive of the clinical diagnosis of OSA among those at high
risk of OSA?
The data analysis for this study was carried out in the following four stages:
1. Validation of the diagnostic and procedure codes in Table 12 for the identification
of clinically recognized OSA by the manual review of 50 randomly selected
records not selected by these codes.
2. Participation bias analysis comparing those participating in round two of the
PAVD study with those from round one who did not participate, and a descriptive
analysis of the resulting sample.
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3. Analysis of OSA risk based on the Berlin Questionnaire and the impact of the
Berlin Questionnaire scoring modifications used in this study.
4. A descriptive, bivariate, and multivariate analysis of those with clinically
recognized OSA in order to identify factors predictive of clinical recognition.
The purpose of stages one through three is to validate the method used to identify
those with clinically recognized OSA, and to assess for bias in the data sets used. Thus,
these analyses are presented first. Subsequently, the research questions are addressed
following the presentation of results for the fourth analytic stage.
Validation of the REP Codes Used for Identification of OSA Clinical Recognition
As described in chapter 3 sleep-related clinical diagnostic and procedure codes
were compiled to electronically identify all participants with clinically recognized OSA.
Through an iterative process using a database of known sleep studies the diagnostic and
procedure codes were refined to efficiently identify all those with PSGs and OSA without
selecting those with other sleep-related diagnoses. The collection of codes used was from
iteration three (Table 12). Note that three codes in this table labeled with an asterisk (*)
were eliminated for iteration three and thus, from this study.
The search for PAVD round one participants with sleep-related diagnoses was
carried out in October 2008 using iteration three codes as noted in Table 12. The medical
records of the 608 identified participants were reviewed beginning after final approval of
the dissertation proposal in April 2009 with these reviews completed in early March
2010. To validate this set of search codes to assure that at least 95% of participants with
PSGs and/or OSA were identified by this process a random sample of 50 participants not
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selected by iteration three codes was drawn in February 2010 and manually reviewed for
evidence of PSG treatment or an OSA-related diagnosis. This review, completed in
March 2010, identified a total of four of these 50 randomly selected participants with a
sleep-related diagnosis as illustrated in Table 13.
Table 13
Sleep-Related Diagnoses Found in the 50 Participant Validation Sample
Sleep-related diagnosis
Diagnostic Date
AHI by PSGa
Periodic leg movements of sleep
January 9, 2008
2
Mild OSA
November 8, 2008
9
Insomnia
January 27, 2009
No PSG
Insomnia
January 4, 2010
No PSG
a
AHI by PSG: apnea-hypopnea index (AHI) by polysomnography (PSG)

Treatment
Iron supplementation
CPAP
Sleep medication
Sleep medication

Only one participant with clinically recognized OSA was identified, and that
clinical diagnosis was not made until after the REP search was carried out. There were
also two participants with other, nonOSA sleep-related diagnoses that were made after
the REP search was performed. In addition, there was one participant that had a sleeprelated diagnosis not related to OSA that was made on January 9, 2008, prior to the REP
search. A review by REP staff indicates that this diagnosis was not identified by the
search because it is likely that the January diagnosis and procedure codes had not yet
been processed into the REP database when the search was carried out in October of
2008 (S. Schrage, personal communication, May 3, 2010).
Thus, in this validation sample there were no participants with clinically
recognized OSA prior to the date of the search that were not identified by the iteration
three collection of diagnostic and procedure codes. With one participant identified in this
50 participant sample with a nonOSA sleep-related diagnosis there is an estimated 2%
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chance that these criteria would not detect a participant with a sleep-related diagnosis
which, in the entire study sample, could include some participants with OSA. Since
those with OSA represent a subset of those with any sleep-related diagnosis, the chance
of this REP search method having failed to identify a participant with OSA is estimated
to be less than 2%. Therefore, this validation analysis confirms that these criteria
identified at least 95% of those with clinically recognized OSA in the PAVD sample.

Round Two Participation Bias and Descriptive Analysis of the Sample
This study was carried out using the population-based community sample
established for the PAVD study as previously described in chapter 2 (Ammar et al., 2006;
Redfield et al., 2003). The primary study using this database had been based on
echocardiographic endpoints. Thus, previous analyses used only participants that had
completed an echocardiogram, which in Round 1 and 2 included 2,042 and 1,402
participants, respectively. Further review of the archived PAVD data revealed that there
were an additional five participants that were invited to participate in Round 2 despite not
having completed the Round 1 echocardiogram. In addition, in Round 2 there were an
additional 15 participants that had completed the Berlin Questionnaire but did not
complete the Round 2 echocardiogram. Because these additional participants had
completed the essential elements for the present study, they have been included in the
analyses which follow giving 2,047 participants in Round 1 and 1,417 participants in
Round 2. The age and gender characteristics of these samples are described in Table 14.
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Overall there was a nearly 70% participation rate from Round 1 to Round 2.
Similar to a previously reported participation analysis for Round 1 (Jacobsen et al.,
2004), there was a somewhat lower Round 2 participation rate for the youngest age
group, and a substantially lower participation rate for the oldest group in both genders. In
addition, similar to that early analysis, there was a somewhat higher participation rate for
men compared to women. Thus, the subsequent bivariate analyses of participation are
age- and gender-adjusted to the population participating in Round 1.
Table 14
Round 2 Participation Rate by Age and Gender
Gender &
Round 1
Round 2
Round 1 Age
Participants
Participants
(yrs)
(n)
(n)
Overall
2047
1417

Participation
Rate
(%)
69.2

67.2-71.2

95% CI

Women
45-54
55-64
65-74
75+

1061
302
312
264
183

714
220
243
278
73

67.3
72.9
77.9
67.4
39.9

64.5-70.1
67.9-77.9
73.3-82.5
61.7-73.1
32.8-47.0

Men
45-54
55-64
65-74
75+

986
299
315
257
115

703
224
245
185
49

71.3
74.9
77.8
72.0
42.6

68.5-74.1
70.0-79.8
73.2-82.4
66.5-77.5
33.6-51.6

Participation bias analysis for the initial Round 1 sample (Jacobsen et al., 2004)
had considered a number of demographic and disease history factors as potentially
associated with Round 1 participation. A similar analysis for Round 2 participation is
presented in Table 15. In this bivariate analysis there was a statistically significant
underrepresentation of those with noncoronary artery disease cardiovascular disease
(nonCAD CV disease), congestive heart failure (CHF), any cardiovascular disease,
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chronic obstructive pulmonary disease (COPD), those with no more than a high school
education, and a higher Charlson Comorbidity Index weighted for age and severity
(Charlson, Pompei, Ales, & MacKenzie, 1987). Relevant to the present study there was
no statistically significant difference in Round 2 participation after age and gender
adjustment related to BMI, having undergone a clinical PSG, or the clinical diagnosis of
OSA.
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Table 15
Participation Rate by Disease History and Demographic Characteristics with Age and Gender Adjustment

Coronary artery disease
Present
Absent
NonCAD CV disease
Present
Absent
Atrial fibrillation/flutter
Present
Absent
CHF
Present
Absent
Hypertension
Present
Absent
Any cardiovascular disease
Present
Absent
COPD
Present
Absent
Diabetes mellitus
Present
Absent
Marital Status
Currently married
Not currently married
Education
At least some college
No more than high school
Race/Ethnicity
Caucasian, non-Hispanic
Non-Caucasian or Hispanic
Charlson Index, Weighted
0
1-2
≥3

Condition
at round 1
(n)

Round 2
participants
(n)

Participation rate
(%)

Age & gender
adjusted participation rate (%)a

pb

248
1799

143
1274

57.7
70.8

65.5
70.1

0.093

515
1532

290
1127

56.3
73.6

63.2
72.2

<0.0001 c

100
1947

48
1369

48.0
70.3

61.5
69.9

0.202

45
2002

16
1401

35.6
70.0

55.6
69.7

0.0006 c

561
1486

352
1065

62.7
71.7

66.5
70.8

0.074

550
1497

316
1101

57.5
73.5

64.1
72.1

0.0002 c

94
1953

39
1378

41.5
70.6

45.8
70.3

0.001 c

153
1894

92
1325

60.1
70.0

63.5
69.8

0.072

1588
447

1138
273

71.7
67.0

70.0
67.0

0.227

1154
759

868
466

75.2
61.4

74.5
63.1

<0.0001 c

1996
51

1385
32

69.4
62.7

69.4
64.8

0.487

259
912
871

204
689
522

78.8
75.5
59.9

82.5
69.6
64.2

<0.0001 c
(table continues)
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Condition
at round 1
(n)

Round 2
participants
(n)

Participation rate
(%)

Age & gender
adjusted participation rate (%)a

pb

<20
20 – 24
25 – 29
30+

49
466
869
662

34
318
617
448

69.4
68.2
71.0
67.7

67.6
68.3
70.9
66.5

0.320

Performed
Not performed

280
1767

204
1213

72.9
68.6

70.4
69.0

0.636

BMI

Clinical PSG
Clinical OSA
Diagnosed
270
197
73.0
70.9
No diagnosis
1777
1220
68.7
68.9
a
Age and gender adjustments are to the standard of the Round 1 participating population.
the Chi square Likelihood Ratio.
multivariate logistic regression.

c

0.505
b

p values are for

Parameter considered statistically significant and retained in the initial
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A multivariate logistic regression analysis comparing those from Round 1 that
participated in Round 2 with those who did not participate was performed initially using
only the conditions identified as statistically significant in the bivariate analysis in Table
15. Age and gender were also included since participation rates had been adjusted for
these factors in Table 15. In this model the continuous variable age was represented by
an ordinal variable, categorized as shown in Table 14. In a stepwise manner, factors with
coefficient p values greater than 0.05 were removed from the model. All of the age group
variables were retained in the model despite the fact that the 65 – 74 year old age group
was not statistically different from the reference group (45 – 54 years old) because of the
lower participation rates in younger and older age groups. When considering the
cardiovascular disease related variables with the other variables in the model only
nonCAD CV disease ultimately remained statistically significant. The Charlson
Comorbidity Index, which summarizes in a single variable comorbidity from spectrum of
chronic disease, appears to be a better predictor of participation in this regression analysis
than many of the individual chronic diseases included in this index (Charlson et al.,
1987). The unadjusted and adjusted odds ratios with 95% confidence intervals are
presented for the variables retained in the final model in Table 16.
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Table 16
Odds Ratios for Logistic Regression Analysis of Factors Predicting Round 2 Participation
Age Group, years

Gender

Unadjusted OR b

Adjusted OR c

Adj. OR 95% CI

45-54 a
55-64
65-74
75+

1
1.24
0.81
0.25

1
1.57
1.31
0.45

1.170 – 2.102
0.941 – 1.832
0.306 – 0.666

Female a
Male

1
1.21

1
1.24

1.002 – 1.525
Education
1
1
At least some college a
No more than high school
0.52
0.59
0.475 – 0.727
COPD
1
1
Absent a
Present
0.30
0.40
0.250 – 0.645
NonCAD CV disease
1
1
Absent a
Present
0.46
0.67
0.528 – 0.862
Charlson Index
1
1
<3 a
3+
0.47
0.73
0.559 – 0.965
Note. Only variables retained in the final logistic regression model are presented.
a

Reference category. b Unadjusted OR based on bivariate analysis prior to age and gender

adjustment. c Adjusted OR from the final logistic regression model including only the
listed factors.

This analysis indicates that those with COPD, nonCAD CV disease, and those
with greater comorbidities as measured by the Charlson Index, were under-represented as
participants in Round 2. Since participation in Round 2 involved completion of a survey
and coming to the research clinic for physical examination and an echocardiogram, it is
not unreasonable that those with a greater disease burden might have found it more
difficult to participate in Round 2. The younger, 45 – 54 year old age group was underrepresented compared to the 55 – 64 year old age group, likely because this group
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probably had a greater proportion that were employed on a full time basis making the
scheduling of Round 2 participation more challenging. Again the groups older than the 55
– 64 year old group were comparatively under-represented likely due to difficulties in
being able to participate in the study. Those better educated had a higher participation
rate possibly on the basis of their having a greater interest in research participation. Men
were also somewhat over represented, though note that the confidence interval nearly
includes one.
In an earlier analysis of participation bias in Round 1 of the PAVD study
(Jacobsen et al., 2004) a similar group of factors had been analyzed, but there only age,
COPD, and education demonstrated a statistically significant differential in participation.
The direction of these earlier participation differentials was the same as that in the present
analysis. Thus, it is important to recognize that in Round 2 these factors will be even
more divergent from the original population-based sample from which Round 1 had been
drawn. These differences from the population at large have been acknowledged in the
interpretation of the study results. However, relevant to endpoints of the present study, as
presented in Table 15 there was no statistically significant difference in participation
related to BMI, having undergone clinical PSG, or having a clinical OSA diagnosis.
This study then considers the resulting PAVD round 2 sample of 1,417
participants. Tables 17 and 18 provide a descriptive analysis of this sample related to
continuous and categorical variables, respectively. An analysis of gender differences in
the sample is also presented.
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Table 17
Descriptive Analysis of PAVD Round 2 Participants (n=1,417 including 49.6% males)
with Gender Comparison for Continuous Variables
standard mean
mean
mean median
na
deviation (male) (female)
Age, round 2 (years)
1417 65.2
64.0
9.6
64.9
65.4
Education, round 2 (years)
1373 14.3
14
2.6
14.6
14.0
BMI, round 1
1417 28.3
27.6
5.1
28.9
27.7
BMI, round 2
1417 28.5
27.9
5.1
29.1
28.0
BMI difference, round 2 – round 1
1417 0.24
0.29
1.9
0.24
0.25
Echocardiographic characteristics,
round 2
Ejection fraction (%)
1073 65.7
66.3
7.7
63.8
67.3
1364 24.7
23.4
8.5
25.7
23.7
Left atrial volume index (ml/m2)
Lipid Profile, round 1
Total cholesterol (mg/dl)
1411 203.1 201.0
34.2
196.4
209.7
Triglycerides (mg/dl)
1413 145.1 126.0
80.1
147.7
142.5
High density lipoprotein (HDL)
1411 46.1
44.0
14.2
39.5
52.6
(mg/dl)
Low density lipoprotein (LDL)
1411 128.0 127.0
31.4
127.3
128.6
(mg/dl)
Charlson Index, round 2
1402 3.27
3.0
2.53
3.51
3.05
Biometric measurements, round 2
Hip circumference (cm)
1416 104.1 103.0
9.8
104.4
103.9
Neck circumference (cm)
1415 37.3
37.0
4.3
40.4
34.3
Waist circumference (cm)
1416 92.2
92.0
14.9
100.2
84.4
Waist-Hip Ratio
1416 0.884 0.889
0.102
0.959
0.810
a
Number of participants with data for variable. b Student t-test for difference of gender means.

pb
0.33
<0.0001
<0.0001
<0.0001
0.94
<0.0001
<0.0001
<0.0001
0.22
<0.0001
0.45
0.0006
0.39
<0.0001
<0.0001
<0.0001
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Table 18
Descriptive Analysis of PAVD Round 2 Participants (n=1417 including 49.6% males)
with Gender Comparison for Categorical Variables
Variable

na

%b

male %c

female %c

pd

Marital status (married vs not-married)
1416
79.1
87.3
71.0
0.04
Education (at least some college vs ≤high school)
1380
65.1
66.7
63.6
0.22
Race/ethnicity (Caucasian, non-Hispanic vs other)
1417
97.7
97.4
98.0
0.44
Atrial fibrillation or Atrial flutter
1417
5.9
7.4
4.3
0.01
Coronary artery disease (CAD)
1417
15.0
23.6
6.6
<0.0001
NonCAD cardiovascular disease
1264
38.3
39.8
36.7
0.26
Any cardiovascular disease
1266
40.8
43.9
37.5
0.02
Congestive heart failure
1417
2.2
2.8
1.5
0.09
COPD
1223
7.1
8.8
5.4
0.02
Cerebral vascular accident
1220
3.4
3.4
3.3
0.90
Hypertension
1417
42.6
42.5
42.7
0.94
Diabetes mellitus, Type 2
1234
11.8
15.7
7.9
<0.0001
REP search identified
1417
29.4
32.1
26.8
0.03
e
Clinically diagnosed OSA
1417
13.5
19.8
7.4
<0.0001
Clinical testing by PSG e
1417
14.4
20.5
8.4
<0.0001
a
Number of participants with data for variable. b Percentage with the first of the two dichotomous choices
listed with the variable; for medical disorders and testing, percentage having the disorder or test.

c

The

proportion of male and female round 2 participants with the first of the two dichotomous choices, the disorder
or test.

d

p-value for Chi Square Likelihood Ratio comparing genders.

e

Based on the validation analysis

presented in Table 13 (and following) the OSA and PSG status for all participants is presumed to have been
ascertained.

The mean age of the round 2 sample was 65.2 ± 9.6 years and a median of 64
years as illustrated in Table 17. This is 2.4 years older than the original round 1 mean
age; however, the mean age difference from round 1 to round 2 for round 2 participants
was 4.03 years, consistent with the original study’s designed four year follow up
(Redfield et al., 2003). Round 2 females were slightly but not significantly older than
males. As a socioeconomic marker, education was evaluated using both the continuous
variable, total years of education (Table 17), and as dichotomous variable (Table 18)
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comparing those with no more than a high school education with those having at least
some college. Education levels when compared by gender using the dichotomous variable
were not significantly different; however, using the continuous variable the mean 0.6 year
difference was highly significant statistically. A large majority, 79.1%, of the sample was
currently married with men statistically more likely to be married (87.3%) than women
(71.0%). The race/ethnicity dichotomous variable considered participants as either,
Caucasian, non-Hispanic, or other, and demonstrated this sample to be quite
homogeneous with 97.7% of the sample identified as Caucasian, non-Hispanic. As table
15 illustrates there was no statistical difference with regard to race and ethnicity from
round 1 to round 2. However, the original round 1 sample and the round 2 sample do
over represent this racial and ethnic category since U.S. Census Bureau data (US Census
Bureau, 2010) indicate that Olmsted County was 95.3% and 89.0% Caucasian, nonHispanic in 1990 and 2000, respectively. Thus, this study’s result should not be
extrapolated to non-Caucasian and Hispanic populations.
Analysis of obesity in the sample demonstrates that the BMI for the round 2
participants had significantly (p<0.0001) increased from round 1 to round 2 (mean BMI
28.5 vs. 28.3), and that men were statistically more obese than women (mean BMI 29.1
vs. 28.0). However, the increases from round 1 to round 2 for men and women were not
statistically different (p=0.94). Two echocardiographic characteristics were considered,
ejection fraction which is a measure of systolic function, and left atrial volume index, a
measure of left atrial size that has been correlated with OSA and atrial fibrillation (Orban
et al., 2008; Rodrigues et al., 2009; Toh et al.). In comparing the genders, both of these
variables were statistically different. Other biometric measures of body habitus show that
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men and women did not differ significantly in hip circumference, whereas there was, as
expected, a statistically significant difference in neck and waist circumference as well as
waist-hip ratio.
Analysis of clinical variables in Table 18 demonstrates that, in this sample, men
were more likely than women to have atrial fibrillation/flutter, CAD, COPD, type 2
diabetes mellitus, and a composite of any cardiovascular disease. This increased
morbidity is also illustrated by a statistically higher Charlson Index for men than women
(3.51 vs. 3.05). However, there was no statistical difference in the prevalence of
cerebrovascular accidents and hypertension between men and women in this sample.
Round 2 participants’ lipid profile data collected at round 1 demonstrated a higher total
cholesterol and HDL cholesterol for women than men with there being no statistical
difference between the genders for triglyceride and LDL cholesterol levels.
As described in more detail in Table 22, chart review found 204 (14.4%) of round
2 participants had undergone a clinical PSG and that 197 (13.5%) had clinically
diagnosed OSA. Men were 2.68 times more likely to have clinically diagnosed OSA than
women, and 2.44 times more likely have undergone PSG with both of these differences
statistically significant (p<0.0001).
In summary, the round 2 sample was relatively gender balanced, with a mean age
of 65.2 years. Multivariate participation bias analysis from round 1 to round 2
demonstrates underrepresentation of the youngest and oldest, women, those less
educated, and those with co-morbidities generally based on the Charlson Index, and
specifically related to COPD and nonCAD cardiovascular disease. There were a number
of gender differences with men being more obese, having greater morbidity related to

123
atrial fibrillation/flutter, CAD, COPD, type 2 diabetes mellitus, and a composite any
cardiovascular disease measure. Men were also far more likely to have undergone PSG
and to be diagnosed with OSA.
OSA Risk by BQ, Analysis of Scoring Modification, and Diagnostic Performance
The round two survey for the PAVD study had included questions for the
modified BQ with participants’ responses having been coded in the PAVD database. For
this study the BQ responses were among the fields extracted from that database and
ultimately merged with the clinical chart review data for analysis in this study. The BQ
responses were scored based on the originally validated algorithm (Netzer et al., 1999;
"Reprinting of the Berlin Questionnaire," 2000) and OSA risk classifications were
assigned. In round two 705 (49.8%) participants were at high risk for OSA as
demonstrated in Table 19 which also includes age and gender specific prevalence rate for
this population.
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Table 19
BQ OSA Risk & Prevalence by Age and Gender
OSA risk by BQ, Netzer scoring algorithm
Gender, round 2
("Reprinting of the Berlin Questionnaire," 2000)
Age (yrs)
Prevalence
Low
High
Total
% (95% CI)
Overall

712

705

1417

49.8

(47.2 - 52.4)

Women

416

298

714

41.7

(38.1 – 45.3)

45-54
55-64
65-74
75+

66
158
117
75

42
112
91
53

108
270
208
128

38.9
41.5
43.8
41.4

(29.7 – 48.1)
(35.6 – 47.4)
(37.1 – 50.5)
(32.9 – 49.9)

296

407

703

57.9

(54.3 – 61.5)

60
97
88
51

71
144
130
62

131
241
218
113

54.2
59.8
59.6
54.9

(45.7 – 62.7)
(53.6 – 66.0)
(53.1 – 66.1)
(45.7 – 64.1)

Men
45-54
55-64
65-74
75+

These prevalence rates are substantially higher than those reported in the literature
as summarized in Table 1. A previous application of the BQ to assess prevalence had
indicated gender specific rates of 37.9% and 27.8% for men and women, respectively,
from a nonpopulation-based sample in Cleveland, Ohio (Netzer et al., 2003). The
previous study (Redline et al., 2003) that most closely approximates the prevalence noted
here was done in a much younger population with a mean age of 32 compared to 65.2 in
the present study. The gender differential and increasing prevalence prior to age 65
demonstrated here is also consistent with previous studies as described in Table 1 and
elsewhere (Young, Peppard et al., 2002). Thus, based on the application of the BQ in this
study it appears that the prevalence of OSA is greater than most prior studies, but follows
a pattern otherwise similar to previous studies.
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As noted in this study’s literature review the wording, use of questions, and the
scoring algorithm for the BQ have varied somewhat in applications reported in the
literature. In the application of the BQ in this study there were two questions regarding
nodding off or falling asleep while driving (Table 3, questions 8 and 9) that were not used
due to concerns regarding vicarious liability (A.S. Gami, personal communication, July
17, 2007). Excluding these questions from this application of the BQ while using the
same scoring algorithm that was used in the original validation study (Netzer et al., 1999;
"Reprinting of the Berlin Questionnaire," 2000) would lead to lower scores in category
two (Table 3) and a lower rate of high OSA risk classification for this study compared to
the instrument’s original application.
Though it is not possible to accurately predict what responses to these questions
might have been in this study, 19.0% of the participants responding to this question in the
original validation study (Netzer et al., 1999) had reported nodding off or falling asleep
while driving (Table 2, p. 488) including 4.4% who reported doing so at least three times
weekly. In that study a total of 231 (31.0%) participants had met the scoring threshold for
a positive category two.
In the present study there were only 177 (12.7%) participants that were positive in
category two. However, among the 1222 participants with a negative category two, 532
(43.5%) were still classified as high risk based on their responses to questions in
categories one and three. Had there been a similar portion (31%) with a positive category
two, there would have potentially been an additional 18.3% of the sample with a positive
category two, though some portion of these would likely have already met the threshold
for high risk based on category one and three responses. Thus, it is likely that the
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exclusion of questions 8 and 9 from Table 3 in this application of the BQ has
underestimated the prevalence of high risk for OSA by no more than about 15%.
An analysis of a difference in the BQ scoring algorithm used previously in our
institution also is an example of the impact on overall BQ performance with a difference
in the algorithm used for a threshold-based classification system. The first published use
of the BQ to assess OSA risk in our institution (Gami et al., 2004) had not scored
question one as part of a positive determination for category one in Table 3. That study
had validated the BQ based on a subset of 44 patients who had clinical PSGs performed
during the course of their care. In this validation set a sensitivity of 86%, specificity of
89%, and a positive predictive value of 97% had been demonstrated. However, the
original validation study for the BQ (Netzer et al., 1999; "Reprinting of the Berlin
Questionnaire," 2000) had scored question 1 as one of the items included in a positive
determination for category one. To evaluate the impact of this variation in scoring
algorithm the BQ responses for this study were scored using both algorithms for
comparison.
In round two of this study 1417 participants completed the BQ with 1355
responding to question one which had included a “don’t know” response. Of these
respondents, 1322 reported knowing their snoring status including 989 indicating that
they snored and 333 that reported not snoring. An additional 33 reported not knowing
their snoring status. Based on these responses the original scoring algorithm (Netzer et
al., 1999; "Reprinting of the Berlin Questionnaire," 2000) would have numerically scored
989 (69.8%) participants differently than the previous application and validation of the
instrument in our institution (Gami et al., 2004). However, because the BQ algorithm
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places participants in a high risk category based on a threshold in each of three
categories, it is possible that these 989 participants met the category one threshold
without having question one scored, or met criteria for the high risk classification in
categories two and three alone. Thus, additional analysis was carried out to determine the
actual impact of this algorithm difference on the BQ OSA risk classification.
This analysis is presented in Table 20. Based on this OSA risk classification
comparison for these two algorithms 168 (11.9%) participants were classified as low risk
for OSA by the Gami algorithm whereas the Netzer algorithm classified them as high
risk. For the 989 (69.8% of the sample) participants that reported snoring that could have
led to BQ risk misclassification comparing the Gami and Netzer algorithms, only 168
were ultimately misclassified. Thus, with a threshold-based scoring system a variation in
the scoring algorithm does not misclassify all those responding to the items associated
with the algorithm variation. Note that, as illustrated in Table 3, this study used the
originally validated scoring algorithm for responses to question 1 rather than the Gami
algorithm.
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Table 20
Comparison of BQ risk classification for Netzer and Gami Scoring Algorithms
BQ score & OSA risk, Netzer algorithm
Low risk
BQ score & OSA risk,
Gami algorithm
Low Risk
0
1
High Risk
2
3
Total

High risk
Total

0

1

2

3

166
0

144
402

0
168

0
0

880

0
0

0
0

442
0

19
76

537

712

705

1417

This study’s REP directed chart review identified 204 participants that had
completed the BQ and had undergone clinical PSG testing. Therefore it is possible to
construct a PSG-based validation analysis for BQ diagnostic performance in assessing
OSA risk. Because the diagnoses made by a clinician evaluating the patient consider a
variety of factors in addition to the PSG-based AHI, there was variation between the
clinical diagnosis and the AHI-based diagnosis for 27 participants. Table 21 presents
two-by-two table analyses of BQ validation and performance for both AHI-based and
clinical OSA diagnoses.
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Table 21
Validation of the BQ with Diagnostic Performance by Clinical and AHI-Based OSA Diagnoses
Clinical diagnosis
AHI-based diagnosis
Risk by BQ
OSA
No OSA
OSA
No OSA
Total
High
148
17
136
29
165
Low
32
7
28
11
39
Total
180
24
164
40
204
BQ diagnostic performance (95% CI)
Sensitivity

148
= 82 .2% ( 77 − 88 %)
180

136
= 82.9% (77 − 89%)
164

Specificity

7
= 29.2% (11 − 47%)
24

11
= 27.5% (14 − 41%)
40

Positive Predictive Value

148
= 89.7% (85 − 94%)
165

136
= 82.4% (77 − 88%)
165

Negative Predictive Value

7
= 17.9% (6 − 30%)
39

11
= 28.2% (14 − 42%)
39

In previous studies of test validation based in clinical practice test verification
bias has been recognized as impacting diagnostic performance in this setting (Roger et
al., 1997). In clinical practice, though it is unlikely that the BQ is formally used broadly,
clinicians now are likely recognize elements of the BQ as OSA risk factors and pursue
PSG for participants likely to have OSA. So it might be expected that those undergoing
PSG are more likely to ultimately be found to have OSA. Indeed in round two only a
minority, 11.8% - 19.6%, of those undergoing clinical PSG ultimately were found not to
have OSA depending on whether a clinical or AHI-based diagnostic criterion was used.
Thus, this BQ validation analysis will be less robust with regard to specificity and
negative predictive value (NPV), and more robust for sensitivity and positive predictive
value (PPV) as is illustrated by the confidence intervals in Table 21.
When comparing the BQ performance in this analysis with the published
literature as displayed in Table 3, values for sensitivity and PPV are similar and
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sometimes higher, whereas those for specificity and NPV are generally lower. Thus,
based on the analysis in this sample with over 80% prevalence of OSA, the BQ appears
to be a substantially better instrument to screen for OSA, than it is to rule out OSA.
Indeed among those that were at high risk for OSA based on the BQ and were studied by
PSG, only 10.3% - 17.6% were ultimately found not to have OSA by clinical and AHIbased diagnostic criteria, respectively. By contrast, for those identified as being at low
risk by the BQ a majority, 71.8% - 82.1%, were ultimately found have OSA and
represent false negatives by the BQ.
Clinical Recognition of Those with OSA by BQ
As previously described this study used the REP resources to identify participants
with diagnostic and procedure codes indicating that a sleep-related diagnosis had been
made or PSG had been performed. That process had identified 608 participants from
round one of the PAVD study. In addition there were five participants not previously
included in round one as an echocardiogram was not completed but that were invited to
round two, and 15 additional participants that had completed the round two survey
including the BQ but had not completed the round two echocardiogram. In addition, as
previously described, 50 round one participants were randomly selected for manual
review to validate the REP search criteria. The clinical records for all of these
participants were manually reviewed; however, because several these participants were
identified for review by more than one of these methods, ultimately there were 666 round
one participants’ records that underwent review, including 460 round two participants.
Among the 666 round one participants a total of 280 participants were identified
with at least one clinical PSG including 204 round two participants. The clinicians caring
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for these 204 participants reported a clinical diagnosis of OSA in 180 of these
participants, whereas AHI-based criteria for OSA were met in only 164 of these
participants. In addition, there were 12 of the 256 round two participants without a PSG
for which there was a clinician reported OSA diagnosis based on clinical symptoms, or
possibly other diagnostic testing such as overnight oximetry. Combining the clinician
reported and AHI-based OSA diagnoses then classified a total of 197 of the 460
participants whose charts were reviewed having clinically recognized OSA. Table 22
tabulates these diagnoses based on the presence of at least one PSG in the available
clinical record.
Table 22
Clinician Reported and AHI-Based OSA Diagnoses
Type of OSA diagnosis

PSG

No PSG

Total

Clinician reported

Present
Absent

180
24

12
244

192
268

AHI-based

Present
Absent

164
40

0
256

164
256

Clinician reported or
AHI-based

Present
Absent
Total

185
19
204

12
244
256

197
263
460

Consideration of the data in Table 22 demonstrates that there were five
participants for whom AHI-based diagnostic criteria for OSA had been met which were
not confirmed by the clinician, 21 clinician reported diagnoses that were not supported by
the PSG performed, and 12 diagnoses made without the benefit of PSG. This analysis
illustrates that, though the PSG is an important element in the clinical diagnosis of OSA it
appears not to represent a sine qua non for OSA. For the purpose of the analyses of the
clinical recognition of OSA which follow, these 197 participants recognized by either
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clinician reported OSA diagnosis or AHI-based OSA diagnostic criteria will be
considered to have been recognized clinically with OSA.
Table 23
Clinical Recognition of OSA in Round two Subjects Considering the BQ’s PPV, and NPV

OSA clinically recognized
Predicted number with OSA
based on BQ PPV & NPV (95% CI) a

BQ
High Risk
(n=705)

BQ
Low Risk
(n=712)

Total
(n=1417)

160

37

197

508
(486-529)

292
(271-313)

800
(757-842)

Clinical recognition rate based on predicted
31.5%
12.7%
24.6%
number with OSA (95% CI) b
(27.5%-35.5%)
(8.9%-16.5%
(21.6%-27.6%)
a
Table 6, AHI>5 without regard to symptoms: PPV 72%, NPV 59%; 95% CI based on the CI for PPV
& NPV from Table 6.

b

95% CI based on portion recognized from the number predicted to have OSA.

Table 23 demonstrates that 160 of the 705 participants with BQ identified high
risk for OSA have been clinically recognized in this sample. This represents 22.7% (95%
CI: 20 – 26%) of those at high risk. However, the BQ is known to have a PPV and NPV
of less than 100%. Using the PPV and NPV values reported from a pooled analysis based
on the 1038 participants in nine published studies in Table 6, a PPV of 72% and a NPV
59% are used to predict the actual number of participants with OSA in the sample in this
study. Based on these estimated numbers of participants with OSA in this sample, an
estimated 24.6% of those with OSA have been clinically recognized.
Consideration of these confidence intervals demonstrates that the rate of clinical
recognition is not significantly different whether assuming a PPV and NPV of 100%, or
an actual PPV and NPV from Table 6. In addition, use of the actual PPV and NPV only
allows prediction of a number of participants likely to actually have OSA based on the
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BQ. It does not allow prediction of the specific participants in high or low BQ risk
groups that will actually have OSA. There are also no reliable data regarding the
variation of the BQ PPV and NPV by age, gender or other variables germane to the
analyses which follow. Therefore, the following analyses will be based on BQ OSA risk
without accounting for the PPV and NPV of the instrument.
Bivariate analysis of demographic characteristics potentially associated with
clinical recognition is displayed in Table 24. Gender difference is highly predictive (p
<0.0001) of clinical recognition with the rate of recognition for males more than twice
that for females. Age, considered as a continuous variable, reaches statistical significance
(p = 0.043) as a predictor of clinical recognition with those recognized being, on average,
1.7 years younger than those with unrecognized OSA. However, when age is considered
as a categorical variable in 10-year increments it is no longer statistically significant in
predicting clinical recognition.
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Table 24
Bivariate Analysis of Demographic Characteristics and Clinical OSA Recognition
BQ High
Mean
Clinically
Demographic Characteristic
Risk
Recognized,
Recognized
(n)
Unrecognized
(%)
Gender
Male
Female
Age
45-54
55-64
65-74
75+
Age by Gender
Male Age
45-54
55-64
65-74
75+
Female Age
45-54
55-64
65-74
75+
Educationb
At least some college
No more than high school
Education by Gender
Male Educationb
At least some college
No more than high school
Female Educationb
At least some college
No more than high school
Marital Status
Currently married
Not currently married
Marital Status by Gender
Male
Currently married
Not currently married
Female
Currently married
Not currently married

407
298

29.5
13.4

705
113
256
221
115

63.8, 65.5 yrs

407
71
144
130
62
298
42
112
91
53

63.9, 65.3 yrs

686
435
254

14.7, 14.1 yrs

395
255
143
291
180
111

14.8, 14.2 yrs

pa

< 0.0001c
0.043 c

20.0
36.9
31.3
11.9

0.20

0.19
33.8
29.9
29.2
24.2

63.4, 65.8 yrs

0.68
0.14

19.1
14.3
13.2
7.6

0.40
0.015 c

23.7
22.4

0.71
0.056 c

31.4
28.0
13.9, 14.1 yrs

0.48
0.58

12.7
15.3

0.54

568
136

23.4
19.9

0.37

360
46

30.3
23.9

0.36

208
90

11.5
17.8

0.16
(table continues)
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Note. Totals for analyses are not always equal to sample and gender totals due to missing
data for individual variables.
a

p-values represent chi square likelihood ratios for categorical variables and comparison

of means and Student t-test for continuous variables. b The continuous education variable
is total years of educational attainment. c Parameter considered statistically significant and
retained in the initial multivariate logistic regression.

Because gender was so highly significant in predicting clinical recognition, age,
education, and marital status were analyzed both in the total sample and segregated by
gender. Years of educational attainment as a continuous variable was predictive of
clinical recognition with those recognized having, on average, 0.6 years more education
than those with unrecognized OSA. Segregated by gender, years of educational
attainment only approached statistical significance for males. When education was
dichotomized to at least some college versus no more than a high school education, it was
not a significant predictor of clinical recognition. Marital status was not a predictor of
clinical OSA recognition in the total sample or when segregated by gender. Among these
demographic factors, gender, age, and education appear to be significant predictors of
clinical recognition, the latter two variables only when considered as continuous
variables.
As previously noted in chapter 2, BMI is a significant OSA risk factor with a one
standard deviation difference in BMI increasing the odds of OSA by 55% (Young,
Shahar et al., 2002), and a longitudinal weight increase of 10% associated with a 32%
increase in OSA severity (Peppard et al., 2000). The standard epidemiology classification
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of BMI includes <20 under weight, 20 – 25 normal weight, 25 – 29 overweight, and >30
obese. This classification was used to assign BMI groups in this study for round 1 and
round 2.
As a longitudinal study PAVD data allows assessment of clinical recognition
based on the BMI at the time of BQ completion (round 2), an average of four years
previously (round 1), and based on the change in BMI during this four year interval. The
bivariate analysis for these BMI characteristics is presented in Table 25 for the entire
sample at high risk of OSA based on the BQ. Note that BMI at either round 1 or round 2
considered as either a continuous or ordinal variable was associated with a statistically
significant difference in clinical recognition with those with a higher BMI most likely to
be clinically recognized. However, the BMI difference from round 1 to round 2 was only
associated with a significant difference in clinical recognition when considered based on
the change in BMI group. It appears that those most likely to be clinically recognized
were those with the least change in BMI.
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Table 25
Bivariate Analysis of BMI Characteristics Comparing Those with Clinically Recognized and
Unrecognized OSA Among Those at High BQ Risk
BQ High
Risk
(n)

Mean
Recognized,
Unrecognized

Round 2
<20
≥20 - <25
≥25 - <30
≥30

705
10
89
212
394

33.5, 30.0

Round 1
<20
≥20 - <25
≥25 - <30
≥30

705
11
82
253
359

33.0, 29.7

BMI Characteristic

Clinically
Recognized
(%)

pa
<0.0001b

0
12.4
15.6
29.4

<0.0001

<0.0001 b
0
14.6
15.0
30.6

<0.0001

Difference, round 2 – round 1
705
0.49, 0.35
0.47
Group difference, round 2 – round 1
2 group decline
2
0
1 group decline
48
10.4
0.012 b
No change in group
573
25.0
1 group increase
82
14.6
a
p-values represent chi square likelihood ratios for categorical variables and comparison of
means by Student’s t-test for continuous variables.

b

Parameter considered statistically

significant and retained in the initial multivariate logistic regression model. Where continuous
and ordinal variables are both significant only the continuous variable was retained.
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As noted above in Table 24 there was a substantial difference in OSA clinical
recognition by gender. Thus, gender specific bivariate analyses of BMI characteristics
were performed. The p-values for these gender specific analyses are summarized in
Table 26. Note that the BMI at either round 1 or 2 was, similar to the overall sample,
statistically associated with a difference in clinical recognition for either gender whether
considered as an ordinal or continuous variable. Again, BMI difference was not
statistically significant for either gender when considered as a continuous variable. In
this gender segregated analysis, however, the BMI group difference between round 1 and
2 was only significant for males with those with no change in BMI group most likely to
be clinically recognized (32.0%) compared to those with increasing (18.2%) or
decreasing (16.0%) BMI group.
Table 26
Bivariate Analysis of BMI Characteristics Comparing Those with Clinically Recognized
and Unrecognized OSA Among Those at High BQ risk by Gender
p-values a
BMI Variable
All
Male
Female
Round 2b
<0.0001 c
<0.0001 c
<0.0001 c
Round 2 group
<0.0001
0.0037
0.0030
Round 1b
<0.0001 c
<0.0001 c
<0.0001 c
Round 1 group
<0.0001
0.0005
0.0056
Difference, round 2 – round 1b
0.47
0.23
0.92
c
c
Group difference, round 2 – round 1
0.012
0.041
0.33
a
p-values represent chi square likelihood ratios for categorical variables and comparison of
means by Student’s t-test for continuous variables.

b

Continuous variable.

c

Parameter

considered statistically significant and retained in the initial multivariate logistic regression
model. Where continuous and ordinal variables are both significant only the continuous
variable was retained.
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OSA is associated with a number of chronic medical problems including
cardiovascular disease (Caples et al., 2007), cerebrovascular disease (Yaggi et al., 2005),
metabolic syndrome (Coughlin et al., 2004), and hypertension (Duran et al., 2001). It is
conceivable that participants with these other medical problems would be more likely to
have been clinically recognized with OSA with the care provided for these problems than
those without such problems. PAVD study participants have been well characterized with
regard to cardiovascular disease, myocardial function, and a variety of other medical comorbidities. Thus, bivariate analyses of selected measures of cardiovascular disease and
other co-morbidities were carried out.

Table 27
Bivariate Analysis of Clinical Characteristics Comparing Those with Clinically Recognized and Unrecognized OSA Among Those at High BQ Risk
BQ
Clinical Recognition (%)b
pc
Mean a
High
Clinical Characteristic
Risk
Recog- UnrecogWith
Without
All
Male
Female
(n)
nized
nized
Atrial fibrillation or flutter
49
28.6
22.2
0.32
0.52
0.92
Coronary artery disease (CAD)
140
23.6
22.5
0.78
0.29
0.83
NonCAD CV disease
279
22.9
23.9
0.77
0.48
0.96
Any CV disease
299
22.4
24.3
0.57
0.19
0.90
Congestive heart failure
23
34.8
22.3
0.18
0.22
0.95
COPD
50
28.0
22.8
0.40
0.57
0.99
Cerebrovascular accident
30
20.0
23.3
0.68
0.98
0.51
0.03 d
0.38
Diabetes mellitus (Type 2)
103
34.0
21.2
0.007 d
Hypertension
459
23.3
21.5
0.59
0.96
0.15
Echocardiogram parameters, round 2
Diastolic myocardial dysfunction
308
23.7
20.4
0.32
0.18
0.92
Systolic myocardial function (EF%)
503
64.7
65.7
0.23
0.55
0.35
680
27.4
25.7
0.039 d
0.20
0.45
Left atrial volume index (ml/m2)
Lipid profile analysis, round 1
0.59
0.46
Total cholesterol (mg/dl)
701
196.9
203.2
0.047 d
0.90
Triglyceride (mg/dl)
702
167.4
154.1
0.088
0.03 d
0.01 d
0.09
HDL (mg/dl)
701
38.2
43.7
<0.0001 d
Calculated LDL (mg/dl)
701
125.3
128.7
0.24
0.32
0.85
Biometric parameters, round 2
Hip size (cm)
705
112.2
106.4
<0.0001 d <0.0001 d <0.0001 d
Neck size (cm)
704
41.3
38.2
<0.0001 d <0.0001 d <0.0001 d
Waist (cm)
705
107.0
96.4
<0.0001 d <0.0001 d <0.0001 d
0.0003 d
0.59
Waist-Hip Ratio
705
0.955
0.905
<0.0001 d
a

The means for the characteristic for those with clinically recognized and unrecognized OSA for both genders.

b

The rate of clinical recognition with

and without the identified clinical characteristics for both genders. c p-values represent chi square likelihood ratios for categorical variables and
comparison of means and Student t-test for continuous variables.

Parameter considered statistically significant and retained in the initial multivariate
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logistic regression model.

d
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Based on the analyses in Tables 25 – 27 the following variables are included in an
initial multivariate logistic regression analyses for OSA clinical recognition: gender, age,
years of education, BMI at rounds 1 and 2, BMI group difference from round 1 to 2, type
2 diabetes mellitus, left atrial volume index, total cholesterol, HDL, hip circumference,
waist circumference, neck size, and waist to hip ratio. Table 28 depicts the subsets of
variables entered into the initial modeling of gender-stratified logistic regression
analyses. In a stepwise manner factors with p values greater than 0.05 were removed
from the model until all remaining variables were statistically significant. The odds ratios
from the resulting final model are depicted in Table 29.
Table 28
Factors Identified from Bivariate Analyses for Inclusion in the Initial Multivariate
Logistic Regression Models for the Prediction of OSA Clinical Recognition
All
Male
Female
Gender
Age (years)
Education (years)
Education (years)
BMI, round 1
BMI, round 1
BMI, round 1
BMI, round 2
BMI, round 2
BMI, round 2
BMI group difference
BMI group difference
Diabetes mellitus, type 2
Diabetes mellitus, type 2
LA volume index
Total cholesterol
Triglycerides
HDL cholesterol
HDL Cholesterol
Hip circumference
Hip circumference
Hip circumference
Neck circumference
Neck Circumference
Neck Circumference
Waist circumference
Waist circumference
Waist circumference
Waist-Hip Ratio
Waist-Hip Ratio
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Table 29
Adjusted ORs for Clinical Recognition of OSA Among Those at High
Risk by BQ with Gender Stratified Analysis
OR
95% CI
p
All (n=686)
Education, total (1 year)
BMI, round 1 (5 kg/m2)
Neck circumference (2.5 cm)

1.10
1.48
1.44

1.03 – 1.19
1.21 – 1.81
1.27 – 1.64
R2=0.1217

0.005
0.0001
<0.0001

1.02 – 1.20
1.19 – 1.44
R2=0.0784

0.01
<0.0001

1.52 – 2.75
R2=0.1021

<0.0001

Male (n=395)
Education, total (1 year)
Waist (5 cm)

1.10
1.31
Female (n=298)

2

BMI, round 1 (5 kg/m )

2.02

This modeling demonstrates that most of the variables in the mixed gender
analysis apply to only one of the two gender-specific analyses. An additional mixed
gender model was therefore constructed with interaction terms for each of these variables
with gender; however, none of these interaction terms remained significant following
stepwise regression. Given the significant differences between the genders a mixed
gender analysis was performed with gender being retained throughout the stepwise
regression even when not statistically significant. The model resulting from this analysis
is depicted in Table 30.
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Table 30
ORs for a Final Logistic Regression Model with Gender Included
OR
95% CI
p
All (n=686)
Gender (male as reference)
Education, total (1 year)
BMI, round 1 (5 kg/m2)
Neck circumference (2.5 cm)

0.76
1.10
1.66
1.27

0.55 – 1.03
1.02 – 1.18
1.31 – 2.11
1.05 – 1.54
R2=0.1259

0.08
0.009
0.0001
<0.0001

This model suggests that education, BMI, and neck circumference are the primary
predictors of clinical recognition with a 1 year educational increase increasing the
likelihood of recognition by about 10%, a BMI increase of 5 kg/m2 increases the
likelihood of recognition by about 66%, and an 2.5 cm increase in neck circumference
increases the likelihood of recognition by 27%. Though gender only approaches
statistical significance, this model suggests that, holding education, BMI, and neck
circumference constant, women are 24% less likely to be recognized than men.
Research Question One
What proportion of those at high risk for OSA based on the Berlin Questionnaire
have been clinically evaluated for OSA?
This study sought to determine the proportion of those at high risk for OSA based
on the BQ that had been clinically-evaluated for OSA. The gold standard for the clinical
diagnosis of OSA is PSG. The analysis that follows is based both on that gold standard,
and a review of narrative descriptions in the clinical record describing participants’
clinical evaluation.
The REP search process had been designed using a broad group of sleep-related
diagnosis and procedure codes in an effort to identify those for whom the diagnosis had
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been considered and evaluation pursued. The REP search had identified 417 participants
in round 2 that had a sleep-related diagnosis or procedure. In addition, there were 37 of
the 50 participants selected at random to valid the REP search criteria and six additional
participants from round 2 that were manually reviewed giving a total of 460 clinical
records that were reviewed.
As demonstrated in Table 31 these reviews identified a total of 192 clinician
reported diagnoses of OSA at the mild level or greater. In addition, there were five
participants that had PSG and met AHI criteria for OSA but did not receive a clinician
verified OSA diagnosis. These five participants had diagnoses reported as mild upper
airway resistance syndrome, REM-related apnea, periodic leg movement disorder (2),
and for one the PSG had been performed only as part of a study protocol. Because these
participants PSGs met criteria for mild OSA with AHI’s ranging from five to 17, these
participants were considered to have clinically recognized OSA for the purpose of this
analysis.
Of the remaining 263 records that were reviewed there were an additional 18 that had
OSA-related diagnoses but were not formally diagnosed as having OSA including six that
had undergone PSG. These diagnoses included upper airway resistance syndrome
(UARS), snoring, and possible sleep disordered breathing (SDB) as well as possible
OSA. Of the 12 of these participants that did not have PSG performed, the clinical record
suggested that eight participants had declined further evaluation including PSG. The
remaining 232 records included nonOSA related sleep diagnoses, most commonly
insomnia or restless leg syndrome (RLS), which had prompted identification by the REP

145
search process. Therefore of the 460 records reviewed, there was evidence that at least
228 had been clinically evaluated more specifically for OSA including 204 for whom
PSG had been performed. The validation of the REP search codes described above
demonstrated that at least 95% of PAVD participants with OSA had been identified.
Table 31
Clinical Diagnosis and PSGs Performed for Round 2 Records Reviewed
Clinical diagnosis

n

PSGs

192

180

5

5

OSA-related diagnosis

6
12a

6
0

NonOSA related diagnoses

13
232

13
0

460

204

OSA, mild or greater
AHI-based criteria for OSA

Total
a

For these 12 participants clinical records indicated that eight had

declined PSG.

Of the 228 clinically evaluated 184 were classified as high risk by BQ, whereas 165
of the 204 undergoing PSG were at high risk. Thus, of the 705 participants at high risk
for OSA based on the BQ, 26.1% (95% CI 22.9 – 29.3%) had undergone clinical
evaluation for OSA including 23.4% (95% CI 20.3 – 26.5%) that had undergone PSG.
Thus, the first null hypothesis for this study, “There is no difference between the
population at high risk for OSA and those that have been clinically evaluated,” is rejected
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and the associated alternate hypothesis, “There is a portion of those at high risk for OSA
that has not been clinically evaluated,” is accepted.
Research Question Two
What is the prevalence of clinically diagnosed OSA among those at high risk for
OSA based on responses to the Berlin Questionnaire?
The prevalence of clinically diagnosed OSA among those classified as high risk
for OSA by the BQ, as described above in Table 23 and following is 22.7% (95% CI 20 –
26%). Recognizing that the BQ does not have a PPV or NPV of 100% the analysis in
Table 23 demonstrated that the recognized prevalence could be as high as 23.6% (95% CI
21 – 26%). A demographic bivariate analysis (Table 24) demonstrated that this
prevalence was substantially higher in males than females, 29.5% (95% CI 25 – 34%) vs
13.4% (95% CI 10 – 17%). In this analysis age also significantly predicts recognition
with those recognized being, on average, 1.4 years younger (p=0.043) than those
unrecognized.
Therefore the second null hypothesis for this study, “There is no difference
between the population at high risk for OSA and those that have been clinically
diagnosed,” is rejected and the associated alternative hypothesis, “There is a portion of
those at high risk for OSA that has not been clinically diagnosed,” is accepted.
Research Question Three
Has the prevalence of clinically diagnosed OSA increased in the past decade?
Previous population-based studies of OSA clinical recognition, as shown in Table
32, reported clinical recognition rates in mixed gender populations from 8.3% and 15.4%
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for moderate to severe OSA, and 6.5% for mild to severe OSA. The present study used
the BQ for OSA identification. The best diagnostic performance of this instrument is for
mild to severe OSA as shown in Table 6. Thus, the more comparable clinical recognition
rates to those found in this study are those reported Young and colleagues (1997) based
on criteria for mild to severe OSA.

Table 32
Previously Reported Prevalence of OSA Clinical Recognition for Those with OSA
Stratified by Gender and Severity
Prevalence of clinical
Number with OSA (n)
recognition among those
Study
Gender
with OSA (95% CI)
moderate to
moderate
mild to
mild to severe
severe
to severe
severe
18.2%
9.0%
Young, Evans et al., 1997
Male
77
93
(9.6 – 26.8%)
(4.5 – 13.5%)
Young, Evans et al., 1997

Female

7.4%
(0 – 17.3%)

2.2%
(0 – 5.1%)

27

155

Young, Evans et al., 1997

All

15.4%
(8.5 – 22.3%)

6.5%
(3.4 – 9.5%)

104

248

Kapur et al., 2002

All

8.3%
(6.2 – 10.4%)

-

650

-

In Table 33 a comparison of these prevalence rates for both genders combined
and gender specific samples, along with the applicable confidence intervals, with those
found in this study demonstrates that the prevalence of clinical recognized OSA has
significantly increased compared to rates reported in 1997. The clinically recognized
prevalence in this study generally appears to be in the range of three to six times as high
as that reported in the most comparable of the previous analyses (Young, Evans et al.,
1997). However, there remains a large majority of OSA, 70.5 – 86.6%, depending on
gender, which remains undiagnosed.
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Table 33
Comparison of the Current Prevalence of OSA Clinical Recognition with Historically Reported Levels
Prevalence of OSA clinical recognition (95% CI)
All
Male
Female
Young et al 1997
6.5% (3.4 – 9.5%)
9.0% (4.5 – 13.5%)
2.2% (0 – 5.1%)
Present study
22.7% (19.6 – 25.8%)
29.5% (25.1 - 33.9%)
13.4% (9.5 – 17.3%)
Prevalence Ratio
3.5 (2.1 – 5.8) a
3.3 (1.9 – 5.7) a
6.2 (1.5 - 25.8) a
a
Confidence interval for rate ratio (Rosner, 2006, p. 757).

Therefore the third null hypothesis for this study, “There has been no change in the
proportion of prevalent OSA that is diagnosed clinically compared to the mid-1990s,” is
rejected and the associated alternative hypothesis, “There has been an increase in the
proportion of prevalent OSA that is diagnosed clinically compared to the mid-1990s,” is
accepted.
Research Question Four
What factors are predictive of the clinical diagnosis of OSA among those at high
risk of OSA?
Bivariate analyses of OSA clinical recognition identified a number of factors
associated with OSA clinical recognition in mixed gender and gender specific strata of
this population as summarized in Table 28. Those factors include the demographic
factors gender, age, and education, the biometric factors BMI, neck, hip, and waist
circumference, and clinical factors related to diabetes and lipid profile. As noted above in
Table 33 there was a statistically significant difference in the prevalence of OSA clinical
recognition between the genders. In gender specific bivariate analysis, the factors
associated with clinical recognition also differed between the genders.
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Multivariate logistic regression analyses using these factors as described above in
Table 29 identifies total years of education, BMI, and waist circumference as statistically
significant predictors of OSA clinical recognition. Gender-specific logistic regression
analysis demonstrates that years of education and waist size predict clinical recognition
for men, whereas BMI is the lone predictor for women.
The unadjusted gender-specific prevalence rates for OSA clinical recognition in
this population demonstrate that men are 2.20 times more likely to be recognized than
women (29.5% vs 13.4%). However, analysis holding gender as a variable in a logistic
regression model regardless of statistical significance suggests that there is only a 24%
(p=0.08) lower clinical recognition rate when years of education, BMI, and neck
circumference are held constant.
The null hypothesis related to this research question was “Among those at high
risk for OSA there is no difference regarding the following characteristics among those
with a clinical diagnosis of OSA than among those undiagnosed: age, gender, BMI, and
socioeconomic status.” In the null hypothesis four factors where hypothesized to be
without difference between those diagnosed and undiagnosed: age, gender, BMI, and
socioeconomic status. Among these factors age was identified as being different in
bivariate, mixed gender analysis (Tables 24 and 28), but was not different in gender
stratified bivariate analyses and not associated with clinical recognition when other
factors were held constant in all of the multivariate analyses (Tables 29 and 30). Thus,
for age, the null hypothesis is accepted.
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Gender was also identified as being different in bivariate analysis (Tables 24 and
28). However, in multivariate analyses (Tables 29 and 30) gender nearly reached
statistical significance with a confidence interval that just included unity (95% CI 0.55 –
1.03) and had a p-value of 0.08. However, because of the divergence of factors associated
with clinical OSA recognition in gender stratified analyses (Tables 24, and 27 – 30)
combined with this near statistical significance, the null hypothesis was de facto rejected
for gender.
With respect to BMI, there was an association with a difference between those
recognized and unrecognized with OSA in mixed gender and gender stratified bivariate
analyses (Tables 25, 26, and 28). In multivariate analyses BMI was found to be
statistically different in mixed gender analyses (Tables 29 and 30), but only for women in
gender stratified multivariate analyses (Table 29). However, for men in gender stratified
multivariate analysis another marker of obesity, waist circumference, was found to be
associated with a clinical OSA recognition difference. Therefore, de facto for BMI
recognized as a measure of obesity, the null hypothesis was also rejected.
Finally, with regard to socioeconomic status, this study represented
socioeconomic status using education variables. Those variables included years of
education, a continuous variable, and the dichotomous variable, “no more than high
school” versus “at least some college.” Only the continuous variable was found to be
associated with a difference between those with recognized and unrecognized OSA in
mixed gender analyses. In gender stratified bivariate analyses this variable was only
associated with a difference for men. Similarly, in multivariate analyses, the variable was

151
only associated with a difference in mixed gender and male specific gender stratified
analyses. Thus, for socioeconomic status, as represented by the variable years of
education, the null hypothesis was rejected.
To summarize, the null hypothesis was accepted for age as follows, “Among
those at high risk for OSA there is no difference regarding the following characteristics
among those with a clinical diagnosis of OSA than among those undiagnosed: age.” By
contrast the null hypotheses were rejected, in some cases de facto, for gender, BMI, and
socioeconomic status, and the following alternative hypothesis was accepted, “Among
those at high risk for OSA the following characteristics will be more common among
those with a clinical diagnosis of OSA than among those undiagnosed: male gender,
higher BMI, and higher socioeconomic status [as represented by years of education].”
Summary
This study used data previously collected as part of the PAVD study (Redfield et
al., 2003) which included responses to a modified BQ. Using the resources of the REP,
those participants likely to have clinically recognized OSA were electronically identified
and their clinical records systematically reviewed manually to obtain data regarding
clinical PSGs performed and OSA diagnoses. To validate the REP identification process
50 randomly selected participants’ records not identified by the REP process were also
manually reviewed. Clinical records for an additional 20 participants not initially
included in PAVD analyses but later identified as having completed the essential
elements for the present study were also manually reviewed. Data from the PAVD
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archive was then merged with data from the record review process to produce the single
database for this study’s analyses.
Analysis of this data first included validation of the REP electronic clinical OSA
identification process. This validation demonstrated that the process was able to identify
more than 95% of participants with clinical OSA with an estimated 98% of sleep-related
diagnoses present at the time of the REP search detected by the process. The PAVD study
was initiated with a population-based sample in 1997 (Ammar et al., 2006; Redfield et
al., 2003). Participation bias had previously been assessed for those participating in round
one of the PAVD study compared to the population-based sample (Jacobsen et al., 2004).
A similar analysis of participation from round one to round two demonstrated
underrepresentation of the youngest and oldest participants, women, those less educated,
and those with co-morbidities generally based on the Charlson Index, and specifically
related to COPD and nonCAD cardiovascular disease.
Descriptive analysis of OSA risk based on responses to the modified BQ
demonstrated that nearly half (49.8%) of round two participants were at high risk of
OSA. Based on comparison with the original BQ validation study (Netzer et al., 1999) it
was estimated that the BQ modifications in this study could have underestimated OSA
prevalence by no more than 15%. The REP guided chart review process identified a total
of 197 round two participants with either a clinician reported or an AHI-based diagnosis
of OSA. Of these 160 were among the 705 participants classified as high risk by the BQ
giving a prevalence of OSA clinical recognition of 22.7% (95%CI 20 – 26%).
Recognizing that this assumes the BQ to have 100% positive and negative predictive

153
values, the prevalence of OSA clinical recognition was recalculated using PPV and NPV
values of 79% and 61%, respectively, for mild to severe OSA from the pooled analysis of
BQ performance representing 586 participants in Table 6. The resulting prevalence of
OSA clinical recognition, 23.6% (95% CI 21 – 26%), did not differ significantly from
that based on the 100% PPV and NPV assumption. Thus, the remainder of the analysis
used BQ high risk as an OSA proxy.
There was a substantial difference in unadjusted gender-specific prevalence rates
for OSA clinical recognition in this population with men 2.20 times more likely to be
recognized than women (29.5% vs 13.4%). Further bivariate analysis of OSA clinical
recognition demonstrated that other demographic factors including age and education,
biometric factors BMI, neck, hip, and waist circumference, and clinical factors related to
diabetes and lipid profile all predicted OSA clinical recognition. However, multivariate
logistic regression analyses identified total years of education, BMI, and waist
circumference as the only statistically significant predictors of OSA clinical recognition
in a mixed gender analysis. Gender-specific logistic regression analysis demonstrated that
years of education and waist size predict clinical recognition for men, whereas BMI is the
lone predictor for women. In mixed gender analysis, holding years of education, BMI,
and neck circumference constant, there was only a 24% (p=0.08) lower clinical
recognition rate for women compared to men.
Finally, though this analysis demonstrates that clinical recognition of OSA is
three to six times greater compared to a previous population based analysis from the
1990s, OSA continues to be substantially (70.5 – 86.6%) under recognized clinically.

CHAPTER 5: SUMMARY, CONCLUSION, AND RECOMMENDATIONS
Overview
OSA is a disorder in which the airway collapses producing airway obstruction
during sleep (Parish & Somers, 2004). It is associated with increased cardiovascular
(Caples et al., 2007) and cerebrovascular (Yaggi et al., 2005) morbidity and mortality,
and increased risk of metabolic syndrome (Coughlin et al., 2004), depression (Peppard et
al., 2006), hypertension (Duran et al., 2001), and automobile accidents (Young, Blustein
et al., 1997). Treatment of OSA, typically with CPAP, attenuates or reverses many of
these associated risks (Doherty et al., 2005; Milleron et al., 2004; Peker et al., 2006).
However, previous studies (Kapur et al., 2002; Young, Evans et al., 1997) based on
1990s data suggest that most OSA is clinically unrecognized.
This study sought to determine the proportion of those with OSA in the
population who have been clinically evaluated and diagnosed. As a longitudinal
benchmark, it also sought to determine if there had been a change compared to earlier
published recognition rates (Kapur et al., 2002; Young, Evans et al., 1997). Finally, the
study sought to identify factors predictive of clinical recognition. Once identified, these
identified factors can then be used to propose strategies for enhanced clinical recognition
that would represent a positive social change.
This study used data previously collected by the PAVD study to identify those at
high risk for OSA based on a modified BQ. The resources of the REP were then used to
identify participants with clinically recognized OSA. Based on a BQ-based OSA proxy,
this study demonstrated that 22.7% (95% CI 20 – 26%) of those with OSA had been
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clinically recognized including 29.5% (95% CI 25 – 34%) of men, but only 13.4% (95%
CI 10 – 17%) of women. Though these rates of clinical recognition represent a three to
six fold increase from those published more than a decade ago (Young, Evans et al.,
1997), it is important to recognize that a majority of OSA remains clinically
unrecognized despite this increased recognition. Multivariate logistic regression analysis
identified education and measures of obesity including waist size for men, and BMI for
women and mixed genders, and neck circumference in mixed gender populations, as
predictors of clinical recognition.
Interpretation of Findings
The first three of the four stages in this study’s analysis were designed to evaluate
(a) the methods used to identify participants with clinically recognized OSA, (b) the
potential for participation bias from round 1 to round 2 of the PAVD study, and (c) the
performance of the high risk classification on the modified BQ as a proxy for OSA in the
sample. Subsequently, in the fourth stage of the analysis, the research questions related to
the prevalence of the clinical recognition of OSA are addressed.
Validation of REP Search Method to Ascertain OSA Clinical Recognition
A collection of sleep-related diagnostic and procedural codes had been used in
search using the resources of the REP to electronically identify those likely to have
clinical recognized OSA. The identified participants’ clinical records were then
systematically reviewed manually to obtain OSA-related data. A validation sample of 50
participants not selected in the electronic search was then manually reviewed to
determine the validity of this electronic process in the identification of clinical recognized
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OSA. The results of this 50 participant review are displayed in Table 13 and demonstrate
that the electronic search had identified more than 95% of participants with clinical
recognized OSA.
This validates the REP search process was being able to comprehensively identify
essentially all participants in the sample with clinically recognized OSA. This method of
ascertaining participants’ status with regard to OSA clinical recognition is in contrast to
those used in previously published studies (Kapur et al., 2002; Young, Evans et al., 1997)
where participant self-report in a survey had been used to ascertain clinical OSA
recognition. The earlier of these two studies had followed up with the 49 participants
who had indicated that they had been told by a physician that they had sleep apnea
(Young, Evans et al., 1997). In follow up, however, 33 of these participants admitted that
they only suspected they had OSA and had not been clinically evaluated or diagnosed.
No attempt was made in either of these studies to validate the responses of participants
indicating that they did not have OSA. Thus, the method used here to ascertain OSA
clinical recognition represents a substantial enhancement compared to previous methods.
Participation Bias from Round one to Round two of the PAVD Study
An earlier PAVD participation bias analysis (Jacobsen et al., 2004) had shown
that, compared to the population-based sample invited, round one participants were more
likely to have more than a high school education and less likely to have COPD. In
addition, those from age 55 – 74 were more likely to have participated than those older or
younger. Because the OSA clinical recognition outcomes in this study are based on the
sample remaining in round two of PAVD, a similar participation bias analysis was carried
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out comparing those participating in round two with those from round one who did not
participate. That multivariate analysis, presented in Table 16, demonstrated that men
were more likely to participate than women, whereas those with less education, COPD,
cardiovascular disease other than coronary artery disease, and greater co-morbidities as
measured by the Charlson Index (Charlson et al., 1987) were less likely to participate.
With education limited to high school and the presence of COPD associated with lower
levels of participation in both analyses, the round two under representation compared to
the population-based sample for these variables is likely to be greater than that suggested
by the Table 16 multivariate logistic regression.
With males over represented by about 24% (95% CI 2 – 53%) in round two, the
overall prevalence of OSA in this sample is likely to be overestimated since men have
been two to three times more likely to have OSA in the general population (Young,
Peppard et al., 2002). Concurrently those with only a high school education are under
represented by about 41% (95% CI 27 – 53%) which, based a previous study (Young,
Evans et al., 1997), was associated with clinical under recognition of OSA. In a large
epidemiologic study, OSA was found not to be associated with COPD (Sanders et al.,
2003). Thus, the overall prevalence of OSA in the round two sample is likely unaffected
substantially by the under representation of those with COPD. Both the Charlson Index
and cardiovascular disease other than coronary artery disease (nonCAD CV disease)
represent mixes of a variety of comorbidities making it difficult to meaningfully predict
the impact of this under representation on the overall prevalence of OSA or its clinical
recognition in the round two sample.
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The participation bias analysis, based only on a consideration of factors for which
prior associations with OSA prevalence or recognition exist, suggests that the round two
sample appears more likely to overestimate the prevalence of OSA and its clinical
recognition than to under estimate these parameters. The magnitude of these deviations
from the original population-based sample invited to round one of the PAVD study,
however, is not possible to predict. Using gender stratified analyses would limit the
impact of the gender differential in round two participation.
Additional variables of particular relevance to this study’s endpoints are those
related to the performance of clinical PSG and the clinical diagnosis of OSA presented in
Table 15. There was no statistical difference after adjustment for age and gender in the
participation rates based on having undergone PSG, or having a clinical diagnosis of
OSA. There also was no statistical difference in the rate of clinical evaluation by PSG (p
= 0.15) or OSA diagnosis (p = 0.15) comparing those in round two with those not
participating in round two prior to age and gender adjustment. Thus, though there may
have been some over representation of those more likely to have OSA among round 2
participants, this appears not to have been significant enough to have led to increased
clinical evaluation or clinical OSA recognition among round 2 participants. Because the
potential over representation appears related to gender, the impact of this potential
participation bias can be attenuated by the gender stratified analyses used in subsequent
analyses.
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Performance of the BQ High Risk Classification as the OSA Proxy
The BQ is an instrument designed to identify those likely to have sleep apnea
(Netzer et al., 1999). As noted in Table 4 it has been used in some 30 previously
published studies sometimes as a proxy for OSA. Table 5 identifies the 10 studies that
have published PSG-based validation data for the instrument whereas Table 6 provides an
analysis of its diagnostic performance at differing levels of OSA severity using data
pooled from these validation studies.
The overall prevalence of OSA in this study based on the BQ OSA proxy was
49.8% (95% CI 47.2 – 52.4%) with gender specific prevalence of 57.9% (95% CI 54.3 –
61.5%) and 41.7% (95% CI 38.1 – 45.3%) for men and women, respectively, as
illustrated in Table 19. This is substantially higher than all but one study (Redline et al.,
2003) of the multiple studies reporting OSA prevalence summarized in Table 1. It is
important to note, however, that the PAVD round two population is substantially older
with a mean age of 65.2 (median 64.0) years and a range from 49.9 to 93.4 years
compared to most studies in Table 1. Knowing that the prevalence of OSA increases with
age (Young, Shahar et al., 2002), this higher prevalence may not be unreasonable for this
older PAVD round 2 population.
The BQ was administered as part of the round 2 follow up evaluations in the
PAVD study conducted from September of 2001 through March of 2005, after many of
the studies in Table 1. With the increasing prevalence of obesity over time the
prevalence of OSA in the population is also increasing (Young, Peppard, & Taheri,
2005). At round two 717 participants (50.6%) had gained weight since round one
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whereas 166 (11.7%) had weights that were unchanged and 534 (37.7%) had lost weight.
Thus the secular trend toward increased obesity prevalence generally, and as
demonstrated for round two participants, would also predict a higher OSA prevalence
compared to earlier studies.
This study’s literature review described the variations in the questions included in
the BQ from published applications of the instrument. The application in this study had
excluded two questions from the original instrument due to concerns regarding vicarious
liability (A.S. Gami, personal communication, July 17, 2007). As described in the
analysis of the BQ results following Table 19, this variation would be expected to
produce an underestimation of OSA prevalence by no more than about 15%. Thus,
despite the BQ yielding an overall prevalence rate higher than most previous studies, the
method used is likely still to have underestimated OSA prevalence.
The analysis of BQ diagnostic performance in this study presented in Table 21
demonstrates that, for those round two participants that underwent a clinical PSG, the
sensitivity and positive predictive value of the BQ was over 80%. Consistent with the
previously described test verification bias when a diagnostic instrument is applied in the
clinical setting (Roger et al., 1997), the specificity and negative predictive value were
much lower, in the range of 17 – 30%. Thus, the BQ in this study, similar to previous
studies as illustrated in Table 5 and 6, was a substantially better instrument for predicting
the presence of OSA than for predicting the absence of OSA.
Table 23 shows that the prevalence of clinical OSA recognition does not differ
significantly when the PPV and NPV of the BQ are considered, compared to a prevalence
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calculation that assumes a 100% PPV and NPV. This confirms that because this study
considers the prevalence of clinical OSA recognition of those with OSA, the limited
ability of the BQ to identify those without OSA has only a modest impact on the study.
In summary, the BQ as applied in this study appears to have been an effective tool
in identifying OSA in the study population with the limitations of the instrument not
significantly impacting the prevalence of OSA recognition. The higher prevalence rate
for OSA compared to most previously reported studies may be related to the relatively
older population studied, and a secular trend toward increasing obesity and OSA in the
general population.
The Clinical Recognition of OSA
The central focus of this study is the four research questions regarding the clinical
recognition of OSA. The results with regard to research questions one and two, as
described in chapter 4 indicate that, of the 705 round two participants with BQ-based
OSA, 26.1% (95% CI 22.9 – 29.3%) had undergone some type of clinical evaluation for
OSA including 23.4% (95% CI 20.3 – 26.5%) that were evaluated with PSG. Of those
with BQ-based OSA 22.7% (95% CI 20 – 26%) had clinically recognized OSA. Thus,
only about one quarter of those with BQ-based OSA have been evaluated, and of those
evaluated a large majority, 87.0%, were found clinically to have OSA. Of note, there
were an additional 44 participants that did not have BQ-based OSA that had been
clinically evaluated including 37 (84.1%) that were found to clinically have OSA.
These results suggest that nearly 75% of those with BQ-based OSA have not been
clinically evaluated. Among those evaluated clinically, most are ultimately found to have
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OSA regardless of whether they have BQ-based OSA. Thus, it appears that if the clinical
care system pursues an OSA clinical evaluation regardless of their BQ-based risk, most
(84.1 – 87.0%) were ultimately be shown to have OSA. However, a majority of those
with OSA are never clinically evaluated or recognized. Therefore it appears that
healthcare system continues to substantially under recognize OSA.
With regard to research question three, as presented in Table 33, a comparison of
these prevalence rates for OSA clinical recognition with those previously published
(Young, Evans et al., 1997) suggests that there has been a substantial improvement over
time. The level of improvement was the most substantial among women with a
prevalence ratio for clinical recognition of 6.2 (95% CI 1.5 – 25.8). Clinical recognition
has increased by 3.3 (95% CI 1.9 – 5.7) times for men since the report of Young and
colleagues in 1997. For a total, mixed gender population, recognition has increased 3.5
(95% CI 2.1 – 5.8) times. Thus, though the prevalence of OSA clinical recognition has
improved substantially compared to rates published more than a decade ago (Young,
Evans et al., 1997), the clinical care system still fails to recognize a substantial majority,
about 75%, of OSA in the community.
Research reports have suggested that there had been increased health practitioner
education regarding OSA during the decade of the 1990s (Haponik, 1992; Papp et al.,
2002). Though there have been no more recent reports quantitatively documenting further
curricular enhancement since 2002, a description of one institution’s use of hand held
digital devices to provide a podcast sleep curriculum to neurology residents has been

163
described (Gamaldo & Salas, 2008) suggesting that at a minimum some institutions have
developed creative solutions to enhancing physician sleep training.
The increased rate of clinical recognition during a time when there was evidence
of increasing sleep instruction for clinicians would be consistent with the theoretical basis
for this research. That basis was the theory of hypothesis generation which requires the
diagnostician have some prior knowledge of a disorder in order for that disorder to be
included among the diagnostic hypotheses generated in evaluating a patient (Bockenholt
& Weber, 1993; Round, 2001). Thus, these results would support an increased physician
awareness of OSA leading to increased clinical recognition.
In addressing research question four regarding factors predictive of OSA clinical
recognition, Tables 29 demonstrated that factors predicting recognition in the mixed
gender model tend to segregate to only one gender in the gender stratified analyses. In
these gender stratified models, increased education and waist size are predictive of
recognition for men, whereas only BMI is predictive for women. In addition, when
gender is retained regardless of statistical significance in a stepwise regression (Table
30), it remains nearly significant (p = 0.08) in the final model with men more likely to be
recognized, whereas greater education, BMI, and neck circumference are statistically
significant predictors of clinical recognition.
Based on this review of this study’s results and the analysis of the null and
alternative hypotheses the following conclusions were drawn:
1. There is a portion of those at high risk for OSA that has not been clinically
evaluated.
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2. There is a portion of those at high risk for OSA that has not been clinically
diagnosed.
3. There has been an increase in the proportion of prevalent OSA that is diagnosed
clinically compared to the mid-1990s.
4. Among those at high risk for OSA there is no difference regarding the following
characteristics among those with a clinical diagnosis of OSA than among those
undiagnosed: age.
5. Among those at high risk for OSA the following characteristics will be more
common among those with a clinical diagnosis of OSA than among those
undiagnosed: male gender, higher BMI, and higher socioeconomic status [as
represented by years of education].
In summary, it would appear that OSA clinical recognition is generally best
predicted by the classic OSA description of the Pickwickian Syndrome (Conti et al.,
2006), that is, primarily those with obesity or male gender. The predictive marker for
obesity varies by gender (Table 29) with waist circumference being the better
multivariate predictor in male populations whereas BMI is more predictive for females.
In the mixed gender model (Table 30) both neck circumference and BMI are statistically
significant predictors. Finally, in predictive models for men and in mixed gender
populations education is a statistically significant predictor of clinical OSA recognition.
Implications for Social Change
This study’s results have implications for public health and for the clinical
practice of medicine. The unadjusted odds ratio for gender as a predictor of OSA clinical
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recognition is 0.37 (95% CI 0.25 – 0.55) suggesting substantially lower clinical
recognition among women. In multivariate analysis, holding education, BMI, and neck
circumference constant, the adjusted odds ratio is only 0.76 (95% CI 0.55 – 1.03)
suggesting a much smaller differential by gender in OSA clinical recognition. It would
seem that strategies targeted toward enhancing clinical recognition in women could be
helpful in addressing this disparity.
The statistically significant disparities associated with the measures of obesity
including BMI, and biometric parameters including hip, waist, and neck size, along with
waist-hip ratio in mixed gender and gender stratified bivariate analyses. In multivariate
analyses both for mixed gender and gender stratified populations a differing measure of
obesity always remained significant in the adjusted models presented in Tables 29 and
30.
A review of the bivariate analysis of OSA clinical recognition stratified by BMI
(Table 25) shows that none of the underweight participants with BQ-based OSA had been
clinical recognized, whereas those in the normal and overweight classifications (BMI 20
– 29) had clinical recognition rates no more than about half of those with obesity (BMI
≥30).
A gender stratification of this bivariate analysis, as shown in Table 34,
demonstrates that prevalence of OSA clinical recognition for the nonobese is less than for
the obese in both genders, and that women are less likely recognized with OSA. The
gender stratified relative risks of recognition for the nonobese compared to the obese are
0.56 (95% CI 0.40 – 0.77) and 0.31 (95% CI 0.15 – 0.64) for males and females,
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respectively. These confidence intervals indicate that, in this sample, the differential in
OSA recognition rates between nonobese and the obese is not statistically different
between males and females. Thus, it seems quite clear that those with OSA who are not
obese are significantly less likely to be clinically diagnosed, and women are much less
likely to be recognized than men regardless of obesity.
Table 34
OSA Clinical Recognition Rates by Obesity (BMI ≥30) and Gender
High risk by BQ, n
OSA clinically recognized, n (%)
All
Male
Female
All
Male
Female

pa

BMI <30

311

177

134

44 (14.2%)

36 (20.3%)

8 (6.0%)

0.0002

BMI ≥30

394

230

164

116 (29.4%)

84 (36.5%)

32 19.5%)

0.0002

Total

705

407

298

160 (22.7%)

120 (29.5%)

40 (13.4%)

<0.0001

a

p-value for the Chi square likelihood ratio for the male - female comparison.

This reduced clinical recognition of OSA among the nonobese appears to confirm
a hypothesis generated from a study of OSA in patient samples drawn from military and
civilian populations where obesity was less prevalent in the military sample (Lettieri et
al., 2005). That study noted that obesity was common among those with OSA, but
recommended that BMI not be used as a criterion for identifying which patients should
undergo evaluation for OSA.
Thus, developing strategies to educate clinicians regarding the overall low clinical
recognition of sleep apnea, with substantially lower recognition rates for those with a
BMI less than 30, and among women would be expected to lead to improved clinical
recognition of OSA with associated increased likelihood of OSA treatment and
prevention of the OSA associated morbidity and mortality. In addition, public education
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efforts to raise the awareness of sleep apnea in general, and the fact that OSA affects both
men and women, and though more common among the obese, is more commonly
unrecognized among the nonobese would also encourage more people to seek evaluation
for OSA. Together these strategies would lead to a positive social change with respect to
the impact of sleep apnea on society.
Strengths of the Study
This study was conducted within a large, population-based longitudinal cohort
study originally focused on ventricular dysfunction (Redfield et al., 2003). Since the
components focusing on OSA were initiated in round two of that study, the study
population was well characterized with regard to many cardiovascular and biometric
variables both at the time of the BQ was administered, and four years previously. Thus,
potential associations between these variables both at the time of BQ administration and
four years previously with OSA clinical recognition were able to be explored.
The two previous studies of OSA clinical recognition (Kapur et al., 2002; Young,
Evans et al., 1997) had used participant self-report to identify those with clinically
recognized OSA. In verifying these reports from a survey by contacting the participants
by telephone Young and colleagues (1997) found that only 33% had actually been
clinically diagnosed whereas the remainder only personally suspected OSA. In addition,
in this study there had been no effort to validate responses indicating the lack of a clinical
OSA diagnosis. Kapur and colleagues (2002) did not attempt to validate self-reported
clinical recognition in their study. Thus, this study is the first population-based study in
which OSA clinical recognition has been validated by review of the clinical records.
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In addition, this study used the resources of the REP to identify records
documenting clinical recognition of OSA. The REP has been shown to retrieve records
for 96% of the Olmstead County population (Melton, 1996). The codes used by the REP
search in this study were validated and demonstrated that more than 95% of those with
OSA in the study population were identified. Thus, the methods used in this study
provide an essentially complete enumeration of all of the participants in this study
population with clinically recognized OSA.
In summary, the primary strength of this study was the use of the resources of the
REP to identify those with clinically recognized OSA and to validate the diagnosis using
the original clinical records. As such, this is the first population based study of OSA
clinical recognition to utilize such a rigorous method to validate clinical recognition. In
addition, the study was carried out in a well characterized population both at the time of
the BQ OSA determination, and longitudinally from four years previously.
Limitations of the Study
The assessment of OSA clinical recognition was conducted as part of the round
two analyses in a larger longitudinal cohort study (Redfield et al., 2003). Thus, the
sample studied represented those returning an average of four years following the initial
round one assessment of the respondents to original population-based invitations to
participate in the study. Those completing the BQ were only those that chose to
participate in the study on two separate occasions four years apart. This method then has
potential for participation bias.
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Round one multivariate participation bias analysis (Jacobsen et al., 2004) had
identified overrepresentation of those with more than a high school education, those
between the ages of 55 – 74 years old, and those without COPD. As presented in Table
16, multivariate participation bias from round one to round two demonstrated the same
age, education, and COPD biases that were identified in round one. In addition, female
gender and the presence of nonCAD CV disease, along with a score of three or greater on
the more general Charlson Index (Charlson et al., 1987) of comorbidities predicted under
representation in round two. However, the clinical diagnosis of OSA and clinical testing
by PSG was not associated with a differential in round two participation. With gender
being among the factors associated with participation, the performance of gender specific
analyses was one means of dealing with gender-based participation bias in this study.
The round two sample was 97.7% Caucasian, non-Hispanic which is an underrepresentation of other races and ethnicities. The US Census had shown that the
Olmstead County population as a whole was only 95.3% and 89.0% Caucasian, nonHispanic in 1990 and 2000, respectively (US Census Bureau, 2010). Thus, the results of
this study cannot be extrapolated to non-Caucasian and Hispanic populations.
With a mean age of 65.2 years and the youngest participant being age 49.9 years
old at the time the BQ was administered, this study’s sample was older than both of the
previous studies of OSA clinical recognition. The mean age in the study by Kapur and
colleagues (2002) though younger was similar at 63.1 years. However, the study by
Young and colleagues (1997) had an age range from 30 – 60 years and the mean ages of
those with screen detected and clinically recognized OSA were all in the 40s, younger
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than the youngest participant in the current study. Thus, comparison of the results in the
present study with those of Young and colleagues (1997) must be done with caution. In
addition, the ability to extrapolate these results to a younger adult population less than
age 50 is also limited.
This study used the high risk classification on the BQ as an OSA proxy whereas
the gold standard for OSA diagnosis is laboratory based PSG. Based on previously
published validation analyses of the BQ and analysis of the clinical PSGs performed in
the study population, the instrument has stronger diagnostic performance for OSA
identification than for identifying those without OSA. In Table 23 a comparative analysis
of OSA clinical recognition when the PPV and NPV of the BQ are considered, compared
to a prevalence calculation that assumes a 100% PPV and NPV demonstrated no
statistically significant difference. However, there may be some segments of the
population in which there is an unrecognized differential in the diagnostic performance of
the BQ. Thus, this study is limited by the lack of a gold standard OSA ascertainment
method.
This study was carried out in Olmsted County, Minnesota where there are two
sleep laboratories, one at Mayo Clinic with 24 beds and performing 4,440 PSGs annually
(Mayo Foundation for Medical Education and Research, 2010), and a second smaller
sleep lab at Olmsted Medical Center (Olmsted Medical Center, 2008). Therefore the
participants in this study have comparatively easy access to sleep medicine services
compared to many communities. Thus, the prevalence of clinical OSA recognition may
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be higher in this community than other settings with comparatively limited access to
sleep medicine services.
In summary, the limitations of this study include differential participation
subsequent to the population-based sampling conducted in 1997 that appears to be related
to age, gender, education, COPD, nonCAD CV disease, and general comorbidities as
measured by the Charlson Index (Charlson et al., 1987). The impact of these biases
appears to be limited as the evaluation rate with clinical PSG and the rate of OSA
diagnosis did not differ between round two participants and nonparticipants. The impact
of the gender-based biases on this study’s results has been attenuated by use of gender
stratified analyses. Because of the sample’s demographics results should not be
extrapolated to non-Caucasian and Hispanic population, or to populations younger than
50 years old. In addition, because the study used the BQ as a proxy for OSA rather than a
laboratory-based PSG method, the diagnostic limitations of the BQ must be considered in
interpreting the results. Finally, the study was conducted in a community with relatively
easy access to sleep medicine services, thus the prevalence of OSA clinical recognition
for this population may be higher compared to other communities with more limited
access to these services.
Recommendations for Action
In 2006 the Institute of Medicine (IOM) concluded that “although clinical
activities and scientific opportunities in the field [of sleep medicine] are expanding,
awareness among the general public and health care professionals is low given the
magnitude of the burden” (Colten & Altevogt, 2006, p. 1). The IOM recommended that
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there be “increase[d] awareness of the burden of sleep loss and sleep disorders among the
general public” (p. 3) and “expand[ed] awareness among health care professionals
through education and training” (Colten & Altevogt, 2006, p. 3).
The present study suggests that, there may have been some improvement in OSA
clinical recognition since the analysis by Young, Evans, and colleagues (1997).
However, the majority, about 75%, of OSA in this older adult population remains
unrecognized, with women, the nonobese, and those less well educated even more likely
to be unrecognized. Thus, this study would support further expansion of both health
professional and public education regarding OSA.
Given the population segments most under-recognized (i.e. women and the
nonobese) these educational efforts should be carefully structured so as not to portray
OSA as a disorder of obese men while still acknowledging that male gender and obesity
are risk factors for OSA. In addition, noting that years of education was a predictor of
OSA clinical recognition (Table 30) such public educational efforts should be structured
in a manner making them meaningful regardless of educational level.
Where there are large clinical care systems that share a common electronic
medical record system, it may also be possible to develop a set of electronic markers that
predict OSA. For example, either using data from already existing tools by which
patients report their symptoms, or by modifying such tools to include OSA-related
symptoms, and adding other electronically recorded data such as BMI and the diagnosis
of hypertension, it may be possible to construct an automated electronic BQ or similar
algorithm predictive of OSA. This electronic BQ could then function in the background
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and provide clinicians an electronic message that the patient is at high risk for OSA and
suggest further testing.
Recommendations for Further Study
Because generalization of these results is limited by the lack of racial and ethnic
diversity, and the relatively older population studied, repeating or expanding the study
population to include younger adults and greater racial and ethnic diversity would be of
value. The additional participants could then be selected using a population-based
sampling method that could further attenuate the participation bias that resulted from this
study’s placement at round two of an ongoing study. With the existing round two cohort
there would also be value in pursuing follow up to assess the impact of the BQ-based
OSA classification on longitudinal outcomes.
With OSA ascertainment in this study having been based on the BQ whereas PSG
represents the gold-standard for OSA diagnosis using PSG-based ascertainment in further
study would be advantageous. Because of the cost of in laboratory PSG, use of in home
unattended PSG may be an acceptable, cost-efficient alternative recognizing that at least
one large population-based study had already used such a method (Quan et al., 1997). An
additional alternative would be to study by PSG a randomly selected sample of the study
population for validation of the BQ.
In parallel with the potential development of an automated electronic BQ for a
larger clinical care system, research analysis of the impact of implementing such a system
would be of significant value. Such research could then be used to validate the electronic
algorithm, and ultimately document the impact of such a system on clinical outcomes
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that, in the long-term could include cardiovascular disease, cerebrovascular accidents,
hypertension, and diabetes.
Thus, this study’s results provide a spring board to pursue OSA-related research
addressing a variety of issues of both scientific and public health value.
Concluding Statement
Obstructive sleep apnea (OSA), a disorder in which the airway collapses causing
an airway obstruction during sleep, is associated with multiple morbidities and increased
mortality. Treatment of OSA, typically with continuous positive airway pressure
(CPAP), attenuates or reverses many of these associated risks. Historically most OSA
was clinically unrecognized and thus, untreated. Improved physician awareness of OSA
and increased availability of sleep medicine services should predict increased recognition
of OSA since it was last evaluated using data from the 1990s.
This study demonstrated an increase in clinical recognition from 6.5% (95% CI
3.4 – 9.5%) to 22.7% (95% CI 19.6 – 25.8%) overall in a mixed gender population.
However, this still indicates that a majority of OSA, about 75%, remains unrecognized
and thus, still untreated. Bivariate and multivariate analyses of OSA clinical recognition
in this study demonstrated that, OSA recognition is most likely for obese men, that is,
those that more closely resemble the classic Pickwickian Syndrome description.
Conversely, women and the nonobese are among those less likely to be recognized with
OSA.
Consistent with the IOM’s 2006 statement titled, Sleep Disorders and Sleep
Deprivation: An Unmet Public Health Problem the results of this study point to the need
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for increased clinician and public education about OSA, its diagnosis and treatment.
Such educational efforts should highlight both the risk factors for OSA and risk factors
that are currently associated with clinical under-recognition of the disorder. Concurrent
development of systems-based tools built into electronic medical record systems that
automatically alert clinicians to their patients’ OSA risk would also have the potential to
enhance OSA recognition and treatment, and lead to a reduction in OSA-related
morbidity and mortality.
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departments. Instructor for History and Physical exam course, Pathophysiology,
and Didactic Clinical Medicine courses.
Oct. 1987 - March 1993

Physician Assistant, Interstate Medical Center, Department of Internal
Medicine, Red Wing MN, and Zumbrota, MN Satellite Clinic: Providing
medical care to patients in the clinic, nursing home, and hospital settings.
Special clinical interests include geriatric care, rural and emergency medicine.
Served on the Medical Center and nursing home Quality Assurance Review
Committees and a nursing home Ethics Committee.

June 1983 - Sept. 1987

Physician Assistant, Park Clinic-Allison, IA Satellite Office: Providing a broad
spectrum of primary care medical services to the residents of Allison, Iowa, a
small, rural community with the supervision of physicians from a larger
multispecialty clinic in Mason City, IA.
Responsibilities included
comprehensive primary care, 24 hour emergency call, EMT education, office
and personnel management, and community relations.

EDUCATION:
2003 – 2010

2006, Fall
2004, Summer

2001, Spring
1981-1983
1976-1977
1972-1976
1972

PhD in Public Health, Epidemiology Emphasis
Cumulative GPA 3.947, Dissertation completion anticipated 2010.
Dissertation title: “Clinical Recognition of Obstructive Sleep Apnea in a
Population-Based Sample”
Walden University, Minneapolis, MN
Graduate Course in Statistics, HSR5535: Introductory Statistical Methods II
(Multivariate Analysis), Mayo Graduate School, Rochester, MN
Graduate Summer Session in Epidemiology. Courses included: Design, conduct
and analysis of clinical trials, Pharmacoepidemiology, and Systematic
review/Meta-analysis
University of Michigan, School of Public Health, Ann Arbor, MI
Graduate special student: STAT 601 Statistics in Health Care Research
Winona State University, Winona, MN
Bachelor of Science in Medicine, Physician Assistant Program,
College of Medicine, University of Iowa, Iowa City, IA
Master of Arts, Science Education
College of St. Thomas, St. Paul, MN
Bachelor of Arts, Chemistry and Natural Science
Augsburg College, Minneapolis, MN
High School Graduate, North High School, West Union, IA

CERTIFICATION:
Physician Assistant-Certified (PA-C), Primary Care. Scored in the top 5% on the Physician Assistant
National Certification Exam, National Commission of Certification of Physician Assistants (NCCPA)
in 1983. Recertified by examination 1990, 1996 2002, and 2008, scoring historically in the top 5% and
most recently the top 3% in 2008.
LICENSURE:
Wisconsin Medical Examining Board, Physician Assistant, Number 507-023, expires February 29, 2012.
Minnesota Board of Medical Practice, Physician Assistant, Number 8874, expires June 30, 2011.
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PEER REVIEWED PUBLICATIONS:
Zellmer, MR, Hadley, RD, A Descriptive Analysis of Capstone Project Requirements in Academic and
Professional Physician Assistant Master’s Degree Programs, Perspective on Physician Assistant
Education, 2004; 15(2):82-87.
Carter, RD, Cawley, JF, Fowkes, V, Hooker, RS, Rackover, MA, Zellmer, MR, Blue Ribbon Panel Report
on Physician Assistant Program Expansion, Perspective of Physician Assistant Education, Winter
1998; 9:(1)20-29.
Zellmer, MR and Valentine, P., The Education of PAs for Underserved Areas, Proceedings of the National
Health Service Corps 20th Anniversary Celebration: A Forum on Primary Care, April 1993.
Zellmer, MR, The Ethics of Head Hunting, Physician Assistant Newsletter of Ethics (P.A.N.E.), Spring
1993; 3(3):4.
Zellmer, MR, A Survey of Minnesota Physicians Regarding Delegation of Prescriptive Practice to PAs,
Journal of the American Academy of Physician Assistants, September 1992; 5:582-6.
GRANT AWARDS:
Author, Rural Interdisciplinary Healthcare Provider Course, Southwest Wisconsin AHEC, $1760 funded,
June 2001.
Co-author of the grant proposal funded by the UW-L General Education Committee to support the
development of cases for the course SAH 105: Analysis of Health, Wellness and Disease for the
Health Care Consumer, $6000 approved, March 2000.
Author, “Analysis of Predictors of PA Program Student and Graduate Performance,” University of
Wisconsin - La Crosse, College of Science and Allied Health, Faculty development grant, 1999-2000,
$1400.
Principle Investigator, “Investigation of Recruitment and Retention Issue for Physician Assistant in Rural
Practice: A Pilot Study,” Southwest Area Health Education Center, Inc, 1996, $3000.
Principle Investigator, PA Training Grant to the University of South Dakota, Division of Health Sciences,
Title VII, Division of Medicine, Bureau of Health Professions, DHHS, 1994-1997, 1 D21 PE10075-01,
$444,060.
BOOK CHAPTER:
Sert Kuniyoshi, FH, Zellmer, MR, Adachi, T, Somers, VK, (2010) Acute and Emergent Cardiac Events in
Obstructive Sleep Apnea. In S. Chokroverty & P. Sahota (Eds), Acute and Emergent Events in Sleep
Disorders. (pp. 15-32), New York: Oxford (in press).
PRESENTATIONS:
“Berlin Questionnaire Diagnostic Performance in published validation studies”, Poster co-authored with
C.S.P. Lam, MD, A.S. Gami, MD, E.J. Olson, MD, S.M. Caples, DO, and V.K. Somers, MD, PhD for
SLEEP 2009, Seattle, WA, June 6-11, 2009.
“Obstructive Sleep Apnea, the Berlin Questionnaire, and the Prevalence of Clinical Recognition”,
Conference presentation for the research fellows in the Virend Somers, MD, PhD, laboratory group,
Mayo Clinic, Rochester, MN, November 18, 2008.
“Research Involvement at Mayo Clinic”, Panel presentation at the semi-annual NP/PA Forum, Mayo
Clinic, Rochester, MN, November 10, 2008.
“Obstructive Sleep Apnea: A Critical Review of Population Prevalence”, Poster Presentation, Internal
Medicine Review for NPs, PAs and Primary Care Physicians, Mayo Clinic, Rochester, MN, September
17-19, 2008.
“A Snoring Lunch for the Heart: Obstructive Sleep Apnea & Related Disorders,” Lunch and Learn
presentation, Inpatient NP/PA Group, Division of Cardiovascular Diseases, Mayo Clinic, Rochester,
MN, May 6, 2008.
“Obstructive Sleep Apnea Risk in a Population-based Sample”, Poster Presentation, Summer Residency,
Walden University, Minneapolis, MN, July 18, 2007.
“Healthcare for Evacuees from Hurricanes Katrina and Rita: Operation Minnesota Lifeline”, poster
presentation, AAPA National Conference, San Francisco, CA, May 27-31, 2006.
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PRESENTATIONS (continued)
“A Descriptive Analysis of Capstone Project Requirements in Academic and Professional Physician
Assistant Master’s Degree Programs,” coauthor with Hadley, RD, poster presentation, Internal
Medicine Review for Nurse Practitioners and Physician Assistants: A Case Study Approach to the
Management of Common Problems, Mayo Clinic, Rochester, MN, September 15-16, 2005.
“A Descriptive Analysis of Capstone Project Requirements in Academic and Professional Master’s Degree
Programs,” coauthor with Hadley, RD, paper presentation, Association of PA Programs Educational
Forum, Phoenix, AZ, October 24, 2003.
“What constitutes a Master’s Project?” co-presenter with Robert Hadley, PhD, PA-C, roundtable
presentation, Association of Physician Assistant Programs, Semiannual Meeting, New Orleans, LA,
May 23, 2003.
“PA Adjunct Faculty Development and Utilization: Models of Inclusion,” co-presenter with Mare Wheeler,
MS, PA-C, roundtable presentation, Association of PA Programs Educational Forum, Miami, FL,
November 7, 2002.
“Update on the Male Genitourinary Exam,” invited presentation, Minnesota Academy of PAs, Fall
Conference, Rochester, MN, 28 September 2001.
“Don’t Judge a Book by its Cover: An Overview of Medical Literature Interpretation,” invited presentation,
Wisconsin Academy of PAs, Fall Conference, Eau Claire, WI, October 21, 2000.
“Using the Medical Literature in Clinical Practice”, invited presentation, American Academy of PAs
Annual Conference, Chicago, IL, May 2000.
“A Review Process for Applying Research Literature to Clinical Practice”, invited presentation, American
Academy of PAs, Annual Conference, Chicago, IL, May 2000.
“Net Essentials for PAs”, invited presentation, American Academy of PAs, Annual Conference, Chicago,
IL, May 2000.
"Using the Medical Literature in Clinical Practice", Minnesota Academy of PAs, Fall CME Conference,
September 1997, presenter.
"The Physician Assistant in Primary Care," in "Perspectives in Primary Care, A Symposium in Celebration
of National Primary Care Day", sponsored by the SW Wisconsin AHEC, La Crosse, WI, September 28,
1995, panelist.
"Physician Assistant Education in La Crosse," Gundersen Medical Foundation Noon Conference, La
Crosse, WI, September 25, 1995, presenter.
"Effective Use of NPs, PAs and CNMs" at the 1995 National Health Service Corps’ "Recruitment in the
1990's: Challenges & Opportunities," May 25, 1995, St. Paul, MN, Co-presenter.
"An Update on PA Education In Minnesota," MAPA Spring CME, St. Louis Park, MN, April 7, 1995.
"Physician Assistants and PA Education in South Dakota," 9th Annual South Dakota Rural Health
Conference, Pierre, SD, November 4, 1993, Presenter.
"The Clintons' Healthcare Reform Proposal in the view of the American Academy of Physician Assistants,"
the Rural Health Policy Board of the National Rural Health Association, November 12, 1993, Chicago,
IL, Presenter.
"The Education of PAs for Underserved Areas", National Health Service Corps 20th Anniversary
Celebration: A Forum on Primary Care, Arlington, VA, June 24, 1992, Co-Presenter.
"Panel Discussion: Physician Assistants in the Emergency Department", Advances in Emergency Medicine
sponsored by the Minnesota Chapter of the American College of Emergency Physicians, Minneapolis,
MN, May 1, 1992, Panelist.
"Rural Health/Inner City Initiatives: Can We Fulfill Our Original Professional Mandate?", North Central
Regional Meeting of the AAPA, Lansing, MI, February 2, 1992, Presenter.
"Panel Discussion: PA Prescribing and Regulation in Minnesota", Minnesota Academy of PA Fall CME,
Duluth, MN, October 27, 1991, Moderator.
"Membership Development Workshop: 24 Great Membership Ideas", AAPA Constituent Chapter Officers
Workshop, Alexandria, VA, September 13, 1991, Panelist.
"Panel Discussion: What's New With Recertification, Information and Discussion", North Central Meeting
of the AAPA, Minneapolis, MN, February 3, 1991, Moderator.
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PRESENTATIONS (continued)
"Panel Discussion: PA Regulation, Which Model is Best, A Comparison of Several States' PA Regulatory
Systems", North Central Meeting of the AAPA, Minneapolis, MN, February 2, 1991, Moderator.
"Practice Demographics and PA Salaries in Two North Central States: Implications for the Profession",
North Central Meeting of the AAPA, Minneapolis, MN, February 2, 1991, Presenter.
ACCREDITATION SITE VISITOR:
Site visitor for the Accreditation Review Commission for Physician Assistant Education (ARC-PA)
Daemen College, Buffalo, NY, April 2006, team chair
Samuel Merritt College, Oakland, CA, June 2005
Grand Valley State University, Grand Rapids, MI, May 2004, team chair
Medical College of Ohio, Toledo, OH, January 2004, team chair
College of Health Sciences, Roanoke, VA, January 2003, team chair
University of Texas Health Science Center, San Antonio, Texas, July 2002, team chair
Central Michigan University, Mount Pleasant, MI, January 2002, team chair
Arcadia University, Philadelphia, PA, July 2001
Medical College of Ohio, Toledo, OH, January 2001
St. Francis University, Fort Wayne, IN, January 2000, team chair
St. Francis College, Loretto, PA, January 1999
New York Institute of Technology, Long Island, NY, July 1998
SUNY Downstate, Brooklyn, NY, January 1998, team chair
Grand Valley State University, Grand Rapids, MI, July 1997
Brooklyn Hospital/Long Island University, Brooklyn, NY, January 1997
OTHER MEDICAL EDUCATION:
2008-present
Advanced Trauma Life Support (ATLS), completion of provider course, St. Cloud, MN.
2007-present
Pediatric Advanced Life Support (PALS), Minnesota Affiliate, American Heart
Association.
1983-present
Advanced Cardiac Life Support (ACLS), Provider 1983-present; Instructor 1983-2007.
Iowa, Minnesota, Dakota and Wisconsin Affiliates of the American Heart Association
1983
Advanced Trauma Management
Emergency Medical Services Learning Resource Center
University of Iowa Hospital and Clinic, Iowa City, IA
1981
Instructor/Coordinator EMT Course, Mount Vernon Extension Class
Kirkwood Community College, Cedar Rapids, IA
1981
Research Assistant for John Weiler, MD, Department of Allergy Immunology, University
of Iowa. Performed Complement tissue culture research.
1980
EMT-Paramedic
Emergency Medical Services Learning Resource Center
University of Iowa Hospital and Clinic, Iowa City, IA
1979-80
EMT, Training Officer and Charter Member, Dumont Ambulance Service, Dumont, IA
1979
EMT-Ambulance, North Iowa Area Community College, Mason City, IA
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OTHER MEDICAL EXPERIENCE:
June 1982- May 1983
Physician Assistant Program Clinical Rotations, University of Iowa PA Program,
Iowa City, IA
Emergency Medicine
Schoitz Hospital, Waterloo, IA
Family Practice
Broadlawns Hospital, Des Moines, IA
Muscatine Health Center, Muscatine, IA
Franklin Medical Center, Hampton, IA
General Surgery
VA Medical Center, Iowa City, IA
Internal Medicine
Park Clinic, Mason City, IA
Obstetrics & Gynecology University of Iowa Hospitals, Iowa City
Orthopedic Surgery
Muscatine General Hosp., Muscatine, IA
Pediatrics
Marshfield Clinic, Marshfield, WI
Psychiatry
VA Medical Center, Des Moines, IA
Sept. 1980 - March 1983 EMT-Paramedic, Mercy Hospital/Area Ambulance, Cedar Rapids, IA:
A hospital emergency room based ambulance service providing assessment,
advanced cardiac life support and transportation to the sick and injured with
ground and helicopter air ambulances.
OTHER WORK EXPERIENCE:
School Years 1978-1980 Senior High Science Instructor, Dumont Community School, Dumont, IA.
Taught Chemistry, Biology, and Physical Science. Coached Football, Basketball
and Track.
Summer 1978
House Parent, Frontier Farm Group Home for Boys, Effie, MN
Parented boys ages 12-18 in the development of positive relations with peers,
family and authority figures on a homestead farm.
School year 1977-78
High School Science Instructor, Villard Public School, Villard, MN: Taught
Chemistry, Physics, Biology, and Life Science.
School year 1976-77
Science teaching intern, Bloomington Lincoln High School, Bloomington, MN.
Summer 1976
Nursing Assistant, Augustana Home for the Aged, Minneapolis, MN.
Summer 1975
Guide/counselor, Wilderness Canoe Base, Grand Marais, MN.
Summer 1974
Youth Service Corps Counselor, Woodward Hosp./School for the Retarded,
Woodward, IA
Summers 1971-73
Camp Counselor, EWALU Bible Camp, Strawberry Point, IA.
GOVERNMENTAL APPOINTMENT:
Member, Rural Health Advisory Committee, Minnesota Department of Health, Office of Rural Health,
1992-1993.
PROFESSIONAL ORGANIZATION MEMBERSHIPS AND OFFICES:
American Academy of Sleep Medicine (AASM), Student member, 2005 to the present.
American Public Health Association (APHA), Student member, 2005 to 2009.
American Academy of Physician Assistants (AAPA), Fellow Member; Member since 1983; Official
Liaison for the AAPA to the National Rural Health Association 1992-98; Chapter and Member
Relations Committee, North Central Region Representative, 1992 - 1994; Member, Advisory
Committee of PA Employment 1991-92; House of Delegates, Reference Committee Member 1993 &
Observer 1992, Delegate 1989, 1992-93, Alternate Delegate 1990 & 1991; Coordinator for the North
Central Regional meeting, February 1991; Reviewer, Taskforce on PA Specialty Practice report, 1993;
Reviewer National Health Program Position Paper, 1990 & 1996; Reviewer of Rural Health Policy
Paper, 1989.
Association of PAs in Cardiology, Member 2006-present.
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PROFESSIONAL ORGANIZATION MEMBERSHIPS AND OFFICES (continued):
Rural Health Caucus of the AAPA, Member, 1991-1996; Newsletter Editor/Board Member At Large,
1992-1996; Charter member and Secretary-Treasurer, 1991-92.
South Dakota Academy of Physician Assistants (SDAPA), Fellow Member 1993-95, Legislative
Committee, 1993-95.
Minnesota Academy of Physician Assistants (MAPA), Fellow Member since 1988; President 1991;
Member Board of Directors 1988-1992; Board Liaison for development of a Minnesota PA Training
Program, 1989-1993; Past Chair Legislative Committee, 1989-91; Past chair, Membership Committee,
1989-90; Member, ad hoc judicial affairs committee, 1992.
Association of Physician Assistant Programs (APAP), Director of member program, 1995-2005; Member,
CASPA Steering Committee, 2004-present; Associate Member, 1990-1995; Member Leadership
Training Institute Advisory Committee, 1994-1997; Reviewer, J. Peter Nyquist Writing Contest, 2003.
National Rural Health Association, Member, 1992-2004; Member Rural Health Policy Board, 1996-1998,
Clinical Services Constituency Group.
American Geriatrics Society, Member, 1991-1995.
University of Iowa Student PA Society, Past Member and Past President, 1981-83.
AWARDS/HONORS:
Who’s Who in Medicine and Healthcare, 1996, 2000, 2002
Who’s Who in America, 1997
Minnesota Academy of Physician Assistants, Presidential Award, 1990 & 1993.
Who's Who Among American and College & University Students, 1975-76
Academic Achievement Award, Science Award, North High School, 1972
National Honor Society, North High School, 1971-72
COMMUNITY SERVICE ACTIVITIES:
Our Savior’s Lutheran Church: Call Committee Chair, 2005, Church Council President, 2002, Board of
Worship and Music, Chair, 1999-2001, Member 1999-present; Church council member, 1999-2003;
Senior Choir Member, 1995-present; Sunday School Teacher, 1997-98, Our Savior’s Lutheran Church,
La Crosse, WI
Lutheran Campus Ministry, Chair, 1998-2003; Directing Committee Member, 1996-2003, Building
Committee member, 2002-2004; La Crosse, WI
Soccer Coach, 1994, Vermillion Youth Soccer League, Vermillion, SD
Sunday School Teacher, 1993-94, Trinity Lutheran Church, Vermillion, SD
EMT Guest Instructor, 1993-94, Vermillion-Clay County Ambulance Service, Vermillion, SD
Sunday School Teacher, 1992-93 & 1989-91, Senior Choir Member, 1987-1993, United Lutheran Church,
Red Wing, MN
Host Parent, American Field Service (AFS), foreign exchange program, 1989-90, Red Wing, MN
Member, Dawnbreaker Kiwanis Club, 1987-1992, Red Wing, MN
Member Red Wing American Field Service Chapter, 1989-1992, Red Wing, MN
Past President, Butler County Chapter, American Heart Association, Allison, IA
Member and President, Allison Lions Club, Allison, IA, 1984-87
Member, Medi-Search, Ltd., 1979-80, a community physician recruitment committee, Hampton, IA
Host Parent, 1979-80, Youth For Understanding, Dumont, IA

